[
  {
    "question": "Are there microbes in human breast milk?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Human breast milk is known to contain various components that support the growth and development of infants. In addition to nutrients, it may also contain various microorganisms. Studies have shown that breast milk can harbor a diverse range of microbes, including bacteria that contribute to the development of the infant's gut microbiome. These microbes are generally considered beneficial and play a role in establishing a healthy microbial community in the baby's digestive system. Therefore, it is likely that there are microbes present in human breast milk.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can breastfeeding confer protection from type I diabetes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Breastfeeding has been associated with various health benefits for infants, including potential protective effects against certain diseases. Some studies suggest that breastfeeding may reduce the risk of type I diabetes in children, possibly due to the immune-boosting properties of breast milk and the delayed exposure to foreign proteins. However, the evidence is not entirely conclusive, and other factors such as genetics and environmental triggers also play significant roles in the development of type I diabetes. While breastfeeding may contribute to a lower risk, it cannot guarantee complete protection against the disease.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can pets affect infant microbiomed?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Research suggests that pets, particularly dogs, can influence the microbiome of infants. Exposure to pets in early life may increase microbial diversity in the infant's gut, which is associated with better immune system development. Studies have shown that infants living in households with pets have different microbiota compositions compared to those without pets. However, the exact mechanisms and long-term effects are still being studied.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there any association between the human gut microbiome and depression?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question asks whether there is any association between the human gut microbiome and depression. I need to determine if research or evidence supports a link between gut microbiota and depression. Studies have shown that the gut-brain axis exists and that gut microbes can influence brain function and mood. Some research suggests that imbalances in gut microbiota may contribute to depression. Therefore, the answer is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is pembrolizumab effective against Ewing's sarcoma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Pembrolizumab is a PD-1 inhibitor used in immunotherapy. Ewing's sarcoma is a type of cancer that primarily affects bones or soft tissue. Clinical trials and current medical literature suggest that pembrolizumab has shown limited effectiveness against Ewing's sarcoma, as these tumors typically do not respond well to immune checkpoint inhibitors. However, research is ongoing, and some studies are exploring combination therapies to improve outcomes.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can gene therapy restore auditory function?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Gene therapy has shown promise in treating various genetic disorders, including those affecting the auditory system. Research in animal models has demonstrated that gene therapy can repair damaged hair cells in the inner ear, which are crucial for hearing. However, clinical applications in humans are still in early stages, and there are challenges such as ensuring safe and effective delivery of the therapeutic genes. While there have been some successful trials, more research is needed to determine the long-term efficacy and safety. Therefore, while gene therapy holds potential for restoring auditory function, it is not yet a widely established treatment.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does vesatolimod inhibit TLR7?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Vesatolimod is a TLR7 agonist, which means it activates TLR7 rather than inhibiting it. Therefore, vesatolimod does not inhibit TLR7.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can simvastatin alleviate depressive symptoms?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Simvastatin is a statin drug primarily used to lower cholesterol levels and reduce the risk of cardiovascular diseases. While some studies have suggested that statins may have anti-inflammatory effects and could potentially influence mood, the evidence regarding their direct efficacy in alleviating depressive symptoms is inconclusive. Clinical trials have shown mixed results, with some indicating a possible modest benefit and others showing no significant effect. Therefore, simvastatin is not typically prescribed as a primary treatment for depression.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does gepotidacin activate bacterial topoisomerase?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Gepotidacin is a novel antibiotic that works by inhibiting bacterial DNA replication. It specifically targets bacterial topoisomerase, which is an enzyme involved in DNA replication and repair. However, instead of activating the enzyme, gepotidacin inhibits its function, leading to the disruption of DNA replication and ultimately bacterial cell death. Therefore, gepotidacin does not activate bacterial topoisomerase but rather inhibits it.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is obesity related to cognitive decline?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Obesity is a condition characterized by excess body fat, and cognitive decline refers to the deterioration of cognitive functions such as memory, attention, and problem-solving. Research has suggested that obesity may be linked to cognitive decline. For instance, studies have shown that individuals with higher body mass index (BMI) may have an increased risk of developing cognitive impairments, including conditions like dementia. The mechanisms behind this relationship could involve factors such as inflammation, insulin resistance, and vascular issues, which are associated with obesity and may affect brain health. However, other studies might present conflicting evidence, and the relationship could be influenced by various factors like age, overall health, and lifestyle. Therefore, while there is some evidence supporting a connection between obesity and cognitive decline, the relationship may not be straightforward and could depend on multiple variables.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are whole-genome duplications more divergent than small-scale duplications in yeast?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Whole-genome duplications (WGDs) involve the duplication of the entire genome, resulting in two copies of each chromosome. Small-scale duplications (SSDs) involve the duplication of individual genes or small chromosomal regions. In yeast, WGDs and SSDs can lead to genetic divergence, but their mechanisms and outcomes differ. WGDs may lead to more extensive divergence due to the simultaneous duplication of all genes, potentially allowing for greater functional redundancy and opportunities for subfunctionalization or neofunctionalization. However, SSDs might lead to more rapid divergence in specific genes or pathways. Studies on yeast have shown that WGDs can result in significant divergence over time, but the extent compared to SSDs depends on factors like mutation rates, selection pressures, and the specific genes involved. Therefore, while WGDs have the potential for greater divergence, the actual divergence relative to SSDs can vary based on context.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do yeast LTR give rise to circular DNA?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Yeast long terminal repeats (LTRs) are sequences found in retrotransposons, which are mobile genetic elements. In some cases, LTRs can mediate the formation of circular DNA intermediates during the process of transposition. For example, in the case of Ty elements in Saccharomyces cerevisiae, circular DNA intermediates have been observed. These circles can arise through recombination between the LTRs. Therefore, yeast LTRs can contribute to the formation of circular DNA.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Copy Number Variants (CNVs) depleted in regions of low mappability?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Copy Number Variants (CNVs) are genomic alterations that result in an abnormal number of copies of a particular DNA segment. Regions of low mappability refer to parts of the genome where it is difficult to uniquely align sequencing reads due to repetitive sequences or other complexities. In such regions, it can be challenging to accurately detect CNVs because the reads may not map reliably, leading to potential underrepresentation or depletion of CNVs in these areas. Therefore, CNVs may indeed be depleted in regions of low mappability due to technical limitations in detection rather than a true biological absence.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Can mitochondria be inherited by both parents in humans?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Mitochondria are typically inherited maternally in humans, meaning they are passed down from the mother to the offspring. The father's mitochondria are usually not transmitted to the child. However, there have been rare cases where paternal mitochondrial inheritance has been observed, but this is extremely uncommon. In general, mitochondrial DNA is considered to be maternally inherited.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Have machine learning methods been used to predict the severity of major depressive disorder(MDD)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Yes, machine learning methods have been used to predict the severity of major depressive disorder (MDD). Researchers have applied various ML techniques, including supervised learning models like support vector machines, random forests, and neural networks, to analyze clinical data, neuroimaging, and other biomarkers to predict MDD severity. These approaches aim to improve diagnosis, treatment personalization, and outcome prediction for individuals with depression.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there any association between suicide and autism in adolescents, yes or no?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether there is any association between suicide and autism in adolescents. I need to determine if there is a link or connection between autism and suicide among adolescents. I will research existing studies and findings to answer this question accurately.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does allele phasing improve the phylogenetic utility of ultraconserved elements?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Allele phasing refers to determining the haplotype of alleles, i.e., which alleles are present on each chromosome. Ultraconserved elements (UCEs) are highly conserved regions of the genome across species. Phylogenetic utility refers to the usefulness of genetic data in reconstructing evolutionary relationships. The question is whether allele phasing enhances the ability to use UCEs in phylogenetic analysis. UCEs are typically used because they are conserved and thus can be aligned across distant species. However, UCEs may have limited variation, which can make phylogenetic inference challenging. Allele phasing could potentially improve phylogenetic utility by resolving haplotypes, allowing for more accurate identification of polymorphisms within UCEs. This could increase the resolution of phylogenetic trees, especially in cases where haplotype information is critical for distinguishing closely related species or populations. However, since UCEs are ultraconserved, they may have minimal allelic variation, so the impact of phasing might be limited. The answer depends on whether the phasing of alleles in UCEs provides additional information that enhances phylogenetic resolution.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are ultraconserved enhancers important for normal development?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Ultraconserved enhancers are DNA sequences that are highly conserved across species and play a role in regulating gene expression during development. Studies have shown that these enhancers are often involved in critical developmental processes, such as patterning and differentiation. Disruption of ultraconserved enhancers can lead to developmental abnormalities, suggesting they are important for normal development.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Bobble head doll syndrome associated with hydrocephalus?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Bobble head doll syndrome is a rare neurological disorder characterized by abnormal head movements. It is typically associated with lesions in the third ventricle, such as cysts or tumors, which can lead to increased intracranial pressure. Hydrocephalus, on the other hand, involves the accumulation of cerebrospinal fluid in the brain's ventricles. While both conditions can involve increased intracranial pressure and may present with similar symptoms like head enlargement, Bobble head doll syndrome is not directly associated with hydrocephalus. The primary distinction lies in the underlying causes and specific symptoms of each condition.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is Tisagenlecleucel effective for B-Cell Lymphoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tisagenlecleucel is a CAR-T cell therapy approved for certain types of B-cell lymphomas. Clinical trials have shown it to be effective in treating relapsed or refractory large B-cell lymphoma. However, its effectiveness may vary based on individual patient factors and the specific type of lymphoma.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is durvalumab used for lung cancer treatment?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Durvalumab is a monoclonal antibody that targets the PD-L1 protein, which is involved in immune system regulation. It is used in the treatment of various cancers, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Specifically, durvalumab has been approved for use in patients with locally advanced or metastatic NSCLC who have not progressed after certain types of chemotherapy. Therefore, durvalumab is indeed used for lung cancer treatment.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does epidural anesthesia for pain management during labor affect the Apgar score of the the infant?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Epidural anesthesia is a common method for managing pain during labor. The Apgar score assesses a newborn's health immediately after birth. Some studies suggest that epidural anesthesia may lead to lower Apgar scores due to factors like fetal distress or complications from the procedure. However, other research indicates that any impact is minimal and not clinically significant. The relationship between epidural use and Apgar scores remains debated, but most evidence suggests no substantial effect.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) been reported to be a plasminogen receptor in pathogenic bacteria?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To answer this question, I need to determine whether Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) has been reported as a plasminogen receptor in pathogenic bacteria. First, I know that GAPDH is an enzyme involved in glycolysis and is often considered a housekeeping protein. However, some studies have shown that GAPDH can have additional functions outside of its enzymatic role, including roles in bacterial pathogenesis. Plasminogen receptors are proteins that bind plasminogen, a precursor to the protease plasmin, which can help pathogens invade host tissues by breaking down extracellular matrix components. If GAPDH has been found on the surface of pathogenic bacteria and shown to interact with plasminogen, then it could act as a plasminogen receptor. I recall that some bacterial surface proteins have been identified as plasminogen receptors, and GAPDH has been found on the surface of certain bacteria. Based on this information, it is plausible that GAPDH has been reported as a plasminogen receptor in pathogenic bacteria.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can exposure to heavy metals like lead(Pb) or cadmium(Cd) cause changes in DNA methylation patterns in Isoetes sinensis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether exposure to heavy metals like lead (Pb) or cadmium (Cd) can cause changes in DNA methylation patterns in Isoetes sinensis, a species of aquatic fern. DNA methylation is an epigenetic mechanism that can regulate gene expression without altering the DNA sequence, and it is known to be sensitive to environmental stressors. Heavy metals are environmental pollutants that can induce various types of stress in plants, including oxidative stress, which may lead to epigenetic changes. Isoetes sinensis, being a plant species, could potentially exhibit altered DNA methylation patterns in response to heavy metal exposure. Scientific studies have shown that heavy metals can affect DNA methylation in various plant species, although the specific effects may vary depending on the species, the metal involved, and the exposure conditions. Therefore, it is plausible that exposure to Pb or Cd could lead to changes in DNA methylation patterns in Isoetes sinensis.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "In clinical trials, the H3 R antagonist CEP-26401 has a positive effect on cognition, yes or no?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether the H3 R antagonist CEP-26401 has a positive effect on cognition in clinical trials. I need to check if there is evidence from clinical trials that CEP-26401 improves cognitive function. H3 receptors are involved in the regulation of histamine release, and antagonists may enhance cognitive performance by increasing histamine levels. I recall that CEP-26401 is a selective H3 receptor antagonist that has been studied for cognitive disorders. However, I need to verify if the clinical trials have shown positive results for cognition. I will check the available data on CEP-26401 clinical trials. Based on my knowledge, CEP-26401 has been investigated in early-phase trials for conditions like ADHD and cognitive impairment, but the results may not have been conclusive or positive across all studies. Some trials might have shown improvements in certain cognitive domains, while others might have failed to demonstrate significant benefits. Without specific data on the outcomes of these trials, it is difficult to confirm a definitive positive effect. Therefore, the answer is likely no, unless there is evidence I am not aware of.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Have yeast prions become important models for the study of the basic mechanisms underlying human amyloid diseases?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Yeast prions are used as models for studying human amyloid diseases because they share similar mechanisms of protein misfolding and aggregation. Research on yeast prions can provide insights into the processes involved in diseases like Alzheimer's and Parkinson's, making them important for understanding the basic mechanisms of these conditions.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there a link between BCL11B haploinsufficiency and syndromic neurodevelopmental delay?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"BCL11B haploinsufficiency is a genetic condition where one copy of the BCL11B gene is missing or nonfunctional. Research has shown that this condition can lead to various developmental issues, including neurodevelopmental delays. Syndromic neurodevelopmental delay refers to delays in neurological development that are part of a broader syndrome. Studies and clinical cases have indicated that individuals with BCL11B haploinsufficiency often exhibit symptoms consistent with syndromic neurodevelopmental delay, such as intellectual disability, speech and motor delays, and other neurological abnormalities. Therefore, there is evidence supporting a link between BCL11B haploinsufficiency and syndromic neurodevelopmental delay.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is the PINES framework being used for the prediction of coding variants?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether the PINES framework is being used for predicting coding variants. I need to check if PINES is related to this application. PINES stands for Pathogenicity Inference using Neural networks and Evolutionary features in Splicing. It is a computational tool designed to predict the pathogenicity of genetic variants, particularly focusing on splicing variants. Coding variants refer to changes in DNA that alter the protein-coding sequence, which can lead to different amino acids being incorporated into proteins, potentially causing diseases. While PINES is focused on splicing, the question is about coding variants. Since splicing and coding are different aspects of gene function, and PINES is specifically designed for splicing variants, it is unlikely that PINES is used for predicting coding variants. Therefore, the answer should be no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Tecovirimat effective for smallpox?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tecovirimat is an antiviral drug developed for the treatment of smallpox. It works by inhibiting the viral protein responsible for the spread of the virus in the body. Clinical studies have shown that Tecovirimat is effective in treating smallpox infections. Therefore, Tecovirimat is effective for smallpox.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is cabozantinib effective for hepatocellular carcinoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Cabozantinib is a tyrosine kinase inhibitor that targets multiple receptors, including MET, VEGFR, and AXL, which are involved in tumor growth and angiogenesis. Clinical trials, such as the CELESTIAL trial, have shown that cabozantinib improves overall survival in patients with advanced hepatocellular carcinoma (HCC) who have previously been treated with sorafenib. Based on these findings, cabozantinib is considered effective for HCC in certain treatment settings.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Baloxavir effective for influenza?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Baloxavir marboxil (Xofluza) is an antiviral medication used for the treatment of influenza. It works by inhibiting the cap-dependent endonuclease activity of the influenza virus polymerase, which is essential for viral replication. Clinical trials have shown that Baloxavir can reduce the duration of flu symptoms and viral shedding compared to placebo. It is generally effective against both influenza A and B viruses. However, its effectiveness may vary depending on the specific strain and the patient's health status. Therefore, Baloxavir is considered effective for treating influenza, particularly when administered early in the course of the illness.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is ibudilast effective for multiple sclerosis?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Ibudilast is a medication that has been studied for its potential use in multiple sclerosis (MS). It works as a phosphodiesterase inhibitor and has anti-inflammatory properties. Some research suggests that it may help reduce inflammation and neurodegeneration in MS patients. However, the evidence is not yet conclusive, and more studies are needed to determine its effectiveness. Regulatory agencies have not universally approved it for MS treatment. Therefore, while there is some promising evidence, it cannot be definitively stated that ibudilast is effective for multiple sclerosis at this time.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is Adar3 involved in learning and memory?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Adar3 is a protein that is part of the ADAR family, which is involved in RNA editing. ADAR proteins are primarily known for their role in converting adenosine to inosine in RNA molecules, a process that can affect protein function and gene expression. While ADAR1 and ADAR2 have been more extensively studied and are known to play roles in various cellular processes, including those related to the nervous system, the specific involvement of ADAR3 in learning and memory is less clear. Some research suggests that ADAR3 may have a regulatory role in the brain, but direct evidence linking it to learning and memory processes is limited. Therefore, while Adar3 is present in the brain and may have some regulatory functions, there is currently insufficient evidence to definitively state that it is directly involved in learning and memory.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is deletion at 6q24.2-26 associated with longer survival of patients with high-grade serous ovarian carcinoma (HGSOCs)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Deletion at 6q24.2-26 is associated with longer survival of patients with high-grade serous ovarian carcinoma (HGSOCs).\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is  LRP1 interacting with Urokinase receptor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1) is known to interact with various ligands and receptors, playing a role in multiple cellular processes including endocytosis and signal transduction. The Urokinase receptor (uPAR) is involved in plasminogen activation and is associated with cell surface proteolysis, cell adhesion, and migration. There is evidence in the scientific literature that LRP1 can interact with uPAR, particularly in the context of regulating proteolytic systems and cell migration. For example, studies have shown that LRP1 can modulate uPAR expression and function, and that the two proteins can co-localize in certain cellular contexts.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is chlorotoxin a peptide?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Chlorotoxin is a toxin found in scorpion venom. It is known to target chloride channels. To determine if it is a peptide, we need to check its molecular structure. Peptides are short chains of amino acids. Scientific literature indicates that chlorotoxin consists of a chain of amino acids, which classifies it as a peptide.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is selenocysteine an aminoacid?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Selenocysteine is a naturally occurring amino acid that contains selenium. It is found in some proteins, where it functions as a catalytic center in certain enzymes. Therefore, selenocysteine is indeed an amino acid.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is phospholipid hydroperoxide glutathione peroxidase a selenoprotein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Phospholipid hydroperoxide glutathione peroxidase (PHGPx) is an enzyme that reduces hydroperoxides in cell membranes. Selenoproteins contain the amino acid selenocysteine. Glutathione peroxidases are known to be selenoproteins because they utilize selenocysteine in their active site. Since PHGPx is a type of glutathione peroxidase, it should also be a selenoprotein.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is P. gingivalis bacteria found in brain?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"P. gingivalis is a bacteria commonly associated with periodontal disease. Recent studies have suggested that it may be involved in the development of Alzheimer's disease by entering the brain through the bloodstream or nerves. However, its presence in the brain is not well established and more research is needed to confirm this link.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "There is no drug available to prevent HIV infection, Pre-exposure prophylaxis (PrEP), yes or no?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking if there is no drug available to prevent HIV infection through Pre-exposure prophylaxis (PrEP). I know that PrEP is a method where people at high risk of HIV take medication to reduce their chances of getting the infection. Drugs like Truvada and Descovy are approved for PrEP. Since these drugs exist, the statement that there is no drug available for PrEP is false.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is cariprazine effective for treatment of bipolar disorder?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Cariprazine is an atypical antipsychotic medication. It is approved by the FDA for the treatment of schizophrenia and bipolar I disorder, specifically for manic or mixed episodes. Studies have shown that cariprazine can help reduce symptoms of mania and may also have efficacy in treating depressive episodes associated with bipolar disorder. However, its effectiveness can vary among individuals, and it is often used as part of a comprehensive treatment plan that includes therapy and other medications.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does Groucho related gene 5 (GRG5) have a role only in late development?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To answer this question, I need to determine if Groucho related gene 5 (GRG5) has a role only in late development. First, I will search for information on GRG5 and its known functions in development. If studies show that GRG5 is involved in early development or has roles in both early and late development, then the answer is no. If GRG5 is only involved in late development, then the answer is yes.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is the yeast (Saccharomyces cerevisiae) genome organized into topologically associated domains (TADs)?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Topologically associated domains (TADs) are regions of the genome that interact more frequently within themselves than with other regions, and they are commonly found in higher eukaryotes. Yeast, such as Saccharomyces cerevisiae, has a simpler genome structure compared to mammals. Studies have shown that yeast does not have TADs like those observed in mammals. Instead, yeast chromatin organization is characterized by different features, such as chromosomal territories and loop structures formed by specific protein bindings.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there any role for HUWE1 in MYC signalling?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"HUWE1 is an E3 ubiquitin ligase that has been implicated in various cellular processes, including DNA repair, cell cycle regulation, and apoptosis. MYC is a transcription factor that plays a central role in cell proliferation, growth, and metabolism. Dysregulation of MYC is associated with many cancers. The question is whether HUWE1 has any role in MYC signaling. Literature suggests that HUWE1 can ubiquitinate and target certain proteins for degradation. For instance, HUWE1 has been shown to regulate the stability of MIZ1, a protein that interacts with MYC. By modulating MIZ1 levels, HUWE1 may indirectly influence MYC signaling. Additionally, HUWE1 may affect MYC through its role in ribosome biogenesis and protein synthesis, which are processes closely linked to MYC activity. However, direct evidence of HUWE1 regulating MYC itself or key components of the MYC pathway is limited. Therefore, while there may be indirect connections, a clear and direct role for HUWE1 in MYC signaling has not been firmly established.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is TIAM1 favoring tumor progression in colorectal cancer (CRC)?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"TIAM1 is a guanine nucleotide exchange factor that activates Rac1, which is involved in cell migration and invasion. In colorectal cancer, the role of TIAM1 appears to be context-dependent. Some studies suggest that TIAM1 may suppress tumor progression by promoting cell-cell adhesion and maintaining epithelial integrity. However, other research indicates that TIAM1 can enhance tumor cell migration and invasion through Rac1 activation, thus favoring tumor progression. The discrepancy might be due to differences in tumor stage, microenvironment, or genetic background. Therefore, while TIAM1 has been implicated in promoting tumor progression in certain contexts, its exact role in CRC remains complex and not entirely clear.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Are de novo mutations in regulatory elements responsible for neurodevelopmental disorders?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"De novo mutations in regulatory elements have been implicated in neurodevelopmental disorders, but their exact role and responsibility are still under investigation. While some studies suggest they contribute to the development of these disorders, more research is needed to confirm their direct involvement and significance.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are recessive coding variants responsible for the majority of undiagnosed nonconsanguineous individuals?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question asks whether recessive coding variants are responsible for the majority of undiagnosed cases in nonconsanguineous individuals. Nonconsanguineous individuals are those whose parents are not closely related, which typically reduces the likelihood of inheriting two copies of a recessive variant. In consanguineous relationships (e.g., first cousins), the risk of autosomal recessive diseases is higher because the probability of inheriting identical recessive alleles from both parents increases. In nonconsanguineous populations, the frequency of such homozygous recessive variants is generally lower. However, some studies suggest that recessive coding variants may still contribute to certain undiagnosed cases, particularly in complex or rare disorders. The \\\"majority\\\" aspect of the question is keyâ€”while recessive variants may play a role in some cases, they are unlikely to account for the majority of undiagnosed individuals in nonconsanguineous populations, as other factors such as de novo mutations, polygenic influences, and environmental factors are also significant contributors. Therefore, the answer is likely no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is the NLM medical text indexer (MTI) still useful and relevant?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The NLM medical text indexer (MTI) is a tool developed by the National Library of Medicine (NLM) to assist in the indexing of biomedical literature. It uses a combination of natural language processing and machine learning techniques to suggest Medical Subject Headings (MeSH) terms for articles. Despite advances in AI and machine learning, MTI remains relevant because it is specifically tailored for biomedical content and is continuously updated to reflect changes in terminology and knowledge. It is widely used in the curation of databases like PubMed, which are critical resources for researchers and healthcare professionals. Therefore, MTI continues to be a valuable tool in the biomedical domain.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is cohesin linked to myeloid differentiation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Cohesin is a protein complex involved in sister chromatid cohesion, DNA repair, and gene regulation. Recent studies have suggested that cohesin plays a role in hematopoiesis, particularly in the regulation of gene expression during blood cell development. Myeloid differentiation refers to the process by which hematopoietic stem cells develop into myeloid lineage cells, such as granulocytes, monocytes, and platelets. Mutations in cohesin subunits have been associated with myeloid malignancies, such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), indicating that cohesin dysfunction may contribute to impaired myeloid differentiation. Therefore, cohesin is linked to myeloid differentiation through its role in regulating gene expression and maintaining genomic stability during hematopoiesis.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is erythropoietin effective for treatment of amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Erythropoietin (EPO) is a hormone that stimulates red blood cell production and is primarily used to treat anemia. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motor neurons. While some studies have explored EPO's neuroprotective properties, there is no conclusive evidence that EPO is effective in treating ALS. Clinical trials have not demonstrated significant benefits in slowing disease progression or improving outcomes for ALS patients. Therefore, EPO is not considered a standard or effective treatment for ALS.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can mogamulizumab be used for the treatment of cutaneous T-cell lymphoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Mogamulizumab is a monoclonal antibody targeting CCR4, which is expressed on certain T-cells. It has been approved for the treatment of adult T-cell leukemia/lymphoma and cutaneous T-cell lymphoma in some countries. Clinical trials have shown its efficacy in treating CTCL, particularly in patients who have relapsed or are refractory to other treatments. Therefore, mogamulizumab can be used for the treatment of cutaneous T-cell lymphoma.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has ivosidenib been FDA approved for use against acute myeloid leukemia?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"I need to check if ivosidenib has received FDA approval for treating acute myeloid leukemia. Ivosidenib is a medication that targets IDH1 mutations. I recall that it has been approved for certain cancers, but I need to confirm the specific indication. Clinical trials and FDA announcements would provide the necessary information. I will verify the approval status and indication for ivosidenib.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can CPX-351 be used for the treatment of tuberculosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"CPX-351 is a liposomal formulation of cytarabine and daunorubicin, which are chemotherapy drugs. It is primarily used in the treatment of acute myeloid leukemia (AML). Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis and is typically treated with antibiotics such as isoniazid, rifampin, ethambutol, and pyrazinamide. Since CPX-351 is not an antibiotic and is designed for cancer treatment, it is not indicated for tuberculosis. Therefore, CPX-351 should not be used for treating tuberculosis.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does lucatumumab bind to CD140?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine whether lucatumumab binds to CD140, I need to analyze the molecular interactions between lucatumumab and CD140. Lucatumumab is a monoclonal antibody, and monoclonal antibodies typically bind to specific antigens. CD140 is a cell surface marker that is expressed on certain cells, such as platelets and endothelial cells. To determine whether lucatumumab binds to CD140, I would need to consult the scientific literature or other reliable sources to see if there is any evidence of a binding interaction between lucatumumab and CD140. If there is no evidence of a binding interaction, then the answer would be no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is lucatumumab a polyclonal antibody?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Lucatumumab is a monoclonal antibody, not a polyclonal antibody. It is specifically designed to target a particular antigen, which is typical of monoclonal antibodies. Polyclonal antibodies are mixtures of different antibodies that recognize multiple epitopes, whereas monoclonal antibodies like lucatumumab are uniform and target a single epitope.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can midostaurin inhibit angiogenesis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Midostaurin is a drug that has been studied for its effects on various cancers. It is known to inhibit certain enzymes like protein kinase C and has been used in the treatment of acute myeloid leukemia (AML) and other conditions. Angiogenesis refers to the formation of new blood vessels, which is a process that can be important in cancer growth and progression. Some drugs that inhibit angiogenesis are used in cancer therapy to prevent the development of blood vessels that supply tumors. Research on midostaurin has indicated that it may have anti-angiogenic properties, meaning it could potentially inhibit angiogenesis. This effect would be beneficial in slowing down tumor growth by limiting the blood supply to cancer cells.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can enasidenib be used for the treatment of acute myeloid leukemia?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Enasidenib is a medication used for the treatment of acute myeloid leukemia (AML) that has a specific mutation in the IDH2 gene. It works by inhibiting the mutated IDH2 enzyme, which helps to promote the differentiation of leukemic blasts into mature cells. Therefore, enasidenib can be used for the treatment of AML with IDH2 mutations.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is lithium effective for treatment of amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Lithium is a medication primarily used to treat bipolar disorder. Some studies have explored its potential neuroprotective effects in various neurological conditions, including amyotrophic lateral sclerosis (ALS). However, the evidence regarding its effectiveness for ALS is limited and inconclusive. While a few small studies or case reports might suggest possible benefits, larger, well-conducted clinical trials have not consistently demonstrated that lithium is effective in slowing the progression of ALS. As such, lithium is not considered a standard or recommended treatment for ALS.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is celecoxib effective for treatment of amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) primarily used to treat pain and inflammation, such as in arthritis. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with no known cure, and its treatment focuses on slowing progression and managing symptoms. While inflammation may play a role in ALS, there is limited evidence that celecoxib specifically is effective for treating ALS. Clinical trials have not demonstrated significant benefits of celecoxib in ALS patients.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is pacritinib effective for treatment of myelofibrosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Pacritinib is a kinase inhibitor that has been studied for the treatment of myelofibrosis, a type of bone marrow cancer. Clinical trials have shown that pacritinib can reduce spleen size and improve symptoms in patients with myelofibrosis, particularly those with certain genetic mutations like JAK2 V617F. However, its effectiveness can vary based on individual patient factors and disease characteristics. Regulatory approvals and guidelines may also influence its use in clinical practice.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do raspberries improve postprandial glucose and acute and chronic inflammation in adults with type 2 Diabetes?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Raspberries are rich in polyphenols and fiber, which may have anti-inflammatory properties and help regulate blood sugar levels. Some studies suggest that polyphenol-rich foods can improve insulin sensitivity and reduce inflammation markers. However, specific evidence on raspberries' effects on postprandial glucose and inflammation in type 2 diabetes is limited and requires further research.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Has Hesperidin any role as a Neuroprotective Agent?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Hesperidin is a flavonoid found in citrus fruits. Research suggests that it has antioxidant, anti-inflammatory, and neuroprotective properties. Studies have indicated that hesperidin may help protect neurons from damage, potentially benefiting conditions like Alzheimer's disease and other neurodegenerative disorders. However, more research is needed to fully understand its efficacy and mechanisms in humans.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there tools for visualizing and processing long-read sequencing data?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Yes, there are several tools available for visualizing and processing long-read sequencing data. Examples include tools like IGV (Integrative Genomics Viewer), which supports visualization of long-read data, and software like Minimap2, which is used for alignment of long-read sequences. Other tools such as Pilon and Canu are used for assembly and error correction of long-read data. These tools help researchers analyze the complex datasets generated by long-read sequencing technologies.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there a deep-learning algorithm for protein solubility prediction?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Deep learning algorithms have been applied to various biological problems, including protein structure prediction. For protein solubility prediction specifically, there are methods that use machine learning models. However, the question is whether a deep learning approach exists. Given the trend towards using deep learning in bioinformatics, it is likely that such algorithms have been developed.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is cabozantinib effective for Hepatocellular Carcinoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Cabozantinib is a tyrosine kinase inhibitor that targets multiple receptors, including MET, VEGFR, and AXL, which are involved in tumor growth and angiogenesis. It has been studied in clinical trials for hepatocellular carcinoma (HCC), particularly in patients who have progressed on prior therapies like sorafenib. The CELESTIAL trial demonstrated that cabozantinib improved overall survival compared to placebo in patients with advanced HCC who had previously received sorafenib. Based on these results, regulatory agencies such as the FDA approved cabozantinib for the treatment of HCC in specific patient populations. Therefore, cabozantinib is considered effective for certain cases of hepatocellular carcinoma.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is dupilumab effective for treatment of asthma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Dupilumab is a monoclonal antibody that targets the interleukin-4 receptor alpha subunit, which is involved in the inflammatory response in asthma. Clinical trials have shown that dupilumab can improve lung function and reduce exacerbations in patients with moderate to severe asthma, particularly those with an eosinophilic phenotype. It is approved by the FDA as an add-on maintenance therapy for patients aged 12 years and older with moderate to severe asthma. Therefore, dupilumab is considered effective for the treatment of asthma in specific patient populations.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is verubecestat effective for Alzheimerâ€™s Disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Verubecestat is a drug that has been studied for the treatment of Alzheimer's disease. It works by inhibiting the production of beta-amyloid, a protein that forms plaques in the brains of Alzheimer's patients. Clinical trials have shown mixed results regarding its effectiveness. Some studies indicated that it could reduce amyloid plaques, but others found that it did not significantly improve cognitive symptoms or slow disease progression. In some cases, there were concerns about potential side effects. Overall, the evidence suggests that verubecestat may not be highly effective in treating Alzheimer's disease, particularly in terms of clinical outcomes.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does Eucommia ulmoides leaf extract ameliorates steatosis/fatty liver induced by high-fat diet?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Eucommia ulmoides, also known as hardy rubber tree, is a traditional Chinese medicine used for various health purposes. Some studies suggest that its leaf extract may have anti-inflammatory and antioxidant properties. Research on animals indicates that Eucommia ulmoides leaf extract might help reduce fat accumulation in the liver caused by a high-fat diet. However, the evidence is not yet conclusive, and more research is needed to confirm its effectiveness in humans.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there ultraconserved regions in the budding yeast (Saccharomyces cerevisiae)?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Ultraconserved regions are DNA sequences that are highly conserved across different species, often indicating functional importance. These regions are typically identified through comparative genomics. In the case of budding yeast (Saccharomyces cerevisiae), it is necessary to check if such regions have been identified within its genome or within closely related yeast species. Research on yeast genomes may reveal whether these ultraconserved elements exist in yeast, similar to those found in higher organisms like mammals.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are there graph kernel libraries available implemented in JAVA?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"I know that there are several graph kernel libraries available, but I'm not sure if any of them are implemented in Java. I recall that some popular graph kernel libraries are written in Python or C++. However, there might be some Java-based libraries available as well. I should check if any of the well-known graph kernel libraries are implemented in Java.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Can you computationally predict Molecular Recognition Features (MoRFs) regions in Intrinsically Disordered Proteins (IDPs)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking if I can computationally predict Molecular Recognition Features (MoRFs) regions in Intrinsically Disordered Proteins (IDPs). MoRFs are regions in IDPs that undergo disorder-to-order transitions upon binding to their partners. Computational prediction of MoRFs is possible using various bioinformatics tools and algorithms that analyze protein sequences and structural features. Several methods have been developed for this purpose, such as MoRFpred, ANCHOR, and others. These tools use machine learning models and sequence-based features to identify potential MoRF regions. Therefore, the answer to the question is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there tools for reviewing variant calls?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking if there are tools available for reviewing variant calls. Variant calls refer to the identification of genetic variations in DNA sequencing data. There are several bioinformatics tools designed specifically for analyzing and reviewing these variant calls to ensure accuracy and reliability. Examples include tools like IGV (Integrative Genomics Viewer), VarScan, and GATK (Genome Analysis Toolkit). These tools help researchers visualize and validate the variants detected in sequencing data. Therefore, the answer to the question is affirmative.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is baricitinib effective for rheumatoid arthritis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Baricitinib is a Janus kinase (JAK) inhibitor that is used to treat rheumatoid arthritis. It works by blocking certain enzymes involved in the inflammatory process. Clinical trials have shown that baricitinib can reduce symptoms and improve physical function in patients with rheumatoid arthritis. Therefore, baricitinib is considered effective for treating rheumatoid arthritis.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is galcanezumab effective for treatment of migraine?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Galcanezumab is a monoclonal antibody targeting calcitonin gene-related peptide (CGRP), which is involved in migraine pathophysiology. Clinical trials have shown that galcanezumab can reduce the frequency of migraine attacks in patients with episodic and chronic migraine. It is approved by the FDA for the preventive treatment of migraine in adults. Therefore, it is effective for the treatment of migraine.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Lasmiditan effective for migraine?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Lasmiditan is a medication used for the acute treatment of migraine. It belongs to a class of drugs known as serotonin (5-HT) 1F receptor agonists. Studies have shown that Lasmiditan can be effective in relieving migraine symptoms, including pain and associated symptoms like nausea and sensitivity to light and sound. It is specifically indicated for the treatment of migraine with or without aura. However, its effectiveness can vary from person to person, and it may not work for everyone. It is important to consult a healthcare provider to determine if Lasmiditan is an appropriate treatment option.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is pimavanserin effective for Parkinson's disease psychosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Pimavanserin is a medication primarily used to treat Parkinson's disease psychosis. It works by targeting specific receptors in the brain to reduce hallucinations and delusions associated with the condition. Clinical trials have shown that pimavanserin can significantly improve symptoms in patients with Parkinson's disease psychosis. Therefore, it is considered effective for this condition.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does an interferon (IFN) signature exist for SLE patients?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether there is an interferon (IFN) signature associated with SLE (Systemic Lupus Erythematosus) patients. SLE is an autoimmune disease, and in the context of immunology and autoimmune disorders, the presence of an IFN signature refers to the overexpression of interferon-regulated genes in patients. Interferons, particularly type I interferons like IFN-alpha and IFN-beta, play a significant role in the immune response and have been implicated in the pathogenesis of several autoimmune diseases, including SLE. Research studies have shown that many SLE patients exhibit an IFN signature, characterized by elevated levels of IFN and IFN-stimulated genes in their blood or affected tissues. This signature is associated with disease activity and severity in some cases. Therefore, based on the existing body of research, an IFN signature does exist for SLE patients.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can Diazepam be beneficial  in the treatment of  traumatic brain injury?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Diazepam is a benzodiazepine medication primarily used to treat anxiety, muscle spasms, and seizures. In the context of traumatic brain injury (TBI), diazepam may be used to manage specific symptoms such as agitation, anxiety, or seizures that can occur following a TBI. However, its direct role in the treatment of the injury itself is limited. While diazepam can help alleviate certain complications associated with TBI, it is not considered a primary treatment for the injury. Therefore, while it may provide symptomatic relief, it is not typically regarded as beneficial in the direct treatment of traumatic brain injury.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are genes that escape X-chromosome inactivation related to mental impairment?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"X-chromosome inactivation (XCI) is a process in which one of the two X chromosomes in females is randomly inactivated to balance gene dosage between males and females. However, some genes on the X chromosome can escape this inactivation, meaning they remain active on both X chromosomes. The question is whether these genes that escape XCI are related to mental impairment. Research has shown that some genes escaping XCI are involved in cognitive functions and neurodevelopment. For example, genes like KDM5C and KDM6A have been associated with intellectual disabilities when mutated. Additionally, variations in the expression of these genes might contribute to the phenotypic variability observed in individuals with X-linked disorders. However, the relationship is not fully understood, and more research is needed to determine the exact role these genes play in mental impairment. Therefore, while there is some evidence suggesting a connection, it is not yet conclusive.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "As of Feb 2019, are major brain gangliosides a target for the treatment of Alzheimer's disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Major brain gangliosides are a target for the treatment of Alzheimer's disease. As of February 2019, research has shown that targeting gangliosides can potentially affect the progression of Alzheimer's by influencing amyloid-beta aggregation and neuroinflammation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is pazopanib an effective treatment of glioblastoma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Pazopanib is a tyrosine kinase inhibitor that is primarily used to treat advanced renal cell carcinoma and soft tissue sarcoma. While it has shown efficacy in these indications, its role in the treatment of glioblastoma is less clear. Clinical trials evaluating pazopanib for glioblastoma have produced mixed results, with some studies suggesting limited efficacy or no significant benefit in overall survival. Therefore, it is not currently considered a standard or highly effective treatment option for glioblastoma.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is avelumab effective for bladder cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Avelumab is a PD-L1 inhibitor that has been approved for the treatment of advanced bladder cancer. It works by blocking the interaction between PD-L1 and PD-1, which helps the immune system recognize and attack cancer cells. Clinical trials have shown that avelumab can be effective in some patients with bladder cancer, particularly those who have disease progression after platinum-based chemotherapy. However, its effectiveness can vary among individuals, and it may not work for everyone.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can pazopanib be used for treatment von Hippel-Lindau disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Pazopanib is a tyrosine kinase inhibitor that is primarily used for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. Von Hippel-Lindau (VHL) disease is a genetic disorder characterized by the development of various tumors, including hemangioblastomas, renal cell carcinomas, and pheochromocytomas. While there is no cure for VHL disease, management typically involves surveillance and treatment of individual tumors as they arise. Although pazopanib is not specifically approved for VHL disease, it may be used off-label in certain cases, particularly for treating renal cell carcinomas associated with VHL. However, its use would depend on the clinical context and the discretion of the treating physician.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Miller-Dieker syndrome associated with abnormalities of chromosome 1?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Miller-Dieker syndrome is a genetic disorder characterized by lissencephaly (smooth brain) and other developmental issues. It is caused by a deletion of genetic material on the short arm of chromosome 17 (17p13.3), not chromosome 1. This deletion affects the LIS1 gene, which is crucial for brain development. Therefore, the syndrome is linked to chromosome 17 abnormalities, not chromosome 1.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should dacomitinib be used for treatment of glioblastoma patients?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Dacomitinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor that is approved for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Glioblastoma is a type of aggressive brain tumor that often has different molecular characteristics compared to NSCLC. The use of dacomitinib for glioblastoma would depend on whether the tumor exhibits specific genetic mutations that make it susceptible to ErbB inhibition. Clinical trials or studies evaluating the efficacy of dacomitinib in glioblastoma would be necessary to determine its appropriateness. As of now, standard treatments for glioblastoma include surgery, radiation, and chemotherapy, often with temozolomide. Unless there is specific evidence or guidelines supporting its use in glioblastoma, dacomitinib is not typically indicated for this condition.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is inositol effective for trichotillomania?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Inositol is a naturally occurring compound that has been studied for its potential effects on various mental health conditions, including anxiety and depression. Some research suggests it may have benefits for obsessive-compulsive disorder (OCD), which shares similarities with trichotillomania. However, there is limited direct evidence specifically examining inositol's effectiveness for trichotillomania. While it may show promise due to its role in neurotransmitter function, more targeted studies are needed to confirm its efficacy for this specific condition.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is eculizumab used for treatment of myasthenia gravis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Eculizumab is a monoclonal antibody that targets complement protein C5, inhibiting the terminal complement cascade. It is primarily used in conditions where complement-mediated damage is implicated, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Myasthenia gravis (MG) is an autoimmune disorder characterized by weakness of skeletal muscles due to antibodies against the acetylcholine receptor or other related proteins. Treatment typically involves immunosuppressive agents, acetylcholinesterase inhibitors, and sometimes thymectomy. While eculizumab has been studied in refractory cases of MG, particularly in those with generalized disease unresponsive to conventional therapies, it is not a first-line treatment. However, in specific cases, especially those involving complement pathway activation, eculizumab may be considered. Therefore, eculizumab can be used in certain situations for the treatment of myasthenia gravis.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Semagacestat effective for treatment of Alzheimer's disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Semagacestat is a gamma-secretase inhibitor that was investigated for the treatment of Alzheimer's disease. However, clinical trials showed that it did not provide significant benefits in slowing cognitive decline and had adverse effects, leading to the discontinuation of its development for this indication.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does simvastatin improve outcomes of aneurysmal subarachnoid hemorrhage?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Simvastatin is a statin drug used to lower cholesterol levels. Some studies have suggested that statins may have neuroprotective effects and could potentially improve outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). However, the evidence is not entirely consistent. While some observational studies and meta-analyses have indicated possible benefits, such as reduced mortality or improved neurological outcomes, randomized controlled trials (RCTs) have not consistently confirmed these findings. For example, the STASH trial did not show a significant benefit of simvastatin in improving outcomes after aSAH. Therefore, the current evidence does not definitively support the use of simvastatin for improving outcomes in aSAH.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does tremelimumab improve survival of mesothelioma patients?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tremelimumab is a monoclonal antibody that targets the CTLA-4 protein, which is involved in regulating the immune system. It has been studied in the context of various cancers, including mesothelioma. Mesothelioma is a rare and aggressive cancer, often linked to asbestos exposure. The effectiveness of tremelimumab in improving survival for mesothelioma patients would depend on clinical trial results. As of the latest available data, tremelimumab has shown some promise in combination with other therapies, such as durvalumab (an anti-PD-L1 antibody), in certain subsets of mesothelioma patients. However, its overall efficacy as a single agent or in combination may vary, and regulatory approvals or standard treatment guidelines would reflect the current evidence. To determine whether tremelimumab improves survival, one would need to refer to phase III clinical trials and peer-reviewed publications that assess overall survival metrics in treated patients compared to control groups.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Axitinib is a tyrosine kinase inhibitor primarily used in the treatment of renal cell carcinoma. Its efficacy in pancreatic cancer has not been established through major clinical trials. Pancreatic cancer treatments typically involve other chemotherapeutic agents or targeted therapies. Therefore, there is no substantial evidence to confirm that Axitinib prolongs survival in pancreatic cancer patients.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does Panitumumab prolong survival of biliary tract cancer patients?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Panitumumab is a monoclonal antibody targeting EGFR, used in some cancers. Biliary tract cancer (BTC) includes cholangiocarcinoma and gallbladder cancer. Current standard treatments for advanced BTC are chemotherapy (e.g., gemcitabine plus cisplatin). Studies on EGFR inhibitors in BTC show mixed results. Some trials suggest possible benefit in specific subgroups (e.g., KRAS wild-type), but overall survival benefit not clearly established. Panitumumab is not currently approved for BTC, and guidelines do not recommend it as standard. Therefore, evidence does not confirm survival prolongation in general BTC patients.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is the enzyme ERAP2 associated with the disease birdshot chorioretinopathy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To determine if the enzyme ERAP2 is associated with birdshot chorioretinopathy, I need to check if there is scientific evidence linking ERAP2 to this specific disease. Birdshot chorioretinopathy is a rare autoimmune eye disorder. ERAP2 (Endoplasmic Reticulum Aminopeptidase 2) is involved in antigen processing and has been linked to other autoimmune diseases, such as ankylosing spondylitis and BehÃ§et's disease. Research on ERAP2's role in birdshot chorioretinopathy specifically needs to be reviewed. Studies or databases connecting ERAP2 to this condition would confirm the association.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is ADP-ribosylation a PTM?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"ADP-ribosylation is a post-translational modification (PTM) that involves the addition of ADP-ribose units to proteins. This modification can affect protein function, localization, and interactions. It is commonly observed in cellular processes such as DNA repair and signal transduction.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is collagen the most abundant human protein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Collagen is a structural protein found in connective tissues, skin, bones, and tendons. It provides strength and elasticity to these tissues. According to various biological sources, collagen is indeed the most abundant protein in the human body, making up about 25% to 35% of the total protein content. It is a major component of the extracellular matrix and plays a crucial role in maintaining the structural integrity of many tissues. Therefore, the statement that collagen is the most abundant human protein is accurate.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Mesenchymal stem cells (MSC) multipotent cells?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Mesenchymal stem cells (MSCs) are known for their ability to differentiate into a variety of cell types, such as osteoblasts, chondrocytes, and adipocytes. This characteristic indicates that they are multipotent, as they can give rise to multiple specialized cell types within a particular lineage.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is TIM-3 a target for cancer immunotherapy in NSCLC?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) is an immune checkpoint receptor expressed on various immune cells, including T cells, and has been implicated in immune evasion by tumors. In non-small cell lung cancer (NSCLC), research has explored its role as a potential target for immunotherapy. Studies have indicated that TIM-3 can contribute to T cell exhaustion and suppression of anti-tumor responses. Targeting TIM-3 with blocking antibodies or other inhibitors has shown promise in preclinical models, suggesting that it could be a viable target for cancer immunotherapy in NSCLC. However, clinical trials are ongoing to determine its efficacy and safety in patients.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are phagosomal proteins ubiquitinated?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Phagosomal proteins can be ubiquitinated. Ubiquitination is a post-translational modification that can target proteins for degradation via the proteasome. In the context of phagosomes, ubiquitination may play a role in the regulation of phagosomal maturation and antigen presentation. However, the extent and specific functions of ubiquitination on phagosomal proteins may vary depending on the cell type and the specific phagosomal cargo.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there any approved treatment for NAFLD?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Non-alcoholic fatty liver disease (NAFLD) is a condition characterized by excess fat accumulation in the liver. The primary approach to managing NAFLD involves lifestyle modifications such as weight loss, dietary changes, and increased physical activity. However, there are some pharmacological treatments that have been studied and approved for specific cases. For example, vitamin E and pioglitazone have shown some efficacy in improving liver health in certain patients with NAFLD, particularly those with non-alcoholic steatohepatitis (NASH). Additionally, in some regions, other medications may be approved for the treatment of NAFLD or its complications. Therefore, while lifestyle changes remain the cornerstone of NAFLD management, there are some approved treatments available for specific scenarios.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Are tumour specific antigens originating from known protein coding genes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tumour-specific antigens (TSAs) are antigens that are uniquely expressed by tumor cells and not by normal cells. These antigens can originate from various sources, including mutations in protein-coding genes, which lead to the production of abnormal proteins. These abnormal proteins are then processed and presented as antigens by the tumor cells. Therefore, TSAs can indeed originate from known protein-coding genes that have undergone mutations.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is treatment with Bacillus Calmette Guerin used for bladder cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Bacillus Calmette-GuÃ©rin (BCG) is a vaccine derived from a weakened strain of Mycobacterium bovis. It is commonly used as an immunotherapy for certain types of bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). BCG works by stimulating the immune system to attack cancer cells in the bladder. It is typically administered directly into the bladder through a catheter. Given this information, BCG is indeed used in the treatment of bladder cancer.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does Rhamnose have any effect on aging?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Rhamnose is a natural sugar that has been studied for various health effects. Some research suggests it may have anti-aging properties by influencing cellular processes, such as promoting collagen production or acting as an antioxidant. However, evidence is limited and more studies are needed to confirm its direct impact on aging in humans.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are apoE mimetics being considered as a treatment against Alzheimer's disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"ApoE mimetics are being studied for their potential role in treating Alzheimer's disease. Research suggests that these compounds may help reduce amyloid-beta accumulation and neuroinflammation, which are key features of Alzheimer's pathology. Clinical trials are ongoing to evaluate their safety and efficacy.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is L-4F an apoE mimetic peptide?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"L-4F is a synthetic peptide that mimics the structure and function of apolipoprotein E (apoE), which plays a role in lipid metabolism and has neuroprotective properties. Since L-4F mimics apoE, it is considered an apoE mimetic peptide.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Can oleuropein aglycone interfere with amyloid aggregation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Oleuropein aglycone is a compound found in olive oil and has been studied for its potential health benefits, including antioxidant and anti-inflammatory properties. Research suggests that it may have neuroprotective effects, which could be relevant to diseases involving amyloid aggregation, such as Alzheimer's disease. Some studies have indicated that oleuropein aglycone can interfere with the aggregation of amyloid-beta peptides, potentially reducing the formation of toxic aggregates. However, the exact mechanisms and the extent of its effectiveness are still under investigation. Therefore, based on current research, it is plausible that oleuropein aglycone can interfere with amyloid aggregation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Crocus sativus compounds being considered against Alzheimer's disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Crocus sativus, commonly known as saffron, contains compounds like crocin and safranal that have shown potential neuroprotective effects in various studies. Some research suggests these compounds may help in reducing amyloid-beta plaque formation and oxidative stress, which are associated with Alzheimer's disease. However, while preliminary findings are promising, clinical evidence in humans is limited, and more research is needed to confirm their efficacy and safety for treating Alzheimer's. Therefore, although Crocus sativus compounds are being studied and considered, they are not yet established as a standard treatment for Alzheimer's disease.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do Crocus sativus extracts loosen the blood-brain barrier?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"I need to determine if extracts from Crocus sativus (saffron) have been shown to loosen the blood-brain barrier. I will check scientific literature for studies on saffron's effects on the blood-brain barrier. Crocus sativus contains compounds like crocin, crocetin, and safranal, which have various pharmacological properties. Some research suggests these compounds may have neuroprotective effects. However, specific evidence regarding their impact on the blood-brain barrier's permeability is needed. A review of existing studies indicates that while saffron has anti-inflammatory and antioxidant properties, there is no direct evidence that it loosens the blood-brain barrier. In fact, some studies suggest it may protect the barrier's integrity. Therefore, the answer is no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Netrin-1 a secreted protein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Netrin-1 is a protein that is involved in axon guidance during neural development. To determine if it is a secreted protein, we need to check if it contains a signal peptide and if it is released outside the cell. According to available biological databases and scientific literature, Netrin-1 contains a signal peptide, which is a characteristic feature of secreted proteins. Additionally, Netrin-1 functions as a guidance cue in the extracellular environment, indicating that it is indeed secreted.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Have apolipoprotein mimetics been used in clinical trials?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Apolipoprotein mimetics are synthetic compounds designed to mimic the functions of apolipoproteins, which play a role in lipid metabolism and have been studied for their potential therapeutic applications, particularly in cardiovascular diseases. To determine whether they have been used in clinical trials, we need to check available clinical trial databases, scientific literature, or regulatory agency records. Based on existing knowledge, several apolipoprotein mimetics, such as certain peptides mimicking apolipoprotein A-I (e.g., CER-001, ETC-642), have entered clinical trials for conditions like atherosclerosis and dyslipidemia. These trials have explored their safety, pharmacokinetics, and potential efficacy. Therefore, it is likely that apolipoprotein mimetics have been tested in clinical trials.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has strimvelis been approved by the European Medicines Agency?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Strimvelis is a gene therapy treatment for a rare immune disorder called adenosine deaminase deficiency (ADA-SCID). I know that it has received approval in certain regions. The European Medicines Agency (EMA) is responsible for evaluating and approving medications in the European Union. I recall that Strimvelis was approved by the EMA, but I need to confirm the specific details.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the protein Asporin related to disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Asporin is a protein that has been studied in relation to various diseases, particularly in the context of cancer and inflammatory conditions. Research suggests that Asporin may play a role in tumor progression and immune response modulation. However, the exact mechanisms and its direct involvement in disease pathology are still under investigation. Therefore, while there is evidence linking Asporin to disease processes, further research is needed to fully understand its role.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is lactotransferrin a tumour suppressor?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Lactotransferrin, also known as lactoferrin, is a multifunctional protein found in milk and other secretions. It has antimicrobial, anti-inflammatory, and immunomodulatory properties. While some studies suggest that lactotransferrin may have anticancer effects, such as inhibiting tumor cell growth and inducing apoptosis, it is not classified as a classical tumor suppressor protein. Tumor suppressors typically regulate cell cycle, repair DNA damage, or promote apoptosis to prevent cancer development. Lactotransferrin's role in cancer prevention is more related to its indirect effects on the immune system and its ability to modulate the tumor microenvironment rather than directly suppressing tumor formation through genetic mechanisms.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Has the protein SIRT2 been associated to cervical cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To determine if the protein SIRT2 has been associated with cervical cancer, I will check if there are any scientific studies or literature that link SIRT2 to cervical cancer. SIRT2 is a member of the sirtuin family of proteins, which are involved in various cellular processes, including aging, metabolism, and stress response. Some sirtuins have been implicated in cancer development. I will search for specific studies that investigate the role of SIRT2 in cervical cancer. If such studies exist, the answer is yes; otherwise, no.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does RUNX2 inhibit astrocyte differentiation?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"RUNX2 is a transcription factor known for its role in osteoblast differentiation and bone development. While its primary function is in bone biology, there is evidence suggesting that RUNX2 may also play a role in neural development. Some studies indicate that RUNX2 can influence the differentiation of neural crest cells and may have inhibitory effects on certain aspects of neural differentiation. However, specific evidence directly linking RUNX2 to the inhibition of astrocyte differentiation is limited. Most research focuses on its role in osteogenesis rather than gliogenesis. Therefore, while RUNX2 might have some influence on neural development, there is insufficient direct evidence to conclusively state that it inhibits astrocyte differentiation.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can miR-122 target RUNX2?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if miR-122 can target RUNX2, we need to check if there is a miR-122 binding site in the 3'UTR of RUNX2. If there is a binding site, then miR-122 can target RUNX2. If there is no binding site, then miR-122 cannot target RUNX2.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can antisense threapy be used for Huntington's disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Antisense therapy involves the use of antisense oligonucleotides (ASOs) to target specific RNA sequences, thereby preventing the translation of harmful proteins. Huntington's disease is caused by a mutation in the HTT gene, which leads to the production of a toxic form of the huntingtin protein. Antisense therapy could potentially be used to reduce the production of this toxic protein by targeting the mRNA transcribed from the mutant HTT gene. Clinical trials have explored the use of ASOs for Huntington's disease, such as the drug tominersen (previously known as IONIS-HTTRx), which has shown promise in reducing levels of the mutant huntingtin protein. However, the effectiveness and long-term safety of antisense therapy for Huntington's disease are still under investigation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can prevnar 13 be used in children?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Prevnar 13 (pneumococcal conjugate vaccine) is approved for use in children. It is typically administered to infants and young children as part of the routine vaccination schedule to protect against pneumococcal diseases.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Was stelara developed by Amgen?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Stelara (ustekinumab) is a medication used to treat certain autoimmune diseases. To determine if it was developed by Amgen, I need to check the manufacturer's information. Stelara is known to be developed by Janssen Biotech, a subsidiary of Johnson & Johnson, not Amgen.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is ustekinumab a polyclonal antibody?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Ustekinumab is a monoclonal antibody that targets interleukin-12 and interleukin-23. It is used to treat autoimmune diseases such as psoriasis and Crohn's disease. Since it is a monoclonal antibody, it is not a polyclonal antibody.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do tumour-associated macrophages have a prognostic role in gliomas?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tumour-associated macrophages (TAMs) are immune cells that infiltrate tumours and can influence cancer progression. In gliomas, studies have shown that TAMs can have both pro-tumorigenic and anti-tumorigenic effects depending on their polarization state (e.g., M1 vs. M2 phenotypes). Their presence and activity may impact patient prognosis, with some research indicating that higher levels of certain TAM subsets correlate with poorer outcomes. However, the exact prognostic role can vary based on the tumour type, grade, and other factors. Current evidence suggests that TAMs do play a significant role in glioma prognosis.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can cardiospheres be produced from skin fibroblasts?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Cardiospheres are typically derived from cardiac tissue, particularly from heart biopsies, where they are isolated from the myocardium. Skin fibroblasts, on the other hand, are connective tissue cells found in the skin and are not naturally part of the cardiac lineage. To produce cardiospheres from skin fibroblasts, a process of cellular reprogramming or directed differentiation would be required to convert these fibroblasts into cardiac progenitor cells capable of forming cardiospheres. While direct reprogramming of fibroblasts into cardiomyocytes has been demonstrated in research settings, the formation of cardiospheres specifically from skin fibroblasts is not a standard or commonly established procedure. Therefore, under normal circumstances, cardiospheres cannot be directly produced from skin fibroblasts without significant experimental intervention.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does the interaction of MOV10 and RNASEH2 promote L1 retrotransposition?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To answer this question, it is necessary to determine whether the interaction between MOV10 and RNASEH2 promotes L1 retrotransposition. First, I will check if MOV10 and RNASEH2 interact. Then, I will assess whether this interaction has a promoting effect on L1 retrotransposition. MOV10 is known to inhibit L1 retrotransposition, while RNASEH2 is involved in RNA processing and DNA replication. Existing research suggests that MOV10 suppresses L1 retrotransposition by unwinding L1 RNA-DNA hybrids, and RNASEH2 may degrade L1 RNA. If their interaction enhances L1 retrotransposition, it would contradict their individual roles. However, if their interaction inhibits L1 retrotransposition, it would align with their known functions. Based on current knowledge, their interaction likely does not promote L1 retrotransposition.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Tocilizumab is an anti-TNF antibody, yes or no?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Tocilizumab is a monoclonal antibody used in the treatment of various autoimmune diseases, such as rheumatoid arthritis. However, it targets interleukin-6 (IL-6) receptors rather than tumor necrosis factor (TNF). Anti-TNF drugs include medications like infliximab and adalimumab. Therefore, tocilizumab is not an anti-TNF antibody.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Velocardial facial syndrome, otherwise known as Di George syndrome  is caused by a deletion in chromosome 21, yes or no?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Velocardiofacial syndrome, also known as DiGeorge syndrome, is a genetic disorder caused by a deletion in the long arm of chromosome 22, specifically at position 22q11.2. This deletion leads to various developmental issues, including heart defects, facial abnormalities, and problems with the immune system. Since the question states that the syndrome is caused by a deletion in chromosome 21, which is incorrect, the answer should be no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Anaplasma phagocytophilum is an obligate gram-negative, intracellular bacterium, yes  or no",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Anaplasma phagocytophilum is an obligate intracellular bacterium that is gram-negative. This means it cannot survive outside of a host cell and has a cell wall that does not retain the crystal violet stain used in the Gram staining method. Therefore, the statement is correct.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are cardenolides inhibitors of Na+/K+ ATPase?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Cardenolides are a type of steroid glycoside that are known to have various biological activities. One of their well-known effects is their ability to inhibit the Na+/K+ ATPase enzyme, which is responsible for maintaining the electrochemical gradient across cell membranes. This inhibition leads to an increase in intracellular sodium and a decrease in potassium, which can affect various cellular processes. Therefore, cardenolides are indeed inhibitors of Na+/K+ ATPase.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is it possible to analyze exosomes with FACS?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Exosomes are small vesicles secreted by cells, and FACS (Fluorescence-Activated Cell Sorting) is a technique used to sort and analyze cells based on fluorescent markers. Due to their small size (typically 30-150 nm in diameter), exosomes are generally below the size limit that can be effectively detected and analyzed by conventional FACS instruments, which are optimized for larger cells. However, recent advancements in flow cytometry technology, such as high-sensitivity flow cytometry or specialized techniques like nano-flow cytometry, may allow for the detection and analysis of exosomes, particularly when they are labeled with specific fluorescent markers. Therefore, while traditional FACS may not be suitable, newer technologies may enable exosome analysis.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can mitochondria transfer from cell to cell?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Mitochondria are organelles within cells responsible for energy production. Recent research has shown that under certain conditions, mitochondria can be transferred from one cell to another. This process can occur through various mechanisms, including tunneling nanotubes, extracellular vesicles, or direct cell-to-cell contact. Mitochondrial transfer has been observed in various organisms and has implications for cellular communication, tissue repair, and disease progression. Therefore, the answer is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can mitochondria pass through membrane nanotubes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Mitochondria are organelles found in eukaryotic cells that are responsible for producing energy in the form of ATP. Membrane nanotubes are thin, tubular structures that connect cells and allow for the exchange of cellular components and signals. Recent research has shown that mitochondria can be transferred between cells through membrane nanotubes. This process has been observed in various cell types and is thought to play a role in cellular communication, tissue repair, and disease progression. Therefore, the answer to the question is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is TNF-Î± an activator of pancreatic stellate cells?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"TNF-Î± (Tumor Necrosis Factor-alpha) is a pro-inflammatory cytokine that plays a role in inflammation and immune responses. Pancreatic stellate cells (PSCs) are involved in pancreatic fibrosis and inflammation. Studies have shown that TNF-Î± can activate PSCs, leading to their proliferation and the production of extracellular matrix proteins, which contribute to fibrosis. Therefore, TNF-Î± is considered an activator of pancreatic stellate cells.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are protamines ubiquitously expressed?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Protamines are a family of small, arginine-rich proteins that are primarily involved in chromatin packaging during spermatogenesis. They are found in the sperm cells of many organisms, including humans. However, their expression is not limited to sperm cells. Studies have shown that protamines are also expressed in somatic tissues, such as the brain and other organs, although their functions in these tissues are not fully understood. Therefore, while protamines are most well-known for their role in sperm development, they are expressed in a variety of tissues, suggesting that they are ubiquitously expressed to some extent.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Can therapeutic levels of  Vedolizumab be found in the breast milk of nursing mothers following treatment for Inflammatory bowel disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Vedolizumab is a monoclonal antibody used to treat inflammatory bowel disease (IBD). It is not known whether vedolizumab is excreted in human milk. However, because of the potential for adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are there any anti-amyloid antibody approved as drug for Alzheimer's disease treatment?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether there are any anti-amyloid antibodies approved as drugs for Alzheimer's disease treatment. I need to check if any such drugs have received regulatory approval, such as from the FDA or EMA. Anti-amyloid antibodies target amyloid-beta plaques, which are a hallmark of Alzheimer's disease. I recall that some monoclonal antibodies have been developed for this purpose. For example, aducanumab was approved by the FDA in 2021, though it was controversial. Another drug, lecanemab, received accelerated approval from the FDA in 2023. These drugs are intended to reduce amyloid plaques in the brain. However, their effectiveness in slowing disease progression is still debated. Despite the controversy, they have been approved, so the answer should be 'yes'.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is subdural empyema a complication of sinusitis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Subdural empyema is a rare complication of sinusitis. It occurs when an infection spreads from the sinuses to the subdural space, leading to the accumulation of pus. This condition is serious and requires prompt medical attention. Given that sinusitis can lead to subdural empyema, the answer to whether it is a complication is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are artificial blood cells available?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Artificial blood cells are a topic of ongoing research. While there have been developments in creating synthetic or artificial blood products, such as oxygen-carrying solutions, fully functional artificial blood cells that can completely replace natural blood cells in all their roles are not yet available for widespread clinical use.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is actin present in the nucleus?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Actin is a protein that is primarily found in the cytoplasm of eukaryotic cells, where it plays a key role in various cellular processes such as muscle contraction, cell motility, and cell division. However, recent studies have shown that actin can also be present in the nucleus, where it is involved in processes like chromatin remodeling and transcriptional regulation. Therefore, while actin is more commonly associated with the cytoplasm, it can also be found in the nucleus under certain conditions.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the Philadelphia chromosome a fusion between parts of chromosomes 1 and 9?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The Philadelphia chromosome is a fusion between parts of chromosomes 9 and 22, not 1 and 9. This chromosomal abnormality is associated with chronic myeloid leukemia (CML) and results in the formation of the BCR-ABL fusion gene. Therefore, the statement that it involves chromosomes 1 and 9 is incorrect.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is collagen matrix of human articular cartilage changing with disease?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether the collagen matrix of human articular cartilage changes with disease. Articular cartilage is the smooth, white tissue that covers the ends of bones where they come together to form joints. It contains collagen, which is a structural protein that provides strength and structure to the cartilage. In diseases such as osteoarthritis, the cartilage can break down, leading to changes in the collagen matrix. This breakdown can result in the loss of collagen and alterations in its structure, which can affect the mechanical properties of the cartilage. Therefore, the collagen matrix does change with certain diseases.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Can TAD disruption lead to disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"TADs (Topologically Associating Domains) are genomic regions that interact more frequently within themselves than with other regions, playing a role in gene regulation. Disruption of TAD boundaries can lead to misregulation of genes, potentially causing diseases such as cancer. Studies have shown that alterations in TAD structure are associated with various disorders. Therefore, TAD disruption can contribute to disease development.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does Estrogen lead to forkhead FoxA1 activation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Estrogen is a hormone that plays a key role in the development and regulation of the female reproductive system and secondary sex characteristics. Forkhead box A1 (FoxA1) is a transcription factor that is involved in various biological processes, including development, metabolism, and cancer. Some studies have suggested that estrogen can regulate the expression of FoxA1. For example, in breast cancer cells, estrogen has been shown to induce the expression of FoxA1, which in turn can modulate the activity of estrogen receptor alpha (ERÎ±) and influence the response to endocrine therapy. Therefore, estrogen can lead to FoxA1 activation in certain contexts.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Apelin usually decreased in diabetes?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Apelin is a peptide hormone involved in various physiological processes, including glucose metabolism and insulin sensitivity. Studies have shown that Apelin levels are often reduced in individuals with diabetes, particularly type 2 diabetes, due to factors like insulin resistance and chronic inflammation. This decrease may contribute to the metabolic dysregulation seen in diabetes.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is Pim-1 a protein phosphatase?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Pim-1 is a serine/threonine protein kinase, not a protein phosphatase. Protein kinases add phosphate groups to proteins, while protein phosphatases remove them. Since Pim-1 functions as a kinase, it is not a phosphatase.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is the crystal structure of Pim-1 available?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To determine if the crystal structure of Pim-1 is available, I would need to check databases such as the Protein Data Bank (PDB) for any entries related to Pim-1. Pim-1 is a serine/threonine kinase involved in cell survival and proliferation. If there are any published crystal structures of Pim-1 in the PDB, then the answer would be yes. If not, then the answer would be no.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is myc a tumour suppressor gene?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Myc is a well-known proto-oncogene, which means it has the potential to cause cancer when it is mutated or overexpressed. Tumor suppressor genes, on the other hand, are genes that help prevent cancer by regulating cell growth and division, repairing DNA damage, or promoting apoptosis. Since Myc promotes cell proliferation and is involved in the development of various cancers when dysregulated, it is not classified as a tumor suppressor gene.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is CD63 an exosomal marker?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"CD63 is a tetraspanin protein that is commonly found on the surface of exosomes, which are small vesicles released by cells. It is often used as a marker to identify and isolate exosomes in research studies.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does association with the nuclear pore promote gene silencing?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question asks whether association with the nuclear pore promotes gene silencing. Nuclear pores are structures that span the nuclear envelope and regulate the transport of molecules between the nucleus and the cytoplasm. Gene silencing refers to the regulation of gene expression, often through mechanisms like chromatin remodeling, DNA methylation, or RNA interference. Research has shown that the nuclear periphery, including the nuclear lamina and nuclear pores, can influence gene expression. Some studies suggest that genes positioned near the nuclear pore can be transcriptionally active, while others indicate that certain regions near the nuclear periphery may be associated with gene repression. However, the direct association between nuclear pore proximity and gene silencing is not fully understood and may depend on specific cellular contexts and gene loci. Therefore, the evidence is not conclusive enough to definitively state that association with the nuclear pore promotes gene silencing.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is the process of DNA loop-extrusion independent of ATP?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"DNA loop-extrusion is a process that involves the formation of loops in DNA, which is important for chromatin organization and gene regulation. This process is primarily mediated by protein complexes such as cohesin and condensin. These complexes are members of the structural maintenance of chromosomes (SMC) family and utilize ATP hydrolysis to perform their functions. The energy derived from ATP hydrolysis is essential for the translocation of these complexes along the DNA, which in turn facilitates the extrusion of DNA loops. Therefore, the process of DNA loop-extrusion is dependent on ATP.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are lamina-associated domains (LADs) associated with transcriptional activation?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Lamina-associated domains (LADs) are genomic regions that interact with the nuclear lamina. The nuclear lamina is a structure that lines the inner nuclear membrane and plays a role\\nin maintaining nuclear shape and organizing chromatin. LADs are typically enriched for heterochromatin marks and are generally considered to be transcriptionally repressed. This is because the\\nheterochromatin is a tightly packed form of DNA that is less accessible to the transcription machinery. Therefore,\\nLADs are not typically associated with transcriptional activation.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are the members of the KRAB-ZNF  gene family promoting gene repression?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The KRAB-ZNF gene family is known for its role in gene regulation. The KRAB domain, found in these proteins, is associated with transcriptional repression. This domain can recruit co-repressor proteins, which can lead to the silencing of target genes. Therefore, members of the KRAB-ZNF gene family are generally considered to be involved in promoting gene repression.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does deletion of cohesin change gene expression?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is whether deletion of cohesin changes gene expression. Cohesin is a protein complex involved in sister chromatid cohesion, chromosome segregation, and gene regulation. Studies have shown that cohesin plays a role in transcriptional regulation by influencing chromatin structure and looping. Deletion or depletion of cohesin subunits can lead to changes in gene expression patterns, either by directly affecting transcription or indirectly through chromatin organization. For example, cohesin has been implicated in the regulation of genes involved in development, cell cycle, and other processes. Therefore, the deletion of cohesin is likely to alter gene expression.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is SATB1 expressed in thymocytes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To determine if SATB1 is expressed in thymocytes, I need to check scientific literature or databases that detail gene expression in these cells. Thymocytes are T-cell precursors found in the thymus, and SATB1 is a nuclear matrix-associated protein involved in chromatin organization. Research indicates that SATB1 plays a role in T-cell development, which suggests it is expressed in thymocytes. For example, studies have shown that SATB1 is involved in the regulation of gene expression during T-cell differentiation, supporting its presence in thymocytes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there negative enhancers?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Enhancers are DNA sequences that can increase the transcription of genes. While most enhancers are considered to be positive regulators, there are also negative enhancers that can decrease gene expression. These negative enhancers work by recruiting repressor proteins or modifying chromatin structure to inhibit transcription. Therefore, the existence of negative enhancers is possible.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is SATB1 necessary for T-cell maturation?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"SATB1 is a nuclear matrix-associated protein that plays a role in chromatin organization and gene regulation. It has been implicated in the development and function of T-cells. Research suggests that SATB1 is important for the proper maturation of T-cells, particularly in the thymus. However, whether it is absolutely necessary can depend on the specific context and stage of maturation. Some studies indicate that while SATB1 contributes to T-cell development, other factors may also play compensatory roles.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does SATB1 regulate the RAG1 and RAG2 genes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"SATB1 is a nuclear matrix-associated protein that plays a role in chromatin organization and gene regulation. It has been shown to regulate the expression of various genes involved in immune system development, including those in T-cell maturation. The RAG1 and RAG2 genes are critical for V(D)J recombination, a process necessary for the generation of diverse antigen receptors in lymphocytes. Research indicates that SATB1 can bind to the regulatory regions of the RAG1 and RAG2 genes, influencing their expression levels during T-cell development. This interaction suggests that SATB1 does play a regulatory role in the expression of RAG1 and RAG2.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is CTCF bound at nucleosome free regions?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"CTCF (CCCTC-binding factor) is a transcription factor known to play a role in chromatin organization and insulation. It binds to specific DNA sequences and is involved in forming chromatin loops and regulating gene expression. Nucleosome-free regions (NFRs) are areas of DNA that are not wrapped around nucleosomes, making them more accessible for transcription factors and other regulatory proteins. Since CTCF requires accessible DNA to bind, it is plausible that it binds at nucleosome-free regions. However, CTCF binding does not necessarily imply that it is exclusively at NFRs, as it can also bind to regions where nucleosomes are present but may be displaced upon binding.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does metformin alleviate atherosclerosis?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Metformin is a medication commonly used to treat type 2 diabetes. Research suggests that metformin may have cardiovascular benefits beyond its glucose-lowering effects. Some studies indicate that it can reduce inflammation, improve endothelial function, and decrease the risk of cardiovascular events. However, the direct effect of metformin on atherosclerosis specifically is not fully established. While it may have protective effects that could slow the progression of atherosclerosis, more research is needed to confirm this. Therefore, it is not definitively proven that metformin alleviates atherosclerosis.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does GRHL2 over-expression lead to EMT?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"GRHL2 (Grainyhead-like 2) is a transcription factor involved in various cellular processes, including epithelial differentiation and wound healing. Epithelial-mesenchymal transition (EMT) is a process where epithelial cells lose their polarity and cell-cell adhesion, gaining migratory and invasive properties. Current research suggests that GRHL2 acts as a suppressor of EMT. It maintains epithelial characteristics by upregulating epithelial markers (e.g., E-cadherin) and downregulating mesenchymal markers (e.g., vimentin, N-cadherin). Over-expression of GRHL2 typically reinforces this epithelial state, thereby inhibiting EMT. However, context-dependent roles cannot be entirely ruled out, as cellular behavior may vary in different tissue types or disease states.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is PRDM9 essential for meiosis?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"PRDM9 is a protein that plays a role in meiosis, particularly in the formation of double-strand breaks (DSBs) in DNA, which are necessary for homologous recombination. However, the term 'essential' can be context-dependent. While PRDM9 is crucial in many organisms, such as mice, for proper meiotic progression, some organisms can undergo meiosis without it, albeit with defects in recombination and fertility. Therefore, whether PRDM9 is essential depends on the organism and the specific context.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does the chromatin remodeling complex, RSC target H2A.Z nucleosomes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The RSC chromatin remodeling complex is known to play a role in chromatin remodeling, which involves altering the structure of chromatin to allow access to DNA. H2A.Z is a histone variant that is incorporated into nucleosomes, and it is known to be involved in various chromatin-related processes, including transcription regulation and DNA repair. Studies have shown that RSC can target nucleosomes containing H2A.Z, facilitating their remodeling. This targeting is important for processes such as gene expression and chromatin dynamics.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the tyrosine kinase BTK implicated in autoimmunity?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To answer this question, I need to determine whether the tyrosine kinase BTK (Bruton's tyrosine kinase) plays a role in autoimmunity. BTK is a key signaling molecule in B cells, and it is well-known for its role in B cell development and activation. Mutations in BTK cause X-linked agammaglobulinemia, a primary immunodeficiency characterized by a lack of mature B cells and antibodies. However, the question is about its involvement in autoimmunity. In autoimmunity, the immune system attacks the body's own tissues, and B cells can contribute by producing autoantibodies. Since BTK is essential for B cell function, it could be involved in autoimmune diseases where B cells play a pathogenic role. Additionally, BTK inhibitors have been studied in the context of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, suggesting that BTK activity contributes to the pathogenesis of these conditions. Based on this information, BTK is likely implicated in autoimmunity.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is induction of interferon by TLR7 higher in males?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether the induction of interferon by TLR7 is higher in males. TLR7 is a toll-like receptor that recognizes viral RNA and triggers immune responses, including the production of interferons. There is evidence that sex differences exist in immune responses, with females generally mounting stronger innate and adaptive immune responses compared to males. This could be due to hormonal differences, such as higher estrogen levels in females, which can enhance immune activation. Some studies suggest that females may have higher interferon production in response to TLR7 activation compared to males. However, the exact mechanisms and the extent of this difference can vary based on the context, such as age, hormonal status, and the specific condition being studied. Therefore, the available evidence suggests that interferon induction by TLR7 is not higher in males but may be higher in females.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does CXorf21 escape X chromosome inactivation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"CXorf21 is a gene located on the X chromosome. X chromosome inactivation (XCI) is a process in which one of the two X chromosomes in females is randomly inactivated to balance gene expression between males and females. Some genes on the X chromosome escape XCI and remain active on both X chromosomes. CXorf21 has been identified as one of the genes that can escape XCI, allowing its expression from both the active and inactive X chromosomes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is SATB1 positioned close to AT-rich sequences?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"SATB1 is a nuclear matrix-associated transcription factor that binds to AT-rich DNA sequences, known as \\\"matrix attachment regions\\\" (MARs), which are typically rich in A-T base pairs. These MARs are thought to be involved in the organization of chromatin into loop domains. SATB1's ability to bind to these AT-rich regions allows it to regulate gene expression by altering chromatin structure and influencing the accessibility of genes to the transcriptional machinery. Therefore, SATB1 is indeed positioned close to AT-rich sequences through its binding to MARs.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Niraparib effective for ovarian cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Niraparib is a PARP inhibitor used in the treatment of ovarian cancer. Clinical trials have shown that it can be effective in treating ovarian cancer, particularly in patients with BRCA mutations. However, its effectiveness may vary depending on individual patient factors and the specific type of ovarian cancer. It is important to consult with a healthcare professional for personalized treatment recommendations.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is palbociclib effective for glioblastoma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Palbociclib is a CDK4/6 inhibitor primarily used in the treatment of hormone receptor-positive, HER2-negative advanced breast cancer. Its efficacy in glioblastoma, a type of aggressive brain cancer, is not well established. While there is ongoing research into the use of CDK inhibitors in various cancers, current clinical evidence does not strongly support palbociclib as a standard treatment for glioblastoma. Therefore, it is unlikely to be considered effective for this specific cancer type based on existing data.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can LB-100 sensitize ovarian carcinoma to cisplatin?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To answer this question, I need to check if there is evidence that LB-100 can sensitize ovarian carcinoma to cisplatin. Sensitizing cancer cells to chemotherapy means making them more susceptible to the effects of the drug. I would look for studies or research articles that investigate the combination of LB-100 and cisplatin in the context of ovarian cancer treatment. Specifically, I would search for information on whether LB-100 enhances the effectiveness of cisplatin against ovarian carcinoma cells. If such evidence exists, the answer would be 'yes'; otherwise, it would be 'no'.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has LB-100 been tested in clinical trials?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"LB-100 is a drug that has been studied for its potential therapeutic effects. To determine if it has been tested in clinical trials, we can check clinical trial databases and scientific literature. According to available information, LB-100 has undergone preclinical studies, but there is no evidence of it having entered human clinical trials as of the latest available data.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can LB-100 downregulate miR-33?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"I need to check if LB-100 can downregulate miR-33. First, I will search for studies or articles that mention LB-100 and its effects on miR-33. LB-100 is a protein phosphatase 2A (PP2A) inhibitor. PP2A is involved in various cellular processes, including regulation of gene expression. MicroRNA-33 (miR-33) is known to regulate cholesterol metabolism and other cellular functions. I will look for any direct evidence in the literature that LB-100 treatment leads to decreased levels of miR-33. If there are studies showing this effect, the answer is yes; otherwise, no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can PRL3-zumab inhibit PRL3+ cancer cells in vitro and in vivo?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether PRL3-zumab can inhibit PRL3+ cancer cells both in vitro (in a controlled environment outside a living organism, such as a test tube or culture dish) and in vivo (within a living organism). To answer this, we need to determine if there is evidence that PRL3-zumab has been shown to inhibit these cancer cells in both settings. If studies have demonstrated its effectiveness in both in vitro and in vivo models, the answer would be yes. If not, the answer would be no.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Can discharge destinations be accurately predicted using the Risk Assessment and Prediction Tool (RAPT)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether the Risk Assessment and Prediction Tool (RAPT) can accurately predict discharge destinations. I need to determine if there is evidence or information indicating that RAPT is effective in predicting where patients will be discharged to (e.g., home, rehabilitation facility, etc.). If studies or data support that RAPT has been validated for this purpose and shows high accuracy, then the answer would be 'yes'. If there is no such evidence or if it's known that RAPT does not perform well in this area, the answer would be 'no'.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is AZD5153 active in prostate cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"AZD5153 is a BRD4 inhibitor. BRD4 inhibitors have shown activity in various cancers, including prostate cancer. However, the specific activity of AZD5153 in prostate cancer may depend on the context of clinical trials or preclinical studies. It is necessary to check the latest research or clinical trial results to confirm its efficacy in prostate cancer.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is GRG5 involved only in late embryonic mouse development?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To answer this question, I need to check if GRG5 is involved only in late embryonic mouse development. First, I will search for information on GRG5's role in mouse development. GRG5 (Groucho-related gene 5) is a member of the Groucho family of transcriptional co-repressors. Studies indicate that GRG5 is expressed in various tissues during embryonic development, including the nervous system, limbs, and organs. Research suggests that GRG5 is active not only in late embryonic stages but also in early development and postnatal processes. For example, GRG5 has been implicated in regulating cell differentiation and tissue homeostasis beyond the embryonic phase. Therefore, GRG5 is not exclusively involved in late embryonic mouse development.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does BNN27 promote memory loss?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"I need to check if there is any scientific evidence or research indicating that BNN27 promotes memory loss. BNN27 might be a compound, drug, or protein. I will look for studies or articles that discuss its effects on memory or cognitive functions.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is BNN20 involved in Parkinson's disease?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if BNN20 is involved in Parkinson's disease, I need to check scientific literature or databases for any studies linking BNN20 (also known as BANP or Btg3-associated nuclear protein) to Parkinson's disease. BNN20 is a gene that encodes a nuclear protein, but there is currently no well-established direct link between BNN20 and Parkinson's disease in the available research. Further investigation into recent studies or genetic analyses related to Parkinson's may be necessary to confirm any potential association.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Has istadefylline been considered as a treatment for Parkinson's disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Istadefylline is a drug that has been studied for its potential use as a treatment for Parkinson's disease. It works by blocking adenosine A2A receptors and has been investigated as an adjunct therapy to levodopa. Clinical trials have explored its efficacy and safety profile. Based on available information up to my knowledge cutoff date of July of this year.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is amantadine ER the first approved treatment for akinesia?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Amantadine ER (extended-release) is a medication used to treat Parkinson's disease and other movement disorders. Akinesia refers to a lack of movement and is a symptom commonly associated with Parkinson's disease. Amantadine was originally approved as an antiviral medication but was later found to have benefits in treating Parkinson's symptoms. However., other medications such as levodopa have been the primary treatment for Parkinson's disease and its symptoms like akinesia. Amantadine ER may be used as an adjunct treatment. To determine if it is the first approved treatment for akinesia specifically., we need to check the FDA approval history. Levodopa was approved in the late 60s., which was the first major effective treatment for Parkinson's disease symptoms including akinesia. Amantadine's approval for Parkinson's came later. Therefore., amantadine ER is not the first approved treatment for akinesia.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has amantadine ER been approved by the FDA?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Amantadine ER refers to an extended-release formulation of amantadine, which is a medication used for the treatment of Parkinson's disease and certain viral infections. To determine whether amantadine ER has been approved by the FDA, it is necessary to check the FDA's official database of approved drugs or consult recent FDA announcements. Standard immediate-release amantadine has been approved for specific indications, but the approval status of the extended-release version may differ. A search in the FDA's drug approval database or a review of recent FDA press releases would provide confirmation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is pimavanserin a typical antipsychotic?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Pimavanserin is a medication primarily used to treat Parkinson's disease psychosis. Typical antipsychotics are a class of drugs generally used to treat psychotic disorders like schizophrenia. They work by blocking dopamine receptors in the brain. Pimavanserin, however, works by selectively blocking serotonin receptors, specifically the 5-HT2A receptor, with minimal effects on dopamine receptors. This mechanism is more characteristic of atypical antipsychotics. Therefore, pimavanserin is not classified as a typical antipsychotic.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has ProSavin undergone phase IV clinical trials by 2018?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To answer this question, I need to determine whether ProSavin has undergone phase IV clinical trials by 2018. ProSavin is a gene therapy product that has been investigated for the treatment of Parkinson's disease. Phase IV clinical trials are conducted after a drug has been approved and is on the market to monitor its long-term safety and effectiveness. I need to check the clinical trial history of ProSavin up to 2018 to see if any phase IV trials were conducted. According to publicly available information, ProSavin completed a phase II clinical trial in 2012, and there were no phase IV trials conducted by 2018. Therefore, the answer is no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does ProSavin use an adenoviral vector?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"ProSavin is a gene therapy product that uses a viral vector to deliver genetic material into cells. The specific type of viral vector used in ProSavin is an adeno-associated viral (AAV) vector, not an adenoviral vector. Adenoviral vectors are different from AAV vectors, although both are derived from viruses. Therefore, ProSavin does not use an adenoviral vector.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is BCL11B involved in schizophrenia?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if BCL11B is involved in schizophrenia, I need to check current scientific literature and databases for any associations between the BCL11B gene and schizophrenia. BCL11B is a gene that encodes a protein involved in the development of the nervous system and immune system regulation. Research may indicate a link between this gene and neurological disorders. If studies have found mutations or variations in BCL11B associated with schizophrenia, the answer would be yes. If no such associations have been established, the answer would be no.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are CD8+ (cytotoxic) T cells and  CD4+ Helper T cells generated in the thyroid and express the T-cell receptor?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"CD8+ and CD4+ T cells are generated in the bone marrow and then mature in the thymus, not the thyroid. Both types of T cells express the T-cell receptor (TCR). The TCR is a critical component that allows T cells to recognize antigens presented by MHC molecules. CD8+ T cells recognize antigens presented by MHC class I molecules, while CD4+ T cells recognize antigens presented by MHC class II molecules. Therefore, while both cell types express the TCR, they are not generated in the thyroid.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do MAIT cells have a role in multiple myeloma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Yes, MAIT cells have been found to have a role in multiple myeloma. Studies have shown that MAIT cells can recognize and respond to antigens presented by MR1, which is expressed on malignant plasma cells in multiple myeloma. This suggests that MAIT cells may contribute to the immune response against the tumor cells. However, the exact mechanisms and the extent of their involvement are still under investigation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the BAGEL algorithm used for arrayed CRISPR screens?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The BAGEL algorithm is a computational method used to analyze data from CRISPR screening experiments. It is specifically designed to identify genes that are essential for cell survival or proliferation. Arrayed CRISPR screens involve testing individual guide RNAs in separate wells, as opposed to pooled screens where multiple guide RNAs are tested together. BAGEL can be applied to both arrayed and pooled CRISPR screens to determine gene essentiality by analyzing the depletion or enrichment of guide RNAs. Therefore, the BAGEL algorithm can be used for arrayed CRISPR screens.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is Ubrogepant effective for migraine?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Ubrogepant is a medication used for the treatment of migraine. It belongs to a class of drugs known as gepants, which work by blocking the calcitonin gene-related peptide (CGRP) receptor. CGRP is involved in the development of migraine headaches. Clinical trials have shown that ubrogepant can be effective in relieving migraine symptoms when taken at the onset of an attack. It is approved by the FDA for the acute treatment of migraine with or without aura in adults. Therefore, the answer is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is modified vaccinia Ankara effective for smallpox?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is whether modified vaccinia Ankara (MVA) is effective for smallpox. MVA is a highly attenuated strain of the vaccinia virus, which is a member of the orthopoxvirus family, like smallpox. It was developed as a safer smallpox vaccine, particularly for people who cannot receive the traditional smallpox vaccine due to weakened immune systems or other health conditions. Studies have shown that MVA can induce an immune response against smallpox, and it has been approved in some countries as a smallpox vaccine. Therefore, MVA is considered effective for smallpox.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Apremilast effective for BehÃ§etâ€™s Syndrome?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that has been approved for the treatment of psoriasis and psoriatic arthritis. Its mechanism of action involves modulating intracellular cyclic adenosine monophosphate (cAMP) levels, which can affect inflammatory responses. BehÃ§etâ€™s Syndrome is a systemic inflammatory disorder characterized by recurrent oral and genital ulcers, uveitis, and other systemic manifestations. While there is some evidence suggesting that PDE4 inhibitors might have a role in treating BehÃ§etâ€™s Syndrome due to their anti-inflammatory properties, clinical trials specifically evaluating Apremilast for BehÃ§etâ€™s Syndrome are limited. Some case reports and small studies have shown potential benefits in reducing oral ulcer frequency and other symptoms, but larger, randomized controlled trials are needed to confirm its efficacy and safety in this condition. Therefore, while there is preliminary evidence supporting its use, it is not yet definitively established as a standard treatment for BehÃ§etâ€™s Syndrome.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Selinexor effective for multiple myeloma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Selinexor is a drug used in the treatment of multiple myeloma. It works by inhibiting the export of tumor suppressor proteins from the nucleus, leading to cancer cell death. Clinical trials have shown that it can be effective in treating certain cases of multiple myeloma, particularly in patients who have not responded to other treatments. However, its effectiveness can vary depending on the individual case and the specific treatment regimen used.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does teplizumab hold promise for diabetes prevention?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Teplizumab is a monoclonal antibody that has been studied for its potential in treating and possibly preventing type 1 diabetes. Clinical trials have shown that teplizumab can delay the onset of type 1 diabetes in individuals who are at high risk. For example, a study published in 2019 demonstrated that the drug could delay the diagnosis of type 1 diabetes by approximately two years in at-risk individuals. This suggests that teplizumab may indeed hold promise for diabetes prevention, particularly in those with early signs of the disease. However, it is important to note that the drug is not yet widely approved for preventive use and further research may be needed to confirm its long-term efficacy and safety in this context.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does nintedanib hold promise for lung disease associated with systemic sclerosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Nintedanib is a tyrosine kinase inhibitor that has been approved for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease (SSc-ILD). Its mechanism of action involves inhibiting multiple growth factor receptors, which are involved in fibrosis. Clinical trials, such as the SENSCIS trial, have demonstrated that nintedanib can slow the progression of lung fibrosis in patients with SSc-ILD. Therefore, nintedanib does hold promise for treating lung disease associated with systemic sclerosis.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is mesothelioma caused by asbestos exposure?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Mesothelioma is a type of cancer that affects the lining of the lungs, abdomen, or heart. It is primarily caused by exposure to asbestos, a naturally occurring mineral that was widely used in construction and industrial materials. When asbestos fibers are inhaled or ingested, they can become lodged in the body's tissues, leading to inflammation and genetic damage over time, which can result in mesothelioma. While there may be other contributing factors, asbestos exposure is the most significant and well-documented cause of this disease.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Hemochromatosis type 4 is caused by a mutation in a recessive gene?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Hemochromatosis type 4, also known as ferroportin disease, is a genetic disorder characterized by excessive iron accumulation in the body. Unlike other types of hemochromatosis, which are typically inherited in an autosomal recessive manner, type 4 is inherited in an autosomal dominant pattern. This means that only one copy of the mutated gene is sufficient to cause the disease. The gene involved in Hemochromatosis type 4 is the SLC40A1 gene, which encodes the ferroportin protein. Mutations in this gene lead to abnormal iron transport and subsequent iron overload. Since it is autosomal dominant, it is not caused by a mutation in a recessive gene.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Huntington's disease is caused by expansion of a CTG repeat in the HTT gene on Chromosome 4?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Huntington's disease is caused by a mutation in the HTT gene on Chromosome 4, which involves an abnormal expansion of a CAG trinucleotide repeat, not CTG. The CAG repeat expansion leads to the production of a mutant huntingtin protein that is toxic to neurons, particularly in the brain's basal ganglia. This results in the progressive neurodegenerative symptoms characteristic of Huntington's disease. Therefore, the statement is incorrect because it refers to a CTG repeat instead of the correct CAG repeat.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can radiation induced meningiomas be treated with radiosurgery?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Radiation-induced meningiomas are tumors that develop as a result of prior radiation exposure. Radiosurgery, such as Gamma Knife or CyberKnife, is a non-invasive procedure that uses focused radiation to treat tumors. While radiosurgery is commonly used for treating meningiomas, the effectiveness for radiation-induced cases may depend on factors like tumor size, location, and the patient's overall health. Some studies suggest that radiosurgery can be a viable option for these tumors, but it may not be suitable for all cases. Therefore, the possibility of treating radiation-induced meningiomas with radiosurgery exists, but it is not universally applicable.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there an increased risk of meningiomas in atomic bomb survivors?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether there is an increased risk of meningiomas in atomic bomb survivors. Meningiomas are tumors that develop from the meninges, the protective membranes covering the brain and spinal cord. Atomic bomb survivors were exposed to high levels of ionizing radiation, which is a known risk factor for various types of cancer, including brain tumors. Studies have been conducted on the long-term health effects of radiation exposure in atomic bomb survivors, particularly those from Hiroshima and Nagasaki. Research has shown an increased incidence of certain cancers, such as leukemia and solid tumors, in these survivors. Regarding meningiomas specifically, some studies have indicated a higher risk among those exposed to radiation, especially at younger ages or with higher radiation doses. Therefore, based on the evidence from radiation exposure studies, it is likely that there is an increased risk of meningiomas in atomic bomb survivors.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does radiation for tinea capitis increases brain tumor risk?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tinea capitis is a fungal infection of the scalp. In the past, radiation therapy was used to treat tinea capitis, particularly in the mid-20th century. However, studies have shown that this practice may increase the risk of brain tumors later in life. The radiation exposure to the head during treatment is believed to be the contributing factor. Therefore, radiation therapy is no longer recommended for tinea capitis, and alternative treatments such as antifungal medications are preferred.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can secondary glioblastoma be caused by brain irradiation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Secondary glioblastoma can be caused by brain irradiation. Brain irradiation is a known risk factor for the development of secondary glioblastoma. The radiation can cause genetic mutations in the brain cells, leading to the formation of tumors. These tumors can develop years after the initial radiation exposure. However, it is important to note that while brain irradiation increases the risk, it is still a relatively rare occurrence for a secondary glioblastoma to develop as a result of radiation therapy.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does head ct increase brain tumor risk?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is whether a head CT scan increases the risk of brain tumors. CT scans involve ionizing radiation, which is a known carcinogen. However, the radiation dose from a single head CT is relatively low. The risk of developing a brain tumor from a single scan is considered to be very small. Medical imaging procedures like CT scans are generally used when the benefits outweigh the potential risks. Therefore, while there may be a minimal increase in risk, it is not significant enough to be a major concern in most medical scenarios.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there an increased risk for meningiomas in childhood leukemia survivors?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Some studies have suggested that survivors of childhood leukemia may have an increased risk of developing meningiomas later in life. This could be due to various factors, including the treatments they received, such as radiation therapy, which is known to increase the risk of secondary cancers, including meningiomas. However, the overall risk is still relatively low, and not all survivors will develop meningiomas. Further research is needed to fully understand the relationship between childhood leukemia survival and meningioma risk.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can radiotherapy cause radiation induced osteosarcoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Radiotherapy is a cancer treatment that uses high-energy radiation to kill cancer cells. However, exposure to ionizing radiation can damage DNA and increase the risk of developing secondary cancers, including osteosarcoma. Studies have shown that radiation-induced osteosarcoma can occur as a late complication following radiotherapy, particularly in patients treated during childhood or adolescence. The risk depends on factors such as radiation dose, age at exposure, and genetic predisposition. Therefore, while radiotherapy is effective in treating cancer, it can potentially cause radiation-induced osteosarcoma in some cases.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Chernobyl survivors at increased risk for breast cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Chernobyl survivors were exposed to radiation, which is a known risk factor for various cancers, including breast cancer. Studies have shown an increased incidence of certain cancers among survivors, particularly those exposed at a young age or to higher radiation doses. However, the evidence for breast cancer specifically may vary depending on the population studied and the radiation exposure levels. Further research is needed to confirm the extent of the risk.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does radiotherapy for Hodgkin disease increases risk for lung cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Hodgkin disease is a type of lymphoma, and radiotherapy is a common treatment for it. There have been studies that suggest that radiotherapy, especially when delivered to the chest area, can increase the risk of developing secondary cancers, including lung cancer. This is because radiation can damage the DNA of healthy cells, leading to mutations that may result in cancer. However, the risk depends on various factors such as the radiation dose, the area treated, and the patient's age at the time of treatment. Therefore, while there may be an increased risk, it is not a certainty and must be weighed against the benefits of the treatment.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does radiotherapy for cervical cancer increases risk of colon cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Radiotherapy for cervical cancer involves targeted radiation to the pelvic region, which could potentially affect nearby organs such as the colon. Studies have shown that exposure to radiation in this area may increase the risk of secondary cancers, including colon cancer, though the absolute risk remains relatively low. Factors such as radiation dose, field size, and individual patient characteristics also influence this risk.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does radiotherapy for prostate cancer increase bladder cancer risk?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Radiotherapy for prostate cancer involves the use of high-energy rays to kill cancer cells. One concern with this treatment is whether it might increase the risk of developing other cancers, such as bladder cancer. Studies have shown that radiation can potentially damage the DNA of healthy cells, which might lead to secondary cancers. However, the evidence regarding the specific risk of bladder cancer following prostate radiotherapy is mixed. Some studies suggest a slight increase in risk, while others find no significant association. Factors such as the patient's age, overall health, and the specific radiation techniques used can influence this risk. Modern radiotherapy techniques aim to minimize exposure to surrounding healthy tissues, potentially reducing the risk of secondary cancers. Therefore, while there may be a small increased risk, it is not definitively established.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there a role for MRPL53 in cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if there is a role for MRPL53 in cancer, I need to check if MRPL53 has been implicated in cancer-related processes such as cell proliferation, apoptosis, DNA repair, or tumorigenesis. This involves reviewing scientific literature or databases that link MRPL53 to cancer. If studies show that MRPL53 is involved in these processes or is dysregulated in cancer cells, then the answer is yes. Otherwise, if there is no evidence or research indicating a connection, the answer is no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is there a role for TET proteins in invariant natural killer T cells (iNKT) cell fate?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"TET proteins are involved in DNA demethylation and gene expression regulation. iNKT cells are a subset of T cells that recognize lipid antigens. Research suggests that TET proteins may play a role in the development and function of various immune cells, including T cells. However, specific evidence regarding their direct role in iNKT cell fate determination is limited. Some studies indicate that epigenetic modifications, which TET proteins influence, are crucial for iNKT cell differentiation and function. Therefore, while TET proteins might indirectly affect iNKT cell fate through epigenetic mechanisms, a direct role remains unclear.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does Uc.63+ promote sensitivity to treatment in prostate cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question asks whether UC.63+ promotes sensitivity to treatment in prostate cancer. I need to check if UC.63+ is a known factor that enhances the effectiveness of treatments for prostate cancer. UC.63+ is not a commonly recognized term in the context of prostate cancer treatment sensitivity. It might refer to a specific protein, gene, or a compound, but without more context, it's hard to determine. Current literature does not widely document UC.63+ in relation to prostate cancer treatment sensitivity. Therefore, based on existing knowledge, there is no evidence to confirm that UC.63+ promotes treatment sensitivity in prostate cancer.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do de novo truncating mutations in WASF1 cause cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if de novo truncating mutations in WASF1 cause cancer, we need to evaluate the available scientific evidence. WASF1 (WAS protein family member 1) encodes a protein involved in actin cytoskeleton regulation. Truncating mutations, particularly de novo ones, can disrupt protein function. However, causation in cancer requires evidence linking such mutations to tumor development. Current databases like ClinVar or COSMIC may list mutations, but pathogenicity classification depends on criteria such as ACMG guidelines. If truncating mutations are recurrent, absent in healthy populations, and functional studies show oncogenic effects, they may be classified as pathogenic. As of now, limited evidence might exist, and further research could be needed.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does the Mcm2-Ctf4-PolÎ± axis play a role in transfer of histones to leading strand DNA at the replication forks?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is about the role of the Mcm2-Ctf4-PolÎ± axis in transferring histones to leading strand DNA at replication forks. To answer this, I need to recall the functions of these proteins in DNA replication and histone management. Mcm2 is part of the MCM helicase complex, which unwinds DNA at replication forks. Ctf4 (also known as AND-1 in humans) is a protein involved in DNA replication and sister chromatid cohesion. PolÎ± (DNA polymerase alpha) is an enzyme that synthesizes RNA primers and initiates DNA synthesis on the lagging strand. Histone transfer during replication involves processes like histone recycling and deposition behind the replication fork, primarily associated with the replisome. While Mcm2 and Ctf4 are involved in replication fork progression and cohesion, PolÎ±'s role is more related to primer synthesis. There is limited evidence directly linking this specific axis to histone transfer to the leading strand. Histone deposition is more commonly associated with other factors like CAF-1 (chromatin assembly factor 1) and histone chaperones such as Asf1. Therefore, the Mcm2-Ctf4-PolÎ± axis likely does not play a direct role in histone transfer to the leading strand DNA at replication forks.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is AND-1/Ctf4 essential for proliferation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether AND-1/Ctf4 is essential for proliferation. To answer this, I need to determine if AND-1/Ctf4 is required for cell proliferation. AND-1, also known as Ctf4 in yeast, is a protein involved in DNA replication and repair. Studies have shown that Ctf4 is important for maintaining genomic stability and efficient DNA replication. In yeast, Ctf4 is required for sister chromatid cohesion and proper chromosome segregation. In mammalian cells, AND-1 is involved in DNA replication and has been implicated in the regulation of the replisome. Depletion of AND-1/Ctf4 can lead to replication stress and cell cycle arrest, suggesting that it plays a critical role in cell proliferation. Therefore, based on its functions in DNA replication and cell cycle progression, AND-1/Ctf4 is likely essential for proliferation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there a BRCA mutation analysis in the Greek population?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether BRCA mutation analysis has been conducted in the Greek population. BRCA1 and BRCA2 are genes associated with an increased risk of breast and ovarian cancer, and mutation analysis of these genes is commonly performed in clinical settings to assess cancer risk. Studies and research on BRCA mutations have been conducted in various populations worldwide, including different ethnic groups. Regarding the Greek population specifically, there is existing research that has analyzed BRCA mutations in Greece. For example, several studies published in scientific journals have examined the prevalence and spectrum of BRCA mutations in Greek individuals, particularly those with a family history of breast or ovarian cancer. Additionally, genetic testing services in Greece may offer BRCA mutation analysis as part of hereditary cancer risk assessment. Therefore, BRCA mutation analysis has indeed been performed in the Greek population.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can Patient-derived organoids (PDOs) recapitulate patient responses in the clinic?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is whether patient-derived organoids (PDOs) can recapitulate patient responses in the clinic. Research indicates that PDOs are increasingly used in personalized medicine because they can mimic the physiological and pathological characteristics of the patient's original tissue. Studies have shown that PDOs can predict individual patient responses to various treatments, including drug sensitivity and resistance, which aligns with clinical outcomes. However, there are limitations, such as the inability to fully replicate the tumor microenvironment and immune interactions. Despite these challenges, the current evidence suggests that PDOs can largely recapitulate patient responses in many clinical contexts.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Verubecestat effective for Alzheimer's Disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Verubecestat is a drug that has been studied for the treatment of Alzheimer's disease. It works by inhibiting an enzyme called BACE1, which is involved in the production of amyloid-beta plaques, a hallmark of Alzheimer's pathology. Clinical trials have shown mixed results regarding its effectiveness. Some studies suggested that it might reduce amyloid-beta levels in the brain, but others found no significant improvement in cognitive symptoms or disease progression. Additionally, safety concerns have been raised, including potential side effects such as liver toxicity and psychiatric symptoms. As of now, Verubecestat has not been approved by regulatory agencies like the FDA for the treatment of Alzheimer's disease, indicating that its efficacy and safety profile have not met the required standards. Therefore, based on the available evidence, Verubecestat is not considered effective for Alzheimer's disease.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "The LINCS L1000 data set contains gene expression data for drug treated human cells, yes or no?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether the LINCS L1000 data set contains gene expression data for drug treated human cells. I know that LINCS stands for Library of Integrated Network-Based Cellular Signatures, which is a program that aims to create a comprehensive library of molecular signatures from cells treated with various perturbagens, including drugs. The L1000 platform is a high-throughput gene expression profiling technology used in the LINCS program to measure the expression levels of about 1,000 landmark genes that can predict the expression of the remaining genes in the genome. Therefore, the LINCS L1000 data set should contain gene expression data for cells treated with drugs, which are perturbagens. So the answer should be yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is bortezomib a Proteasome inhibitor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Bortezomib is a drug used in the treatment of certain cancers, such as multiple myeloma. It works by inhibiting the proteasome, which is a complex involved in breaking down proteins in cells. By blocking the proteasome, bortezomib prevents the degradation of proteins that regulate cell growth and survival, leading to the death of cancer cells. Therefore, bortezomib is indeed a proteasome inhibitor.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are breaks in double stranded DNA associated with ionizing radiation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Double stranded DNA breaks can be caused by various factors, including radiation. Ionizing radiation, such as X-rays or gamma rays, has enough energy to ionize atoms and molecules, leading to DNA damage. One of the primary types of damage caused by ionizing radiation is double stranded breaks in DNA. Therefore, breaks in double stranded DNA are indeed associated with ionizing radiation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Thymoquinone is ineffective against radiation induced enteritis, yes or no?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"I need to determine whether thymoquinone is ineffective against radiation-induced enteritis. Thymoquinone is an active compound found in Nigella sativa, known for its antioxidant and anti-inflammatory properties. Radiation-induced enteritis is inflammation of the intestines caused by radiation therapy. Studies suggest that thymoquinone may protect against radiation-induced damage due to its antioxidant effects. Therefore, it is likely effective, making the statement that it is ineffective incorrect.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Autophagy is the process where a virus obtains nutrients from it's host, yes or no?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Autophagy is a cellular process where the cell degrades and recycles its own components, not a process where a virus obtains nutrients from its host. Viruses rely on the host's machinery for replication, but autophagy specifically refers to the cell's self-digestion mechanism.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are stretch enhancers transcribed more than super-enhancers?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To answer this question, we need to compare the transcription levels of stretch enhancers and super-enhancers. Stretch enhancers are a type of enhancer element that are longer in length compared to typical enhancers, while super-enhancers are clusters of enhancers that drive high levels of gene expression. Studies have shown that super-enhancers are associated with high transcriptional activity and are often found near genes that are critical for cell identity and disease. However, the term 'transcribed more' can be ambiguous. If it refers to the level of transcription of the enhancer itself, then super-enhancers may show higher levels of enhancer RNA (eRNA) transcription due to their clustered nature and high activity. If it refers to the level of transcription of the target genes, then super-enhancers are generally associated with higher gene expression. Stretch enhancers, while longer, may not necessarily have higher transcription levels compared to super-enhancers. Therefore, the answer depends on the context of what is being transcribed, but generally, super-enhancers are associated with higher transcriptional activity.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is the FIP virus thought to be a mutated strain for the Feline enteric Coronavirus?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The FIP virus, or Feline Infectious Peritonitis virus, is known to originate from a mutation of the Feline Enteric Coronavirus (FECV). FECV typically causes mild or no symptoms in cats, but when it mutates into FIP virus, it leads to a much more severe and often fatal disease called Feline Infectious Peritonitis. This mutation allows the virus to replicate more aggressively and affect the cat's immune system, leading to the characteristic symptoms of FIP. Therefore, the FIP virus is indeed considered a mutated form of the Feline Enteric Coronavirus.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is poliosis circumscripta another term for a white or unpigmented patch of hair or skin?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Poliosis circumscripta refers to a condition characterized by a localized absence of pigment in hair, resulting in white or unpigmented patches. It can affect hair on the scalp, eyebrows, or eyelashes. While it primarily involves hair, it is not typically used to describe unpigmented patches on the skin. Therefore, the term is specific to hair rather than skin.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are stem cell transplants used to treat acute kidney injury?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Stem cell transplants are primarily used in the treatment of various blood cancers and certain genetic disorders. Acute kidney injury (AKI) is typically managed through supportive care, such as dialysis, fluid management, and addressing the underlying cause. While there is ongoing research into regenerative medicine and stem cell therapy for kidney diseases, including AKI, these approaches are not yet standard clinical practice. Therefore, stem cell transplants are not currently a standard treatment for acute kidney injury.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Do circular exons increase gene expression?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Circular exons are a type of RNA structure formed during alternative splicing, where exons are joined in a non-linear order. Some studies suggest that circular RNAs (circRNAs) can regulate gene expression by acting as microRNA sponges, influencing transcription, or interacting with RNA-binding proteins. However, the direct impact of circular exons on increasing gene expression is not well established and may depend on specific cellular contexts or regulatory mechanisms. More research is needed to determine their precise role in gene expression regulation.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are there lncRNAs that control the extent of neuronal outgrowth?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether long non-coding RNAs (lncRNAs) control the extent of neuronal outgrowth. lncRNAs are a type of RNA molecule that do not code for proteins but can regulate gene expression. Neuronal outgrowth refers to the process by which neurons extend their axons and dendrites to form connections with other neurons. There is evidence that lncRNAs play a role in regulating neuronal development and function. For example, some studies have shown that lncRNAs can regulate the expression of genes involved in axon guidance and synapse formation. Additionally, lncRNAs have been implicated in the regulation of neuroplasticity, which is the ability of the brain to change and adapt in response to experience. However, it is not clear whether lncRNAs directly control the extent of neuronal outgrowth or whether they indirectly influence this process through their effects on other aspects of neuronal development and function. Further research is needed to fully understand the role of lncRNAs in neuronal outgrowth.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Selumetinib effective for low-grade glioma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Selumetinib is a MEK inhibitor that has shown activity in clinical trials for certain types of low-grade gliomas, particularly those with specific genetic mutations such as NF1 or BRAF alterations. It works by targeting the MAPK pathway, which is often dysregulated in these tumors. While it has demonstrated efficacy in some cases, its effectiveness can vary depending on the tumor's molecular profile and other factors. Further research and clinical trials are ongoing to better understand its role in treating low-grade gliomas.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does gavestinel improve outcomes of stroke patients?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"I need to check if gavestinel improves outcomes of stroke patients. First, I will search for clinical trials or studies that have investigated the effects of gavestinel on stroke patients. I will look for information on its mechanism of action and any reported results. I will also check for any systematic reviews or meta-analyses that have evaluated its effectiveness. If there is evidence showing that gavestinel leads to better outcomes, such as reduced disability or improved recovery, then the answer is yes. If there is no evidence or if the evidence suggests it does not improve outcomes, then the answer is no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can Enlimomab improve stroke outcomes?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Enlimomab is a monoclonal antibody that targets the CD11/CD18 integrin complex on neutrophils, which plays a role in inflammation. Inflammation is a key component in the pathophysiology of stroke, particularly in the secondary injury following ischemic stroke. By inhibiting the adhesion of neutrophils to endothelial cells, Enlimomab may reduce the inflammatory response and subsequent tissue damage. However, clinical trials are necessary to confirm its efficacy and safety in improving stroke outcomes. Without specific evidence from clinical studies demonstrating a benefit, it is not possible to definitively state that Enlimomab improves stroke outcomes.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should tirilazad be used for treatment of ischemic stroke?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Tirilazad is a drug that has been studied in the context of ischemic stroke. It acts as a thromboxane A2 receptor antagonist and has anti-inflammatory properties. Some clinical trials have investigated its potential neuroprotective effects in acute ischemic stroke. However, the evidence regarding its efficacy and safety in this specific indication may be limited or inconclusive. Regulatory approval and clinical guidelines would influence whether it is recommended for use. Further research might be necessary to establish its role definitively.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Aptiganel effective for treatment of stroke?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Aptiganel is a drug that has been studied for its potential neuroprotective effects in conditions like stroke. However, clinical trials have not conclusively shown it to be effective for the treatment of stroke. Some studies suggested possible benefits, but the overall evidence remains inconclusive, and it is not currently approved for this use.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should Lubeluzole be used for treatment of ischemic stroke?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Lubeluzole is a drug that has been studied for its potential neuroprotective effects in the treatment of ischemic stroke. It acts as a sodium channel blocker and has anti-inflammatory properties. Some clinical trials have investigated its efficacy, but the results have been mixed. While some studies suggest it may improve outcomes when administered early, others have not found significant benefits. Additionally, Lubeluzole is not currently approved by major regulatory agencies like the FDA or EMA for the treatment of ischemic stroke. Given the lack of consistent evidence and regulatory approval, it is not recommended for routine use in clinical practice.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is there a vaccine for peanut allergy?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Peanut allergy is a common food allergy, and traditionally, there is no vaccine to prevent or treat it. However, there are ongoing research and clinical trials exploring immunotherapy options, such as oral immunotherapy (OIT) or epicutaneous immunotherapy (EPIT), which aim to desensitize individuals to peanuts. These treatments are not vaccines in the traditional sense but are therapeutic approaches. As of now, no vaccine has been approved for peanut allergy.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Have toll-like receptor 2 activators been found in food?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Toll-like receptors (TLRs) are proteins that play a key role in the innate immune system by recognizing pathogen-associated molecular patterns (PAMPs). TLR2 specifically recognizes bacterial lipoproteins and other microbial components. Activators of TLR2 are typically associated with pathogens, but there is some research indicating that certain components in food might interact with TLRs. For example, some studies have suggested that dietary components like certain fats, plant compounds, or microbial products present in food could modulate immune responses through TLRs, including TLR2. However, the extent to which specific TLR2 activators have been identified in food is not well established. The primary activators of TLR2 are microbial in origin, and while food can contain microbial components (e.g., from bacteria in fermented foods), it is unclear whether these are considered TLR2 activators in the same sense as pathogenic PAMPs. More research may be needed to confirm the presence of specific TLR2 activators in food.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Rad4/XPC a DNA damage sensing protein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Rad4/XPC is a DNA damage sensing protein. It is involved in the recognition of DNA damage during nucleotide excision repair.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there interactions between short and long noncoding RNAs?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Yes, there are interactions between short and long noncoding RNAs. These interactions can occur through various mechanisms, such as base pairing, RNA-RNA duplex formation, or through shared binding sites for RNA-binding proteins. For example, long noncoding RNAs (lncRNAs) can act as molecular sponges for microRNAs (miRNAs), which are short noncoding RNAs, thereby regulating gene expression by sequestering these miRNAs and preventing them from targeting messenger RNAs (mRNAs). Conversely, short noncoding RNAs can also influence the stability, localization, or function of lncRNAs. These interactions play important roles in various biological processes, including development, differentiation, and disease.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is indinavir effective for treatment of amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Indinavir is a protease inhibitor used in the treatment of HIV. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. There is no evidence or approved indication for indinavir in treating ALS. The primary treatments for ALS focus on symptom management and slowing disease progression, not protease inhibitors.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is golimumab effective for sarcoidosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Golimumab is a TNF-alpha inhibitor, which is primarily used for autoimmune diseases like rheumatoid arthritis and psoriatic arthritis. Sarcoidosis is an inflammatory disease that can affect multiple organs, and TNF-alpha inhibitors have been explored as a treatment option for sarcoidosis. However, the effectiveness of golimumab specifically for sarcoidosis is not well-established. Most clinical evidence for TNF-alpha inhibitors in sarcoidosis comes from studies involving infliximab or adalimumab. There is limited data or clinical trials specifically supporting the use of golimumab for sarcoidosis. Therefore, while TNF-alpha inhibitors may be effective in some sarcoidosis cases, golimumab's efficacy for this condition is not clearly proven.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is marimastat effective for small-cell lung cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Marimastat is a matrix metalloproteinase (MMP) inhibitor that has been studied in various cancers, including small-cell lung cancer (SCLC). Clinical trials have evaluated its efficacy in SCLC, but results have not shown significant effectiveness. Marimastat has not been approved for the treatment of SCLC, and current standard therapies remain the primary options.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are astronauts in higher risk for developing cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Astronauts are exposed to higher levels of radiation in space, which is a known risk factor for cancer. However, the overall risk depends on various factors such as the duration of exposure, the type of radiation, and individual susceptibility. Studies on astronauts have shown mixed results, with some indicating an increased risk and others showing no significant difference compared to the general population. Therefore, while there are potential risk factors, it is not definitively established that astronauts are at a higher risk for developing cancer.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is g-H2AX a marker for double strand breaks?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether gamma-H2AX (g-H2AX) is a marker for double-strand breaks (DSBs). DSBs are a type of DNA damage where both strands of the DNA molecule are broken, and they can lead to genomic instability and cell death if not properly repaired. g-H2AX refers to a phosphorylated form of the histone protein H2AX, which is a component of chromatin. When DSBs occur, H2AX is rapidly phosphorylated at serine 139 to form g-H2AX, which serves as a marker for the presence of DNA damage. This phosphorylation event is mediated by members of the phosphatidylinositol 3-kinase-related kinase (PI3KK) family, such as ATM, ATR, and DNA-PK. The formation of g-H2AX occurs within minutes after DSB induction and is essential for the recruitment of repair proteins to the site of damage. Therefore, g-H2AX is widely used as a sensitive and reliable biomarker for detecting DSBs in cells.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does natalizumab improve disease course of secondary progressive multiple sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Natalizumab is a monoclonal antibody that targets Î±4-integrin and is primarily used in the treatment of relapsing-remitting multiple sclerosis (RRMS). It works by preventing immune cells from crossing the blood-brain barrier, thereby reducing inflammation and lesion formation. However, its efficacy in secondary progressive multiple sclerosis (SPMS) is less clear. Clinical trials, such as the AFFIRM and SENTINEL studies, primarily demonstrated benefits in RRMS, showing reduced relapse rates and disability progression. For SPMS, which is characterized by a more gradual worsening of symptoms without distinct relapses, the evidence is limited. Some studies suggest that natalizumab may slow disability progression in patients with SPMS who still have evidence of inflammatory activity, such as gadolinium-enhancing lesions on MRI. However, there is no conclusive evidence that it significantly alters the overall disease course in the broader SPMS population. Therefore, while natalizumab may be beneficial in certain cases of SPMS with active inflammation, it is not generally considered a first-line treatment for SPMS.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are multipotent adult progenitor cells effective for treatment of stroke?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The effectiveness of multipotent adult progenitor cells (MAPCs) for the treatment of stroke is a topic of ongoing research. Some preclinical studies and early-phase clinical trials have suggested that MAPCs may have potential in promoting recovery after stroke, possibly through mechanisms such as reducing inflammation, promoting neuroprotection, and supporting tissue repair. However, the evidence from large-scale, randomized controlled trials is still limited, and more research is needed to establish their efficacy and safety conclusively. Therefore, while there are promising indications, it cannot be definitively stated that MAPCs are effective for stroke treatment at this time.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is ozanezumab effective for amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Ozanezumab is an investigational monoclonal antibody that targets a protein called EphA4, which has been implicated in the progression of amyotrophic lateral sclerosis (ALS). Preclinical studies and early clinical trials have suggested that ozanezumab may have potential as a treatment for ALS by reducing neurodegeneration. However, as of the latest available data, there is no conclusive evidence from large-scale, phase III clinical trials confirming its efficacy and safety for widespread use in treating ALS. Therefore, while preliminary results are promising, it cannot be definitively stated that ozanezumab is effective for ALS.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are gut microbiota profiles altered by irradiation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether gut microbiota profiles are altered by irradiation. Gut microbiota refers to the community of microorganisms living in the digestive tract, and irradiation refers to exposure to ionizing radiation. Ionizing radiation can damage DNA and other cellular components, which can affect microbial communities. Studies have shown that radiation exposure can lead to changes in the composition and diversity of gut microbiota. For example, radiation therapy for cancer can cause gastrointestinal side effects, which may be related to alterations in the gut microbiome. Therefore, it is likely that irradiation does alter gut microbiota profiles.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are genomic regulatory blocks (GRBs) any different than TADs?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Genomic regulatory blocks (GRBs) and topologically associating domains (TADs) are both structural features of chromatin organization, but they differ in their definitions and functions. GRBs are regions of the genome that contain clusters of cis-regulatory elements, such as enhancers and silencers, which regulate gene expression. These blocks are often conserved across species and are associated with the regulation of key developmental genes. TADs, on the other hand, are regions of the genome where the chromatin interacts more frequently within the domain than with regions outside of it. TADs are identified through techniques like Hi-C, which maps the three-dimensional organization of the genome. While GRBs focus on regulatory elements and their target genes, TADs emphasize the physical organization and interaction patterns of chromatin. Although there can be some overlap between GRBs and TADs, they represent different concepts: GRBs are functional regulatory units, whereas TADs are structural units based on interaction frequencies.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is Nivolumab (Opdivo) a PD-L1 inhibitor?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Nivolumab (Opdivo) is a monoclonal antibody that targets the programmed death-1 (PD-1) receptor, not PD-L1. It works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby enhancing T-cell activation and immune response against cancer cells.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is PF-05190457 an inverse agonist of the ghrelin receptor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"PF-05190457 is a compound developed by Pfizer. The ghrelin receptor, also known as the growth hormone secretagogue receptor (GHSR), is involved in various physiological processes, including appetite regulation and energy homeostasis. An inverse agonist is a type of ligand that binds to a receptor and induces a response opposite to that of an agonist. In the case of PF-05190457, studies have shown that it acts as an inverse agonist at the ghrelin receptor, meaning it reduces the constitutive activity of the receptor. This property makes it a potential therapeutic agent for conditions such as Prader-Willi syndrome, where excessive hunger is a significant issue.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients, we need to examine the existing scientific literature on this topic. LY6K is a member of the lymphocyte antigen 6 (Ly-6) superfamily, which has been implicated in various biological processes, including cell signaling and immune regulation. In the context of cancer, the expression levels of certain Ly-6 family members have been linked to tumor progression and patient outcomes. However, the specific role of LY6K in NSCLC prognosis is not well established. Some studies may suggest that overexpression of LY6K could be associated with more aggressive tumor behavior or poorer outcomes, while others might not find a significant association. Without specific evidence indicating a positive correlation between LY6K overexpression and improved prognosis in NSCLC, it is not possible to affirm that such a relationship exists.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does the BRAFV600E mutation have an effect on clinical response to radioiodine therapy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The BRAF V600E mutation is a genetic alteration commonly found in papillary thyroid cancer. Studies have shown that this mutation is associated with more aggressive tumor behavior and a poorer prognosis. Regarding radioiodine therapy, some research suggests that the presence of the BRAF V600E mutation may be linked to reduced uptake of radioiodine in cancer cells, potentially leading to a less effective treatment response. However, the evidence is not entirely conclusive, and further research is needed to fully understand the relationship between this mutation and radioiodine therapy outcomes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does metformin has as an antitumor effect?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Metformin is a drug commonly used to treat type 2 diabetes. Some studies have suggested that metformin may have potential antitumor effects, possibly due to its ability to reduce insulin resistance and lower insulin levels, which can promote cancer cell growth. However, more research is needed to confirm these effects and determine the extent of metformin's role in cancer prevention or treatment.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine whether xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS), it is necessary to evaluate clinical evidence and research findings. Xaliproden is a neuroprotective agent that has been investigated for its potential benefits in neurodegenerative diseases, including ALS. However, the effectiveness of xaliproden in improving ALS prognosis depends on the results of clinical trials and peer-reviewed studies. As of the latest available data, there is insufficient conclusive evidence to confirm that xaliproden significantly improves the prognosis of ALS. Further research may be required to establish its efficacy in this context.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is celecoxib effective for amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) primarily used for pain and inflammation. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. While inflammation may play a role in ALS progression, clinical evidence does not strongly support celecoxib as an effective treatment. Some studies suggest potential benefits, but results are inconclusive. The primary treatments for ALS are riluzole and edaravone, which have demonstrated efficacy in clinical trials. Therefore, celecoxib is not considered a standard or proven effective therapy for ALS.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should Pentoxifylline be used for treatment of amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Pentoxifylline is a phosphodiesterase inhibitor that has been studied in the context of various neurological conditions. However, for amyotrophic lateral sclerosis (ALS), the evidence supporting its use is limited and inconclusive. Major clinical guidelines, such as those from the ALS Association and other neurology organizations, do not recommend pentoxifylline as a standard treatment for ALS. While some studies have explored its potential neuroprotective effects, the results have not been consistent or robust enough to warrant routine use. Therefore, based on current evidence and guidelines, pentoxifylline should not be used for the treatment of ALS.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does clinical trial data support the use of minocycline for amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"I need to check if there are clinical trials that support the use of minocycline for amyotrophic lateral sclerosis (ALS). Minocycline is an antibiotic with potential neuroprotective properties. Some studies have investigated its use in neurodegenerative diseases, including ALS. However, clinical trial results may vary. I should look for evidence from randomized controlled trials (RCTs) or systematic reviews evaluating minocycline's efficacy in ALS. If there are positive findings from such trials, the answer would be 'yes'; otherwise, 'no'.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Dexmecamylamine effective for depression?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Dexmecamylamine is a neuromuscular blocking agent, primarily used in anesthesia to induce muscle relaxation and facilitate tracheal intubation. It is not indicated for the treatment of depression. Depression is typically managed with antidepressants such as SSRIs, SNRIs, or other psychiatric medications. Therefore, Dexmecamylamine is not effective for depression.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is NicVAX vaccine effective for smoking cessation?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"NicVAX is a vaccine that was developed to help people quit smoking by targeting nicotine. The vaccine works by stimulating the immune system to produce antibodies that bind to nicotine, preventing it from reaching the brain and producing the pleasurable effects associated with smoking. Clinical trials have shown mixed results regarding its effectiveness. Some studies indicated that it could help reduce smoking rates, particularly in certain subgroups, but overall, the efficacy has not been consistently strong enough to lead to widespread approval or use. As of now, NicVAX is not approved by the FDA for smoking cessation, which suggests that it has not met the necessary standards for effectiveness and safety required for approval. Therefore, while there is some evidence that it might be beneficial for certain individuals, it is not considered a standard or highly effective treatment for smoking cessation.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Figitumumab effective for non-small cell lung cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if figitumumab is effective for non-small cell lung cancer (NSCLC), I need to check clinical trial data and regulatory approvals. Figitumumab is a monoclonal antibody targeting the RANK ligand, and while it has been studied in various cancers, its approval and efficacy specifically for NSCLC need verification. A review of recent studies and FDA/EMA guidelines will provide clarity.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Semagacestat effective for Alzheimer's Disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Semagacestat is a gamma-secretase inhibitor that was investigated for the treatment of Alzheimer's disease. However, clinical trials showed that it did not provide cognitive benefits and was associated with adverse effects, including skin cancer. As a result, its development for Alzheimer's disease was discontinued. Therefore, Semagacestat is not considered effective for Alzheimer's disease.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can Systemic Lupus Erythematosus cause seizures?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can affect various organs and tissues. One of the potential complications of SLE is neurological involvement, which can lead to seizures. Therefore, SLE can cause seizures.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is MAGE-A3 immunotherapeutic effective for non-small-cell lung cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine the effectiveness of MAGE-A3 immunotherapeutic for non-small-cell lung cancer (NSCLC), I need to consider clinical trial results and current medical guidelines. MAGE-A3 is a cancer-testis antigen that has been studied as a target for immunotherapy in various cancers, including NSCLC. Research has focused on vaccines or other immunotherapies designed to target MAGE-A3. However, clinical trials have not consistently shown significant efficacy of MAGE-A3-targeted therapies in NSCLC. For example, large trials of the MAGE-A3 vaccine in NSCLC patients did not demonstrate a significant improvement in overall survival or disease-free survival. As a result, MAGE-A3 immunotherapeutic is not currently considered effective for NSCLC, and it is not a standard treatment option.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Impetigo a viral infection that affects the skin?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Impetigo is a skin infection. I need to check if it's caused by a virus. From what I remember, impetigo is usually caused by bacteria, specifically Staphylococcus aureus or Streptococcus pyogenes. Viral infections would be different, like herpes or warts. So the answer should be no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Î±CGRP a member of the CGRP family?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking if Î±CGRP is part of the CGRP family. I know that CGRP refers to Calcitonin Gene-Related Peptide, which is a neuropeptide involved in various physiological processes, including vasodilation and pain transmission. There are different forms of CGRP, such as Î±CGRP and Î²CGRP. These are isoforms of the CGRP peptide, which are produced from different genes or through alternative splicing. Since Î±CGRP is one of the forms of CGRP, it is indeed a member of the CGRP family.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do genes with monoallelic expression contribute proportionally to genetic diversity in humans?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Monoallelic expression refers to the expression of only one allele of a gene, which can occur through various mechanisms such as genomic imprinting or X-chromosome inactivation. In contrast, genetic diversity is typically measured by the presence of multiple alleles within a population. Since monoallelic expression involves the expression of only one allele, it does not contribute to genetic diversity in the same way as biallelic expression, where both alleles are expressed and can lead to a greater variety of phenotypes. Therefore, genes with monoallelic expression do not contribute proportionally to genetic diversity in humans.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is deletion at 6q24.2-26 associated with shorter survival for ovarian cancer patients?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Deletion at 6q24.2-26 is a genetic alteration that may impact the prognosis of ovarian cancer patients. To determine if this deletion is associated with shorter survival, we need to refer to clinical studies or genomic research that links this specific chromosomal deletion to patient outcomes. Existing literature suggests that certain chromosomal deletions can lead to the loss of tumor suppressor genes, which may result in more aggressive cancer behavior and poorer survival rates. However, the specific association of 6q24.2-26 deletion with survival in ovarian cancer patients requires direct evidence from survival analysis studies, such as those using Kaplan-Meier curves or Cox proportional hazards models. If such studies show a statistically significant correlation between the presence of this deletion and reduced overall or progression-free survival, then the answer would be 'yes.' Otherwise, if no significant association is found, the answer would be 'no.'\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does promoter shape vary across populations?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Promoters are regions of DNA that initiate transcription of a gene. Their shape can influence gene expression by affecting the binding of RNA polymerase and other transcription factors. Genetic variation across populations can lead to differences in promoter sequences, which may alter their three-dimensional structure. Such variations might result in population-specific gene expression patterns. Studies on population genetics have shown that regulatory regions, including promoters, can exhibit variability. Therefore, it is plausible that promoter shapes vary across populations due to genetic differences.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the CADM2 gene associated with differences in information processing speed?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To answer this question, I need to determine if the CADM2 gene is associated with differences in information processing speed. First, I will recall what I know about the CADM2 gene. CADM2, also known as Cell Adhesion Molecule 2, is a gene that encodes a protein involved in cell adhesion and signaling. Previous research has suggested that CADM2 may play a role in brain development and function. For example, genome-wide association studies (GWAS) have linked CADM2 to cognitive traits, including processing speed. Processing speed refers to the time it takes for an individual to process and respond to information, which is a component of cognitive ability. If CADM2 has been found in studies to be significantly associated with processing speed, then the answer would be yes. If there is no strong evidence or conflicting evidence, the answer would be no. Based on my knowledge, CADM2 has been implicated in cognitive functions and has been associated with processing speed in some studies. Therefore, the answer is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is KAT2A involved in Acute myeloid leukemia (AML)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"KAT2A (lysine acetyltransferase 2A), also known as GCN5, is an enzyme that plays a role in histone acetylation and gene regulation. Dysregulation of histone acetylation has been implicated in various cancers, including leukemia. In the context of Acute Myeloid Leukemia (AML), several studies have investigated the role of KAT2A. Research suggests that KAT2A may contribute to leukemogenesis by affecting the acetylation status of histones and other proteins involved in cell proliferation and differentiation. In particular, KAT2A has been shown to interact with certain fusion proteins, such as those involving MLL (Mixed Lineage Leukemia) gene rearrangements, which are associated with AML. These interactions may lead to aberrant gene expression patterns that promote leukemic transformation. Therefore, KAT2A is considered to be involved in the pathogenesis of AML.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "AhR ligands are attractive drug targets for pharmaceutical development due to their induction of Cyp1a1, yes or no?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"AhR ligands are attractive drug targets for pharmaceutical development due to their induction of Cyp1a1. The question is whether this statement is correct. AhR (aryl hydrocarbon receptor) is a ligand-activated transcription factor involved in the regulation of various genes, including those involved in xenobiotic metabolism. Cyp1a1 is a cytochrome P450 enzyme that is known to be induced by AhR activation. The induction of Cyp1a1 is often associated with the metabolism of xenobiotics, including drugs and environmental toxins. However, whether AhR ligands are considered attractive drug targets specifically because they induce Cyp1a1 requires further analysis. In pharmaceutical development, drug targets are typically selected based on their role in disease pathways, and the induction of Cyp1a1 may not necessarily be the primary reason for targeting AhR. In some cases, activation of AhR and subsequent induction of Cyp1a1 may be considered an adverse effect, as it can lead to the metabolism and potential detoxification or bioactivation of compounds. Therefore, the statement may not be accurate.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Glucoraphanin from broccoli can help reduce obesity , yes or no?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Studies suggest that glucoraphanin, found in broccoli, may have anti-obesity effects by influencing metabolism and fat cell regulation, but more research is needed to confirm its efficacy in humans.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has saracatinib been tested in clinical trials?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Saracatinib (AZD0530) is a small molecule tyrosine kinase inhibitor that has been studied in various preclinical and clinical settings. It was initially developed by AstraZeneca for the treatment of cancer, particularly solid tumors and hematologic malignancies. Saracatinib has been evaluated in several clinical trials, primarily in phase I and II studies, to assess its safety, tolerability, and efficacy in treating various types of cancer, including breast cancer, prostate cancer, and leukemia. Some of these trials have been completed, while others may have been terminated or are ongoing. Therefore, based on the available information, saracatinib has indeed been tested in clinical trials.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does saracatinib promote oncogenesis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Saracatinib is a small molecule tyrosine kinase inhibitor that targets several kinases, including Src family kinases. It was being investigated for the treatment of various cancers. Inhibiting kinases involved in cell proliferation and survival pathways would generally be expected to suppress oncogenesis rather than promote it. However, the exact effects can depend on the specific cellular context and the presence of other mutations or factors. Based on the known mechanism of action of saracatinib, it is more likely to inhibit rather than promote cancer development.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has MLE4901 been tested in phase III clinical trials?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"I need to check if MLE4901 has undergone phase III clinical trials. First, I will search for information on MLE4901 and its clinical trial phases. If I find evidence of phase III trials, the answer is yes; otherwise, no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does ESN364 activate the hypothalamic-pituitary-gonadal axis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine whether ESN364 activates the hypothalamic-pituitary-gonadal (HPG) axis, I would need to check scientific literature or reliable sources for any studies or information regarding ESN364 and its effects on the HPG axis. Since ESN364 does not appear to be a widely recognized compound or term in standard scientific databases or literature, there may be no established evidence indicating its role in activating the HPG axis. Further clarification or context about ESN364 might be necessary to provide a definitive answer.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is traditional Chinese medicine associated with a decreased risk of heart failure in breast cancer patients receiving doxorubicin treatment?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether traditional Chinese medicine (TCM) is linked to a lower risk of heart failure in breast cancer patients who are undergoing treatment with doxorubicin. Doxorubicin is a chemotherapy drug known to have potential cardiotoxic side effects, which can lead to heart failure. Some studies suggest that certain TCMs may have cardioprotective properties that could potentially mitigate the damage caused by doxorubicin. However, the evidence is not yet conclusive, and more rigorous clinical trials are needed to establish a definitive association. Therefore, while there may be some promising preliminary findings, it cannot be definitively stated that TCM decreases the risk of heart failure in this context.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is the protein ABCG2 (ATP-Binding Cassette, subfamily G, member 2, transporter) excreting uric acid?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"ABCG2 is a member of the ATP-binding cassette (ABC) transporter family, which is involved in the transport of various molecules across cell membranes. It has been shown to play a role in the excretion of uric acid, a waste product of purine metabolism. Studies have indicated that ABCG2 is expressed in tissues such as the liver and kidney, which are involved in the elimination of uric acid from the body. Mutations in the ABCG2 gene have been associated with hyperuricemia, a condition characterized by elevated levels of uric acid in the blood, suggesting that ABCG2 plays a significant role in uric acid excretion. Therefore, it can be concluded that ABCG2 is involved in the excretion of uric acid.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the protein ABCG2 transmembrane?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"ABCG2, also known as ATP-binding cassette sub-family G member 2, is a protein that is involved in transporting various molecules across cell membranes. Proteins involved in transport across cell membranes are typically transmembrane proteins, meaning they span the lipid bilayer of the cell membrane. Given that ABCG2 is part of the ATP-binding cassette (ABC) transporter family, which is known for its members being transmembrane proteins, it is likely that ABCG2 is transmembrane.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can brain derived exosomes carry APP molecules?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Exosomes derived from the brain can carry various proteins, including amyloid precursor protein (APP). Studies have shown that exosomes can transport APP and other related proteins, which may play a role in the pathogenesis of neurodegenerative diseases like Alzheimer's disease.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can Flotillin be used as exosomal marker?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Flotillin is a protein that is commonly found in lipid rafts and has been implicated in various cellular processes, including membrane trafficking and signal transduction. Exosomes are small vesicles that are released by cells and contain various proteins, lipids, and nucleic acids. Some proteins are commonly used as markers for exosomes, such as CD63, CD81, and TSG101. Flotillin has been found in exosomes in some studies, but it is not one of the most commonly used markers. Therefore, while Flotillin may be present in exosomes, it is not typically used as a primary marker for exosomes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has the Spanich flu virus been reconstructed?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The Spanish flu virus, also known as the 1918 influenza virus, has been a subject of scientific interest. Researchers have studied preserved tissue samples from victims of the 1918 pandemic to understand its genetic makeup. In 2005, a team of scientists successfully reconstructed the virus's genome using RNA fragments extracted from a victim buried in Alaska. This reconstruction allowed for the study of the virus's properties and its high virulence. Therefore, the Spanish flu virus has indeed been reconstructed.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Liâ€“Fraumeni syndrome a rare, autosomal recessive, hereditary disorder that predisposes carriers to cancer development?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Liâ€“Fraumeni syndrome is a rare, autosomal dominant, hereditary disorder that predisposes carriers to cancer development. The key point here is the inheritance pattern: it's autosomal dominant, not autosomal recessive. Therefore, the statement in the question is incorrect.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are ICAMS, Intracellular Adhesion Molecules, part of the immunoglobulin superfamily?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"ICAMS, or Intracellular Adhesion Molecules, are known to play a role in cell adhesion. The immunoglobulin superfamily includes proteins with immunoglobulin-like domains. Researching whether ICAMS have these domains or are classified under this family is necessary. Upon checking, ICAMS do contain immunoglobulin-like domains and are indeed part of the immunoglobulin superfamily.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The Paramyxovirus genome is a single-stranded, negative-sense RNA. It is not segmented, meaning it exists as a single piece rather than multiple segments. This structure allows the virus to use its RNA-dependent RNA polymerase to transcribe mRNA.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is there a vaccine for rotavirus?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Rotavirus is a common cause of severe diarrhea in infants and young children. Vaccines have been developed to prevent rotavirus infection. Two main vaccines are currently available: Rotarix and RotaTeq. These vaccines are part of the routine immunization schedule in many countries and have been shown to be effective in reducing severe rotavirus disease. Therefore, the answer is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Spinal Intradural Primary Malignant Peripheral Nerve Sheath Tumors(MPNST) rare in neurofibromatosis patients?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Spinal intradural primary MPNSTs are rare in neurofibromatosis patients because MPNSTs typically arise from peripheral nerves outside the spinal cord. Neurofibromatosis patients are more prone to developing benign nerve sheath tumors like neurofibromas and schwannomas, but malignant transformation into MPNSTs within the spinal intradural space is uncommon.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does AZD3759 cross the blood brain barrier?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"AZD3759 is a drug candidate that has been studied for its ability to cross the blood-brain barrier. The blood-brain barrier is a protective mechanism that prevents many substances from entering the brain from the bloodstream. For a drug to be effective in treating central nervous system (CNS) disorders, it often needs to cross this barrier. AZD3759 has been specifically designed to have properties that allow it to penetrate the blood-brain barrier, making it a potential treatment for conditions affecting the CNS. Based on available information, AZD3759 does cross the blood-brain barrier.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is PTEN a tumour suppressor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"PTEN is a well-known tumour suppressor gene. It encodes a phosphatase that negatively regulates the PI3K/AKT/mTOR signaling pathway, which is involved in cell survival, growth, and proliferation. Loss or mutation of PTEN leads to activation of this pathway, contributing to tumorigenesis. Therefore, PTEN functions as a tumour suppressor.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is MLL3 part of the ASCOM complex?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To answer this question, I need to determine if MLL3 is a component of the ASCOM complex. MLL3 (Mixed Lineage Leukemia 3) is a protein involved in histone methylation and gene regulation. The ASCOM complex (also known as the ASCOM-N-CoR complex) is a multi-protein complex involved in transcriptional repression and chromatin remodeling. Research indicates that MLL3 is part of the ASCOM complex, where it contributes to the complex's histone methyltransferase activity. Therefore, MLL3 is indeed a component of the ASCOM complex.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are astrocytes part of the blood brain barrier?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Astrocytes are a type of glial cell in the brain and spinal cord. They perform various functions, including maintaining the extracellular environment, providing metabolic support to neurons, and contributing to the repair and scarring process of the central nervous system. The blood-brain barrier (BBB) is a highly selective semipermeable membrane barrier that separates the circulating blood from the brain extracellular fluid in the central nervous system (CNS). The BBB is primarily formed by brain endothelial cells that are connected by tight junctions. However, astrocytes are involved in the regulation and maintenance of the BBB. They send out processes called endfeet that wrap around blood vessels and release factors that influence the formation and function of the BBB. Therefore, while astrocytes are not the structural components of the BBB themselves, they play a supportive role in its function.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is the protein MCL-1 anti-apoptotic?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"MCL-1 (Myeloid Cell Leukemia 1) is a member of the BCL-2 family of proteins, which are known to regulate apoptosis. Specifically, MCL-1 functions as an anti-apoptotic protein by inhibiting the activation of pro-apoptotic proteins such as BAX and BAK. This inhibition prevents mitochondrial outer membrane permeabilization, thereby blocking the release of cytochrome c and subsequent activation of caspases that lead to apoptosis. Therefore, MCL-1 plays a crucial role in promoting cell survival and preventing programmed cell death.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are bacteria in the genus Clostridium facultative anaerobes?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Bacteria in the genus Clostridium are generally obligate anaerobes, meaning they cannot tolerate oxygen and require an oxygen-free environment to grow. Facultative anaerobes, on the other hand, can grow with or without oxygen. Since Clostridium species are not known to survive in the presence of oxygen, they are not classified as facultative anaerobes.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has ORMD-0801 been tested in patients?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether ORMD-0801 has been tested in patients. To answer this, I need to check if there is any clinical trial data or published research indicating that ORMD-0801 has undergone human testing. If ORMD-0801 is a drug or medical device, its testing phase (preclinical vs. clinical) would determine the answer. If there is no available information on clinical trials or patient testing, the answer would be 'no'.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Was vivotif licensed in Europe and the US at the same time?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Vivotif is a typhoid vaccine. I need to check if it was licensed in both Europe and the US simultaneously. I recall that Vivotif was developed by a Swiss company, so it might have been approved in Europe first. However, I'm not sure about the exact timeline of its licensing in the US. I should verify the dates of approval in both regions to determine if they were simultaneous.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can AGY be used as antidiuretic replacement therapy?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"AGY is not a recognized antidiuretic hormone or medication. The primary antidiuretic hormone is vasopressin (ADH), and synthetic versions like desmopressin are used in replacement therapy. AGY does not appear to be relevant in this context.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Have the rotavirus vaccines changed the predominant rotavirus genotypes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Rotavirus vaccines have been shown to reduce the overall incidence of rotavirus infections. However, there is ongoing research to determine if these vaccines have led to a change in the predominant genotypes of the virus circulating in the population. Some studies suggest that while vaccine-targeted genotypes have decreased, non-vaccine genotypes may be becoming more prevalent. Therefore, it is possible that rotavirus vaccines have influenced the distribution of genotypes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can leuprorelin acetate be used as androgen deprivation therapy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Leuprorelin acetate is a synthetic analog of gonadotropin-releasing hormone (GnRH). Androgen deprivation therapy (ADT) is a treatment that reduces the levels of male hormones, such as testosterone, in the body. GnRH agonists like leuprorelin acetate work by suppressing the production of testosterone from the testes, which is a key component of ADT. Therefore, leuprorelin acetate can be used as part of androgen deprivation therapy.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can MVA85A confer immunity against smallpox?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"MVA85A is a vaccine candidate designed to boost immune responses against tuberculosis (TB). It is a modified vaccinia Ankara (MVA) vector expressing the TB antigen Ag85A. Smallpox is caused by the variola virus, and its immunity is typically conferred by vaccines such as ACAM2000 or JYNNEOS. Since MVA85A is specifically targeted at TB and not smallpox, it is unlikely to confer immunity against smallpox.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is the drug Exubera currently (March 2020) available?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Exubera is an inhaled insulin that was approved by the FDA in 2006 but was discontinued in 2007 due to poor sales and concerns about its effectiveness and safety. As of March 2020, there is no indication that Exubera has been reintroduced to the market. Therefore, it is likely that Exubera is not available as of March 2020.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has the drug Afrezza been approved by the FDA?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"I need to check if Afrezza has received FDA approval. I recall that Afrezza is a medication used for diabetes, but I'm not sure about its approval status. I should verify this information by consulting the FDA's official website or a reliable medical database.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the Fluzone intradermal and the Fluzone intradermal quadrivalent vaccine produced by different companies?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether Fluzone intradermal and Fluzone intradermal quadrivalent vaccines are produced by different companies. First, I need to identify the manufacturers of these vaccines. Fluzone is a brand of influenza vaccine produced by Sanofi Pasteur. Both the intradermal and quadrivalent versions are part of the Fluzone product line. Since both vaccines are under the same brand and company, they are produced by the same company.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can Daptacel be used instead of IPOL?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Daptacel is a vaccine used for immunization against diphtheria, tetanus, and pertussis. IPOL is a vaccine used for immunization against polio. Since they target different diseases, Daptacel cannot be used instead of IPOL.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can CMB305 be used against sarcomas?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if CMB305 can be used against sarcomas, I need to check if there is any research or clinical evidence supporting its efficacy for this specific type of cancer. Sarcomas are a diverse group of cancers that develop in connective tissues, and treatment options often depend on the specific subtype. CMB305 is an investigational immunotherapy that targets certain antigens, so its effectiveness would depend on whether those antigens are present in sarcoma cells. I will review available clinical trials, scientific literature, and regulatory approvals to find relevant information.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Has ZP-PTH been tested in a phase II clinical trial?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To answer this question, we need to determine if ZP-PTH has undergone testing in a phase II clinical trial. This would involve checking clinical trial databases, scientific literature, or official announcements from the drug's developer or regulatory agencies. If there is documented evidence of a phase II trial, the answer is \\\"yes\\\"; otherwise, it is \\\"no\\\".\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is SARS virus interacting with ACE2 encoded protein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether the SARS virus interacts with the ACE2 encoded protein. The SARS virus, specifically SARS-CoV, is known to use the ACE2 receptor to enter human cells. ACE2 is a protein encoded in the human genome, and it serves as the entry point for the virus into the cell. Therefore, the SARS virus does interact with the ACE2 encoded protein.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is ACE2 expressed on cell surfaces?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"ACE2 is a protein that is encoded by the ACE2 gene in humans. It is a receptor for the SARS-CoV-2 virus, which causes COVID-19. ACE2 is primarily expressed on the surface of cells in the lungs, but it is also found in other tissues such as the heart, kidneys, and intestines. The expression of ACE2 on cell surfaces allows the virus to enter the cells and cause infection. Therefore, the answer to the question is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is cathepsin L active in endosomes?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Cathepsin L is a lysosomal cysteine protease that is involved in various cellular processes, including protein degradation and antigen processing. Endosomes are membrane-bound compartments that are part of the endocytic pathway, and they can mature into lysosomes. Since cathepsin L is primarily active in lysosomes, and endosomes can transition into lysosomes, it is possible that cathepsin L becomes active in endosomes as they mature. However, cathepsin L is typically considered to be most active in the acidic environment of lysosomes. Therefore, while cathepsin L may be present in endosomes, its activity is likely more pronounced in lysosomes.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is endotrophin derived from collagen?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Endotrophin is a protein that has been studied in relation to various biological processes. To determine if endotrophin is derived from collagen, one would need to examine its molecular origin. Collagen is a structural protein, and if endotrophin is a fragment or product of collagen processing, then the answer would be yes. However, if endotrophin is a distinct protein produced independently, the answer would be no. Research indicates that endotrophin is actually a cleavage product of collagen VI, specifically from the alpha-3 chain of collagen type VI. This means that endotrophin is indeed derived from collagen.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Protoporphyrinogen oxidase localized to the mitochondrium?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Protoporphyrinogen oxidase (PPO) is an enzyme involved in the heme biosynthesis pathway. Heme is a critical component of hemoglobin, myoglobin, and various enzymes. The heme biosynthesis pathway occurs in multiple cellular compartments, including the mitochondria and the cytoplasm. Specifically, PPO catalyzes the oxidation of protoporphyrinogen IX to protoporphyrin IX, which is the penultimate step in heme synthesis. This reaction takes place in the mitochondria, where the final step of heme synthesis, the insertion of iron into protoporphyrin IX, also occurs. Therefore, PPO is localized to the mitochondria to facilitate its role in heme production.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is aggrephagy a variant of autophagy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Aggrephagy is a type of selective autophagy that specifically targets aggregated proteins for degradation. Since it is a selective form of autophagy, it can be considered a variant of autophagy.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does protein ALEX1 contain armadillo repeats?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if protein ALEX1 contains armadillo repeats, I would need to check its amino acid sequence for the characteristic 42-amino acid repeat motif found in armadillo proteins. This can be done using bioinformatics tools such as BLAST or Pfam to search for known armadillo repeat domains in the ALEX1 protein sequence.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is Bcl-2-like protein 1 an pro apoptotic protein?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Bcl-2-like protein 1 (BCL2L1), also known as Bcl-x, is a member of the Bcl-2 family of proteins, which are key regulators of apoptosis. The Bcl-2 family includes both pro-apoptotic and anti-apoptotic proteins. BCL2L1 has two main isoforms: Bcl-xL, which is anti-apoptotic, and Bcl-xS, which is pro-apoptotic. The question does not specify which isoform is being referred to. However, when referring to BCL2L1 in general, it is often associated with its anti-apoptotic function due to the prominence of the Bcl-xL isoform. Therefore, BCL2L1 is generally considered an anti-apoptotic protein, not a pro-apoptotic one.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do nematodes contain a CTCF gene?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Nematodes, such as Caenorhabditis elegans, are model organisms in genetic studies. CTCF (CCCTC-binding factor) is a highly conserved zinc finger protein involved in chromatin organization and gene regulation in vertebrates. However, invertebrates like nematodes lack the CTCF gene. Studies have shown that CTCF is present in deuterostomes (e.g., vertebrates) but absent in protostomes (e.g., nematodes and arthropods). Therefore, nematodes do not contain a CTCF gene.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does steroid 5A-Reductase deficiency lead to hermaphroditism?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Steroid 5-alpha-reductase deficiency is a genetic disorder that affects the body's ability to convert testosterone to dihydrotestosterone (DHT). DHT is crucial for the development of male external genitalia during fetal development. Individuals with this deficiency may have ambiguous genitalia at birth, which can sometimes be mistaken for hermaphroditism. However, hermaphroditism typically refers to the presence of both ovarian and testicular tissue, which is not the case in 5-alpha-reductase deficiency. Instead, the condition results in underdeveloped or ambiguous genitalia due to insufficient DHT.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is the TFR1 gene dispensable for erythropoiesis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The TFR1 gene encodes the transferrin receptor protein 1, which is crucial for iron uptake in cells. Erythropoiesis, the process of red blood cell formation, requires significant amounts of iron for hemoglobin synthesis. Since TFR1 facilitates iron absorption, its presence is essential for erythropoiesis. Therefore, the TFR1 gene is not dispensable for this process.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are somatic mutations positioned towards the nuclear periphery?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Somatic mutations refer to genetic changes that occur in non-germline cells, and their distribution within the nucleus can vary depending on various factors such as cell type, genomic region, and functional elements. The positioning of somatic mutations towards the nuclear periphery is not a general rule but may occur in specific contexts. The nuclear periphery is associated with heterochromatin and gene-poor regions, and mutations in these regions might be less likely to have functional consequences. However, mutations can occur throughout the genome, including both the nuclear periphery and more central regions, depending on the specific circumstances.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is Mediator present at super enhancers?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Mediator is a coactivator complex that is involved in transcriptional regulation. Super enhancers are clusters of enhancers that drive high levels of gene expression. Studies have shown that Mediator is recruited to enhancers and plays a role in their function. Therefore, it is likely that Mediator is present at super enhancers.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Tcf3 associated with the Wnt pathway?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tcf3, also known as Transcription Factor 3, is a member of the TCF/LEF family of transcription factors. These proteins are known to play a role in the Wnt signaling pathway, where they act as transcriptional effectors. In the absence of Wnt signals, TCF proteins like Tcf3 typically repress gene expression, while in the presence of Wnt signals, they interact with beta-catenin to activate transcription of Wnt target genes. Therefore, Tcf3 is indeed associated with the Wnt pathway.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Nanog repressed in pluripotent stem cells?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Nanog is a transcription factor that plays a crucial role in maintaining pluripotency in stem cells. In pluripotent stem cells, such as embryonic stem cells (ESCs), Nanog is typically expressed at high levels. Repression of Nanog would lead to differentiation, as it is essential for self-renewal and pluripotency. Therefore, Nanog is not repressed in pluripotent stem cells under normal conditions.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do nematodes contain architectural proteins like CTCF?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Nematodes are a type of worm that are commonly used in biological research. CTCF is a protein that is involved in the regulation of gene expression and is known to be involved in the formation of chromatin structure. It is found in many animals, including humans. However, it is not clear whether nematodes contain CTCF or other architectural proteins. To answer this question, I would need to search for scientific literature that has investigated the presence of CTCF in nematodes. If there is evidence that nematodes do contain CTCF or other architectural proteins, then the answer would be yes. If there is no evidence, then the answer would be no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do polycomb group proteins (PcG) mediate the formation of chromatin loops?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Polycomb group proteins (PcG) are known to play a role in chromatin structure and gene regulation, primarily by modifying histones and compacting chromatin to repress gene expression. Chromatin loops are formed through various mechanisms involving architectural proteins like CTCF and cohesin, which help organize the genome into domains. While PcG proteins contribute to chromatin compaction and higher-order structure, there is limited evidence directly linking them to the formation of chromatin loops. Their primary function seems to be in maintaining repressive chromatin states rather than loop formation, which is more associated with other factors like CTCF and cohesin.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are super enhancers structurally insulated in chromatin loops?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Super enhancers are clusters of enhancers that drive high levels of gene expression and are often associated with genes critical for cell identity. Chromatin loops are structures formed by the three-dimensional organization of chromatin, which can bring distant genomic regions into close proximity. Structural insulation in chromatin loops refers to the ability of certain genomic elements, such as CTCF binding sites, to block inappropriate interactions between enhancers and promoters. While super enhancers can be located within chromatin loops, the question is whether they are structurally insulated within these loops. Insulation would imply that the chromatin loop boundaries prevent the super enhancer from interacting with other regions outside the loop. Current research suggests that super enhancers are often found in large chromatin loops that are insulated by CTCF and cohesin complexes, which help maintain the specificity of enhancer-promoter interactions. Therefore, super enhancers are structurally insulated within chromatin loops by these boundary elements.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Are there negative enhancers?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Enhancers are DNA sequences that can increase the transcription of genes. They are typically considered to be positive regulators of gene expression. However, some studies have suggested that there may be negative enhancers, which can decrease gene expression. These negative enhancers may work by recruiting repressive chromatin modifiers or by interfering with the function of positive enhancers. However, the existence and mechanism of negative enhancers are still under investigation and not yet fully understood.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are enhancers directional in their targeting of gene promoters?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Enhancers are DNA sequences that can increase the transcription of genes. They can be located upstream, downstream, or even within the genes they regulate. Enhancers work by binding specific transcription factors and other proteins, which then interact with the promoter region of the target gene to enhance transcription. However, enhancers are not directional in their targeting of gene promoters. They can act on promoters regardless of their orientation (forward or reverse) relative to the promoter. This is because the proteins bound to the enhancer can loop around the DNA to interact with the promoter, regardless of the enhancer's orientation. Therefore, the answer to the question is no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is the zelda transcription factor a chromatin remodeller?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The Zelda transcription factor is known for its role in gene regulation, particularly in Drosophila development. Chromatin remodellers are proteins that modify chromatin structure to regulate gene expression. While Zelda can influence chromatin accessibility and gene activation, it is primarily classified as a transcription factor rather than a chromatin remodeller. Its function involves binding to DNA and recruiting other factors, but it does not directly modify chromatin structure like canonical chromatin remodellers do.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is methotrexate used for the treatment of Rheumatoid Arthritis (RA)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Methotrexate is a disease-modifying antirheumatic drug (DMARD) commonly prescribed for Rheumatoid Arthritis. It helps reduce inflammation and slow the progression of the disease by suppressing the immune system. It is often considered a first-line treatment for RA.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can ATAC-Seq be employed in single-cell mode?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"ATAC-Seq (Assay for Transposase-Accessible Chromatin using sequencing) is a technique used to study chromatin accessibility across the genome. It involves the use of a transposase enzyme to fragment DNA at open chromatin regions, which are then sequenced to identify accessible regions. Single-cell ATAC-Seq is a variation of the method that adapts the protocol for use with individual cells, allowing the analysis of chromatin accessibility at the single-cell level. This adaptation typically involves microfluidics or other methods to isolate individual cells and perform the ATAC-Seq protocol on each cell separately. Therefore, ATAC-Seq can indeed be employed in single-cell mode.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is yeast fbp1 affected by glucose starvation stress?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether the yeast fbp1 gene is affected by glucose starvation stress. To answer this, I need to determine if the expression or activity of the fbp1 gene in yeast is influenced by conditions of glucose starvation. Fbp1 is known to encode fructose-1,6-bisphosphatase, an enzyme involved in gluconeogenesis, which is the process of synthesizing glucose from non-carbohydrate precursors. In yeast, gluconeogenesis is typically activated when glucose levels are low, suggesting that fbp1 expression might be upregulated under glucose starvation conditions. Studies have shown that under glucose starvation, yeast cells switch to using alternative carbon sources, and genes involved in gluconeogenesis, including fbp1, are indeed induced. Therefore, the yeast fbp1 is affected by glucose starvation stress, as its expression is regulated in response to glucose availability.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does an antiphlogistic promotes inflammation?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether an antiphlogistic promotes inflammation. The prefix 'anti-' typically indicates opposition or prevention. The term 'phlogistic' relates to inflammation. Therefore, an antiphlogistic would likely inhibit or reduce inflammation rather than promote it.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can SMAD6 variants cause craniosynostosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Craniosynostosis is a condition where the bones in an infant's skull close prematurely, leading to abnormal skull shape and potential developmental issues. SMAD6 is a gene involved in the BMP (bone morphogenetic protein) signaling pathway, which plays a role in bone development. Research has indicated that mutations in SMAD6 can be associated with certain craniosynostosis syndromes, particularly in non-syndromic cases or in combination with other genetic factors. For example, studies have shown that loss-of-function mutations in SMAD6 can lead to increased BMP signaling, which may contribute to the premature fusion of cranial sutures. However, SMAD6 variants are not the most common cause of craniosynostosis, as other genes like FGFRs (fibroblast growth factor receptors) and TWIST1 are more frequently implicated in syndromic forms of the condition. In summary, while SMAD6 variants can contribute to craniosynostosis in some cases, they are not the primary cause in most instances.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can propofol cause green urine?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Propofol is a medication primarily used for anesthesia. One of its known side effects is a condition called propofol infusion syndrome, but this is rare. Regarding green urine specifically, there are no widely reported or recognized cases of propofol causing green urine. Green urine is more commonly associated with other factors such as certain foods, medications, or medical conditions. Therefore, it is unlikely that propofol directly causes green urine.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can radiosurgery be used for the DNET tumors?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Dysembryoplastic neuroepithelial tumor (DNET) is a benign, mixed neuronal-glial tumor typically found in children and young adults, often associated with epilepsy. The primary treatment for DNET is complete surgical resection, which is usually curative. Radiosurgery, such as stereotactic radiosurgery (SRS), is a non-invasive procedure that delivers high-dose radiation to a targeted area. While radiosurgery is used for various brain tumors, especially in cases where surgery is not feasible, DNETs are generally treated with surgery due to their benign nature and the potential for complete cure through resection. However, in cases where complete resection is not possible or if there is recurrence, radiosurgery may be considered as an adjunctive treatment. Therefore, radiosurgery can be used for DNET tumors under certain circumstances.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Was golimumab tested for diabetes?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Golimumab is a medication used to treat autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis. It works by targeting tumor necrosis factor-alpha (TNF-alpha), which is involved in inflammation. While it may have some effects on metabolic processes, it is not primarily tested or indicated for the treatment of diabetes. Therefore, the answer is no.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Nelson's syndrome is a condition that occurs after removal of both adrenal glands in patients with Cushing's disease, leading to increased ACTH levels and pituitary tumor growth. Cabergoline is a dopamine agonist used to treat hyperprolactinemia and Parkinson's disease. It is not typically used for Nelson's syndrome, which is usually managed with radiation therapy or surgery. Therefore, the answer is no.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is proton beam therapy used for treatment of craniopharyngioma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Craniopharyngioma is a type of brain tumor that typically occurs near the pituitary gland and hypothalamus. Treatment options for craniopharyngioma often include surgery, radiation therapy, and sometimes chemotherapy. Proton beam therapy is a specialized form of radiation therapy that uses protons instead of X-rays to target tumors with precision, potentially reducing damage to surrounding healthy tissues. Given its precision, proton beam therapy can be a suitable option for treating tumors located in sensitive areas like the brain. Therefore, it is plausible that proton beam therapy is used for treating craniopharyngioma, especially when surgery is not fully effective or when there is a need to minimize radiation exposure to nearby critical structures.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can Panitumumab cause trichomegaly?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Panitumumab is a monoclonal antibody used in the treatment of certain cancers, such as colorectal cancer. It works by targeting the epidermal growth factor receptor (EGFR). Trichomegaly refers to the abnormal growth or elongation of hair. While Panitumumab's side effects include skin-related issues like rash, itching, and dry skin, there is no widely reported or established association between Panitumumab and trichomegaly in medical literature or clinical trial data. Therefore, it is unlikely that Panitumumab causes trichomegaly.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Do exon 38 or 39 KMT2D missense variants cause Kabuki syndrome type 1 (KS1)?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Kabuki syndrome type 1 (KS1) is primarily caused by mutations in the KMT2D gene, which are typically loss-of-function variants such as nonsense, frameshift, or splice site mutations. Missense variants in exons 38 or 39 of KMT2D are not commonly associated with KS1, as these exons are not hotspots for pathogenic mutations in this syndrome. Most disease-causing variants lead to haploinsufficiency of the KMT2D protein. Therefore, missense variants in exons 38 or 39 are unlikely to be causative for KS1.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is tirabrutinib effective for lymphoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tirabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor, which is primarily used in the treatment of certain types of lymphomas, such as mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). It works by blocking the BTK enzyme, which is involved in the survival and proliferation of cancerous B-cells. Clinical trials and studies have shown that tirabrutinib can be effective in treating these conditions, particularly in patients who have relapsed or are refractory to other treatments. However, its effectiveness can vary depending on the specific type of lymphoma and individual patient factors.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is fusobacterium associated with Lemierre's syndrome?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Lemierre's syndrome is a rare but serious condition characterized by septic thrombophlebitis of the internal jugular vein, often following a recent oropharyngeal infection. The primary causative agent associated with Lemierre's syndrome is Fusobacterium necrophorum, an anaerobic gram-negative bacillus commonly found in the oropharynx. The infection typically starts as a sore throat or tonsillitis, which then progresses to a peritonsillar abscess. From there, the bacteria can spread to the internal jugular vein, leading to thrombophlebitis and septic emboli, which can affect various organs, particularly the lungs. The association between Fusobacterium and Lemierre's syndrome is well-documented in medical literature, with Fusobacterium necrophorum being the most frequently isolated organism in cases of this syndrome.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is progeria caused by an autosomal recessive gene?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Progeria is a rare genetic disorder characterized by the rapid aging of children. It is caused by a mutation in the LMNA gene, which is responsible for producing the lamin A protein. This mutation leads to the production of an abnormal protein called progerin. The inheritance pattern of progeria is typically autosomal dominant, meaning that a single copy of the mutated gene is sufficient to cause the disorder. However, in some cases, it can also occur as a new mutation in individuals with no family history of the condition. Since the question asks if progeria is caused by an autosomal recessive gene, the answer would be no because it is primarily an autosomal dominant disorder.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there a genetic cause of craniostenosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Craniostenosis, also known as craniosynostosis, is a condition where one or more of the fibrous sutures in an infant's skull prematurely fuse, leading to restricted skull growth and potential complications. Research has shown that there are both genetic and environmental factors that can contribute to this condition. Some cases of craniosynostosis are associated with specific genetic mutations, particularly those involving the FGFR (fibroblast growth factor receptor) genes, such as FGFR1, FGFR2, and FGFR3. These mutations can lead to syndromic forms of craniosynostosis, such as Apert syndrome, Crouzon syndrome, and Pfeiffer syndrome, which are inherited in an autosomal dominant manner. Additionally, other genetic syndromes, like Saethre-Chotzen syndrome and Muenke syndrome, are also linked to craniosynostosis. However, many cases are non-syndromic and may occur sporadically without a clear genetic cause, possibly due to a combination of genetic predispositions and environmental influences. Therefore, while not all cases of craniosynostosis have a definitive genetic cause, a significant portion do involve genetic factors.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is acupotomy used to treat muscle stiffness?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Acupotomy, also known as needle knife therapy, is a traditional Chinese medicine technique that involves inserting a small needle into specific points on the body to relieve pain and improve function. It is often used for musculoskeletal conditions, including muscle stiffness, by releasing tension and promoting blood flow. Therefore, acupotomy can be used to treat muscle stiffness.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is carpal tunnel syndrome a type of nerve entrapment?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Carpal tunnel syndrome occurs when the median nerve is compressed as it passes through the carpal tunnel in the wrist. Nerve entrapment refers to a condition where a nerve is compressed or pinched, leading to pain, numbness, or weakness. Since carpal tunnel syndrome involves the compression of a nerve, it fits the definition of nerve entrapment.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there any role of genotoxic pks + E. coli in cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether there is any role of genotoxic pks+ E. coli in cancer.  Genotoxic pks+ E. coli refers to a strain of Escherichia coli that produces a genotoxic substance called pks (polyketide synthase).  Pks is a toxin that can damage DNA.  Several studies have investigated the potential role of pks+ E. coli in cancer development.  Some studies have found an association between the presence of pks+ E. coli and certain types of cancer, such as colorectal cancer.  However, other studies have not found a consistent association.  The evidence is currently inconclusive.  More research is needed to determine if there is a causal relationship between pks+ E. coli and cancer.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is avelumab effective for urothelial carcinoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Avelumab is a PD-L1 inhibitor that has been approved for the treatment of certain cancers, including urothelial carcinoma. It works by blocking the interaction between PD-L1 and PD-1 receptors, which helps the immune system recognize and attack cancer cells. Clinical trials have shown that avelumab can be effective in treating advanced or metastatic urothelial carcinoma, particularly in patients who have progressed after platinum-based chemotherapy. Therefore, avelumab is considered effective for urothelial carcinoma in specific clinical settings.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does a comet assay measure radiation induced mutations?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The comet assay, also known as single-cell gel electrophoresis, is a technique used to detect DNA damage at the level of individual cells. It is commonly used to assess DNA strand breaks, which can be caused by various factors including radiation. However, the comet assay does not specifically measure mutations; rather, it detects DNA damage such as single and double-strand breaks. Mutations are changes in the DNA sequence that may result from unrepaired or incorrectly repaired DNA damage. While radiation can induce mutations, the comet assay itself does not directly measure these mutations but rather the initial damage that could potentially lead to mutations if not properly repaired.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is MIS-C or Multisystem  Inflammatory syndrome in children a complication of Covid-19?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"MIS-C, or Multisystem Inflammatory Syndrome in Children, is a rare but serious condition associated with COVID-19. It typically occurs in children who have been infected with the virus or have been exposed to someone with the virus. The syndrome causes inflammation in various body parts, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs. While the exact cause is not fully understood, it is considered a post-infectious complication that can develop weeks after the initial infection. Therefore, MIS-C is recognized as a potential complication of COVID-19.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is SLIC-CAGE used for quantification of translation?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"SLIC-CAGE is a method used in molecular biology. It combines aspects of SLIC (Sequence and Ligation Independent Cloning) and CAGE (Cap Analysis Gene Expression). CAGE is primarily used for identifying transcription start sites and quantifying gene expression at the RNA level. SLIC is a cloning technique that allows for the insertion of DNA fragments into vectors without the need for restriction enzymes or ligase. The combination, SLIC-CAGE, might be used for cloning specific regions of interest followed by CAGE analysis. Since CAGE quantifies RNA transcripts, it relates to transcription rather than translation. Therefore, SLIC-CAGE is likely not used for quantification of translation but rather for analyzing transcription start sites and RNA expression.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is adenosine signaling prognostic for cancer outcome?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Adenosine signaling has been implicated in various physiological and pathological processes, including cancer. In the context of cancer, adenosine can promote tumor growth, metastasis, and resistance to therapy through its immunosuppressive effects and influence on the tumor microenvironment. However, whether adenosine signaling is specifically prognostic for cancer outcomeâ€”that is, whether it can predict the course or outcome of cancerâ€”requires a review of clinical studies linking adenosine-related biomarkers to patient prognosis. Some studies have suggested that elevated adenosine levels or the overexpression of adenosine receptors (e.g., A2AR, A2BR) in tumor tissues may correlate with poorer clinical outcomes, such as reduced survival or increased tumor progression. These findings suggest that adenosine signaling could have prognostic value in certain cancers. However, the evidence may vary depending on the cancer type, stage, and the specific components of the adenosine signaling pathway being measured. Therefore, while there is some evidence supporting a prognostic role for adenosine signaling, further research is needed to establish its reliability and clinical applicability across different cancers.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does bleomycin cause lung toxicity?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Bleomycin is a chemotherapy drug used to treat various cancers. One of the known side effects of bleomycin is lung toxicity, which can lead to conditions such as pneumonitis and pulmonary fibrosis. This toxicity is a significant concern, especially in older patients or those with pre-existing lung conditions. Therefore, bleomycin can indeed cause lung toxicity.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there sex differences in oncogenic mutational processes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether there are differences between sexes in the processes that cause cancer through mutations. This involves examining if the mechanisms that lead to cancer-causing mutations vary between males and females. Research in oncology and genetics may provide evidence on whether such differences exist, considering factors like hormonal influences, genetic predispositions, and environmental interactions. The answer would depend on current scientific findings related to sex-based variations in mutational processes leading to cancer.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is co-loss of BRCA2-RB1 associated with better prognosis for prostate cancer patients?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether the co-loss of BRCA2 and RB1 genes is associated with a better prognosis for prostate cancer patients. BRCA2 and RB1 are both tumor suppressor genes, and their loss or mutation can lead to genomic instability and cancer progression. In prostate cancer, alterations in these genes are often associated with more aggressive disease and poorer clinical outcomes. However, some studies may suggest different implications based on specific contexts or patient subgroups. To answer this question accurately, it is necessary to refer to clinical studies or literature that specifically investigate the prognostic significance of BRCA2 and RB1 co-loss in prostate cancer patients. Current evidence generally indicates that the loss of these genes is linked to worse prognosis, but ongoing research may provide more nuanced insights.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is there a role for Dickkopf-1 (DKK1) in prostate cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Dickkopf-1 (DKK1) is a protein that plays a role in the Wnt signaling pathway, which is involved in various cellular processes, including cell proliferation and differentiation. In the context of prostate cancer, research suggests that DKK1 may act as a tumor suppressor by inhibiting the Wnt/Î²-catenin pathway, which is often dysregulated in cancer. However, some studies have also indicated that DKK1 can have oncogenic properties in certain contexts, depending on the cellular environment and other factors. Therefore, the role of DKK1 in prostate cancer may be complex and context-dependent.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Benralizumab effective for Chronic Spontaneous Urticaria?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Benralizumab is an interleukin-5 receptor antagonist primarily used for the treatment of severe asthma. Chronic Spontaneous Urticaria (CSU) is a condition characterized by hives without a specific trigger. While Benralizumab targets eosinophils, which are involved in some allergic reactions, the primary mediators in CSU are mast cells and histamine. There is limited evidence supporting the use of Benralizumab for CSU, and current guidelines recommend other therapies such as antihistamines, omalizumab, or corticosteroids. Therefore, Benralizumab is not considered effective for CSU.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is belimumab effective for the lupus nephritis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Belimumab is a monoclonal antibody that targets B-lymphocyte stimulator (BLyS), which is involved in the survival of B cells. It is approved for the treatment of systemic lupus erythematosus (SLE) in patients who have not responded adequately to standard therapies. Lupus nephritis is a complication of SLE that affects the kidneys. Clinical trials have shown that belimumab can reduce disease activity and improve outcomes in patients with SLE, including those with lupus nephritis. However, its effectiveness can vary among individuals, and it is typically used as an add-on therapy rather than a first-line treatment.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is liraglutide effective for weight reduction?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Liraglutide is a medication primarily used for the treatment of type 2 diabetes, but it has also been approved for weight management. It works by mimicking a hormone called GLP-1, which regulates appetite and food intake. Clinical trials have shown that liraglutide can lead to significant weight loss in individuals who are overweight or obese, especially when combined with lifestyle changes such as diet and exercise. Therefore, liraglutide is considered effective for weight reduction.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Eflornithine and Sulindac are effective for prevention of progression in Familial Adenomatous Polyposis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Eflornithine and Sulindac are not typically used for the prevention of progression in Familial Adenomatous Polyposis (FAP). FAP is a genetic disorder characterized by the development of numerous polyps in the colon and rectum, which can progress to cancer if not managed. The primary management for FAP is usually surgical removal of the colon (colectomy) and/or rectum (proctectomy), depending on the extent of polyp involvement. Surveillance with regular colonoscopies and rectoscopies is also crucial. While some studies have explored the use of nonsteroidal anti-inflammatory drugs (NSAIDs) like sulindac in reducing polyp burden, their role is limited and not considered a primary preventive measure for progression. Eflornithine is primarily used for the treatment of African trypanosomiasis and for hirsutism in women, and it is not indicated for FAP. Therefore, the effectiveness of Eflornithine and Sulindac for the prevention of progression in FAP is not established.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is ofatumumab effective for multiple sclerosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Ofatumumab is a monoclonal antibody that targets CD20, a protein found on the surface of B cells. It is primarily used in the treatment of certain types of cancer, such as chronic lymphocytic leukemia (CLL) and follicular lymphoma. However, its use in multiple sclerosis (MS) has been explored in clinical trials. In MS, the immune system attacks the central nervous system, and therapies that target B cells have shown promise. Clinical trials have indicated that ofatumumab may reduce relapse rates and MRI lesion activity in patients with relapsing-remitting MS. Based on available evidence, ofatumumab demonstrates efficacy in treating MS.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Olaparib effective for prostate cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Olaparib is a PARP inhibitor that is primarily used for treating certain types of ovarian and breast cancer, particularly those associated with BRCA gene mutations. However, recent studies have explored its effectiveness in treating prostate cancer, especially in cases with specific genetic mutations, such as those involving DNA repair genes like BRCA1, BRCA2, or ATM. Clinical trials have shown that Olaparib may have some efficacy in treating advanced prostate cancer in patients with these mutations. Therefore, while Olaparib is not a first-line treatment for prostate cancer, it may be effective in specific cases with particular genetic profiles.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has tocilizumab been assessed against Covid-19?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tocilizumab is an interleukin-6 receptor inhibitor that has been studied in the context of various inflammatory conditions. Regarding its assessment against COVID-19, clinical trials and research have been conducted to evaluate its efficacy and safety in treating patients with severe or critical illness. Based on available data, tocilizumab has been included in some treatment guidelines for specific patient populations under certain conditions.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is tocilizumab a tumor necrosis factor inhibitor?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor. It is used to treat conditions like rheumatoid arthritis and cytokine release syndrome. Tumor necrosis factor (TNF) inhibitors, on the other hand, target TNF-alpha, a different cytokine involved in inflammation. Since tocilizumab works on IL-6 and not TNF-alpha, it is not classified as a TNF inhibitor.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is tofacitinib a JAK inhibitor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tofacitinib is a drug used to treat certain autoimmune diseases. It works by inhibiting specific enzymes involved in the immune response. JAK inhibitors are a class of drugs that target Janus kinases, which are enzymes involved in the signaling pathways of cytokines. Tofacitinib specifically inhibits JAK1 and JAK3, which are members of the JAK family. Therefore, tofacitinib is indeed a JAK inhibitor.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does the use of bDMARDs during pregnancy impact neonatal development?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Biologic disease-modifying antirheumatic drugs (bDMARDs) are used to treat autoimmune diseases such as rheumatoid arthritis. Their use during pregnancy raises concerns about potential effects on the developing fetus. Some studies suggest that certain bDMARDs may cross the placenta, particularly in the third trimester, potentially affecting the neonate's immune system. However, the overall evidence is mixed, with some research indicating no significant adverse outcomes, while others suggest a possible increased risk of infections or developmental issues. Guidelines often recommend caution and individualized risk-benefit assessments. Given the complexity and variability in research findings, the impact on neonatal development is not definitively established but warrants careful consideration.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is tocilizumab a csDMARD?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Tocilizumab is a biologic DMARD (bDMARD) that targets the interleukin-6 (IL-6) receptor. csDMARDs, such as methotrexate, sulfasalazine, and leflunomide, are conventional synthetic DMARDs typically used as first-line treatments in rheumatoid arthritis. Since tocilizumab is a biologic agent rather than a conventional synthetic drug, it is not classified as a csDMARD.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is vocimagene amiretrorepvec effective for glioblastoma?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To determine if vocimagene amiretrorepvec is effective for glioblastoma, I need to check clinical trial results and medical literature. Vocimagene amiretrorepvec is a gene therapy that delivers the herpes simplex virus thymidine kinase gene into tumor cells, making them susceptible to the antiviral drug ganciclovir. Clinical trials have shown some promise in extending survival in patients with glioblastoma when used in combination with ganciclovir. However, the overall effectiveness may vary, and it is not yet widely approved as a standard treatment. Further analysis of recent studies is needed to confirm its efficacy.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does addition of valproic acid improve survival of patients with diffuse intrinsic pontine glioma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Valproic acid (VPA) is an anticonvulsant and mood-stabilizing drug commonly used in the treatment of epilepsy and bipolar disorder. Some studies have suggested that VPA may have anti-tumor effects due to its ability to inhibit histone deacetylases (HDACs), which can lead to changes in gene expression that might suppress tumor growth. In the context of diffuse intrinsic pontine glioma (DIPG), a highly aggressive and difficult-to-treat brain tumor primarily affecting children, there has been interest in exploring VPA as an adjunct therapy. However, clinical trials and systematic reviews have not consistently shown a significant improvement in survival outcomes for DIPG patients treated with VPA in combination with standard therapies like radiation. While some preclinical studies and case reports suggest potential benefits, the overall evidence from rigorous clinical trials remains limited and inconclusive. Therefore, based on current data, the addition of VPA does not demonstrate a clear survival benefit for DIPG patients.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is capmatinib effective for glioblastoma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Capmatinib is a targeted therapy drug primarily used for treating non-small cell lung cancer (NSCLC) with specific genetic mutations, such as MET exon 14 skipping mutations. Glioblastoma, a type of aggressive brain cancer, has different molecular characteristics and treatment approaches. While research into targeted therapies for glioblastoma is ongoing, there is currently no widely accepted evidence or FDA approval indicating that capmatinib is effective for glioblastoma. Clinical trials may explore its potential in this context, but as of now, it is not a standard treatment for glioblastoma.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should cerebrolysin be used for aneurysmal subarachnoid hemorrhage?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Cerebrolysin is a neuroprotective drug that has been studied in various neurological conditions, including aneurysmal subarachnoid hemorrhage (aSAH). Its mechanism involves promoting nerve growth and protecting neurons from damage. However, the evidence regarding its efficacy in aSAH is mixed. Some studies suggest potential benefits in improving outcomes, while others show no significant effect. Guidelines from major neurological associations do not currently recommend its routine use due to insufficient conclusive evidence. Therefore, based on current guidelines and available research, the use of cerebrolysin for aSAH is not routinely advised.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Tranexamic acid effective for intracerebral haemorrhage?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tranexamic acid is an antifibrinolytic agent that is used to reduce bleeding by preventing the breakdown of blood clots. Its effectiveness in intracerebral haemorrhage (ICH) has been studied, particularly in the context of acute ICH to limit haematoma expansion. Some clinical trials have suggested that it may be beneficial in certain scenarios, such as when administered early after symptom onset. However, the overall evidence is mixed, and guidelines may vary. The effectiveness may depend on factors like timing of administration, patient selection, and the specific population studied. Further research may be needed to establish definitive recommendations.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Can thiotepa be recommended for treatment of osteosarcoma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Thiotepa is an alkylating agent primarily used in the treatment of various cancers, including breast cancer, ovarian cancer, and certain types of leukemia. However, its use in osteosarcoma is not commonly documented. Osteosarcoma treatment typically involves a combination of surgery and chemotherapy, with drugs like methotrexate, doxorubicin, cisplatin, and ifosfamide being more commonly used. There is limited evidence or standard guidelines recommending thiotepa as a primary treatment for osteosarcoma. Therefore, it is unlikely that thiotepa would be recommended for this specific condition.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does hypofractionated radiotherapy offers any benefit for DIPG?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Hypofractionated radiotherapy delivers higher doses of radiation over fewer sessions compared to conventional fractionation. For diffuse intrinsic pontine glioma (DIPG), which is an aggressive and difficult-to-treat brain tumor in children, conventional radiotherapy has been the standard of care, providing temporary tumor control and symptom relief. However, DIPG remains uniformly fatal. Research into hypofractionated regimens has explored whether this approach could offer improved tumor control or survival, particularly given the poor prognosis with standard treatment. Some studies have investigated hypofractionated schedules to potentially intensify the radiation effect while maintaining safety, but results have not consistently shown a significant survival benefit. Therefore, while hypofractionated radiotherapy may offer logistical advantages by shortening treatment duration, its clinical benefit in terms of survival or tumor control for DIPG remains uncertain and not clearly superior to conventional approaches.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is isradipine effective for Parkinson's disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Isradipine is a calcium channel blocker primarily used to treat hypertension. While some research suggests it may have neuroprotective properties and could potentially slow the progression of Parkinson's disease by reducing calcium influx in neurons, clinical evidence is still limited and inconclusive. It is not currently approved as a treatment for Parkinson's disease.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should nerinetide be used for treatment of ischaemic stroke?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Nerinetide is a drug that has been studied for the treatment of ischaemic stroke. According to recent clinical trials, such as the ENDO-AV study, nerinetide has shown potential in improving outcomes when used in conjunction with thrombectomy. However, its use may depend on specific patient factors and the clinical context. Current guidelines may not universally recommend it, but it could be considered in certain cases under medical supervision.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Lanabecestat effective for Alzheimer's disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Lanabecestat is a drug that has been studied for the treatment of Alzheimer's disease. It works by inhibiting the production of beta-amyloid, a protein that accumulates in the brains of individuals with Alzheimer's. Clinical trials have shown mixed results regarding its effectiveness. Some studies suggest it may slow cognitive decline, while others indicate limited benefits. The drug's efficacy can vary based on the stage of the disease and individual patient factors. Ongoing research is necessary to determine its overall effectiveness and safety profile.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should minocycline be used for mild Alzheimer disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Minocycline is a tetracycline antibiotic with anti-inflammatory properties. While some studies have explored its potential neuroprotective effects in neurodegenerative diseases, there is limited evidence supporting its use specifically for Alzheimer's disease. Current guidelines do not recommend minocycline as a standard treatment for Alzheimer's, including mild cases. Treatment typically focuses on FDA-approved medications like cholinesterase inhibitors. Therefore, minocycline should not be used for mild Alzheimer's disease.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is MK-1602 a CGRP antagonist?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if MK-1602 is a CGRP antagonist, I need to check if it blocks the calcitonin gene-related peptide (CGRP) receptors or inhibits CGRP signaling. CGRP antagonists are typically used for migraine treatment by preventing CGRP from binding to its receptors. I will verify MK-1602's pharmacological profile to confirm its role as a CGRP antagonist.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Has ubrogepant entered clinical phase III trials?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Ubrogepant is a medication used for the acute treatment of migraine. To determine if it has entered clinical phase III trials, we need to check its development timeline. Phase III trials typically involve large-scale testing to confirm efficacy and monitor side effects. According to available data, ubrogepant successfully completed phase III trials and was approved by the FDA in 2019. Therefore, it has progressed beyond phase III.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are there small molecule CGRPs under development for the treatment of migraine?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether there are small molecule CGRPs under development for the treatment of migraine. CGRP stands for calcitonin gene-related peptide, which is a neuropeptide involved in migraine pathophysiology. There are currently several CGRP-targeting therapies in development, including monoclonal antibodies and small molecule inhibitors. Small molecule CGRPs are being investigated as potential treatments for migraine due to their ability to cross the blood-brain barrier and target the CGRP pathway. Based on this information, the answer to the question is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is eptinezumab a small molecule?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Eptinezumab is a monoclonal antibody, which is a type of large molecule biologic drug. Small molecules are typically chemically synthesized drugs with low molecular weight, while monoclonal antibodies are proteins produced by living cells and have much higher molecular weights. Therefore, eptinezumab is not a small molecule.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is gabapentin effective for chronic pelvic pain?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Gabapentin is primarily used to treat seizures and neuropathic pain. Chronic pelvic pain can have various causes, including neuropathic components. Some studies suggest gabapentin may help in cases where neuropathic pain is involved. However, its effectiveness can vary, and it is not typically a first-line treatment for chronic pelvic pain. Medical guidelines and individual patient factors play a role in determining its use.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does trimetazidine protect from myocardial injury after percutaneous coronary intervention?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Trimetazidine is a medication used to treat angina and other cardiovascular conditions. It works by improving myocardial energy metabolism and reducing ischemia. Some studies suggest that trimetazidine may have protective effects against myocardial injury, particularly in the context of ischemia-reperfusion injury. However, the evidence regarding its specific protective role after percutaneous coronary intervention (PCI) is mixed. While certain studies indicate potential benefits, such as reduced biomarkers of myocardial injury and improved clinical outcomes, others have not found significant protective effects. Therefore, the current evidence is not entirely conclusive.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does inactivation of CYLD help in colorectal cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether inactivation of CYLD helps in colorectal cancer. CYLD is a deubiquitinating enzyme that acts as a tumor suppressor in various cancers. Inactivation of CYLD has been implicated in the development and progression of several types of cancer, including colorectal cancer. When CYLD is inactivated, it can lead to increased cell proliferation and survival of cancer cells. Therefore, inactivation of CYLD does not help in colorectal cancer; rather, it contributes to the disease's progression.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is there a role for TFII-I in megakaryopoiesis?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if TFII-I plays a role in megakaryopoiesis, I need to check if there is any scientific evidence or research studies that link TFII-I to the process of megakaryocyte development or platelet formation. TFII-I is a transcription factor known to be involved in various cellular processes, but its specific involvement in megakaryopoiesis is not well-documented. A literature search would be required to confirm any direct or indirect roles in this particular biological pathway.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is istiratumab effective for pancreatic cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"I need to check if istiratumab is effective for pancreatic cancer. First, I will search for clinical trials or studies involving istiratumab and pancreatic cancer. Istiratumab is a monoclonal antibody targeting RANKL, which may be involved in cancer progression. I will look for evidence of its efficacy in treating pancreatic cancer, either as a single agent or in combination with other therapies. If there are no clinical trials or studies showing positive results, then the answer would be no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does erenumab target the calcitonin gene-related peptide?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Erenumab is a monoclonal antibody used for the prevention of migraines. It works by targeting the calcitonin gene-related peptide (CGRP) receptor, not the CGRP itself. By blocking the receptor, it prevents the activation of pathways involved in migraine pain. Therefore, the question is whether erenumab targets the CGRP or its receptor.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is there a link between rare variants in PPARG and type 1 diabetes?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"PPARG (peroxisome proliferator-activated receptor gamma) is a nuclear receptor that plays a key role in adipocyte differentiation and glucose metabolism. It is primarily associated with type 2 diabetes, as rare variants in PPARG have been linked to insulin resistance and lipodystrophy. However, type 1 diabetes is an autoimmune disease characterized by the destruction of pancreatic beta cells, which is different from the metabolic dysregulation seen in type 2 diabetes. While PPARG is involved in metabolic processes, there is no strong evidence to suggest a direct link between rare variants in PPARG and type 1 diabetes. Research has focused more on its role in type 2 diabetes and related metabolic disorders.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is there an association of alterations in ADCY7 and ulcerative colitis?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if there is an association between alterations in ADCY7 and ulcerative colitis, I need to check current medical literature and genetic studies. ADCY7 (adenylate cyclase 7) is involved in cyclic AMP production, which plays a role in cellular signaling. Some studies have linked genetic variations in ADCY7 to autoimmune and inflammatory diseases. Ulcerative colitis is an inflammatory bowel disease with a genetic component. Research suggests that multiple genes contribute to ulcerative colitis susceptibility. However, specific evidence linking ADCY7 mutations or polymorphisms directly to ulcerative colitis is limited. Further investigation into genome-wide association studies (GWAS) and functional studies would clarify this potential association.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there high nucleotide diversity in the Drosophila suzukii species?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Drosophila suzukii, also known as the spotted wing drosophila, is an invasive pest species that has spread rapidly across various regions. High nucleotide diversity typically indicates a large, stable population with a long evolutionary history. However, because D. suzukii has undergone recent range expansion and population bottlenecks during its invasion, it is likely to have lower nucleotide diversity. Studies on genetic variation in this species have shown reduced genetic diversity in invasive populations compared to native ones.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Î‘re plants from the genus Strychnos the original source of curare?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Curare is a poison traditionally used by indigenous peoples in South America for hunting. It is derived from various plants, including those from the genus Strychnos. Strychnos species, particularly Strychnos toxifera, are known to be one of the primary sources of curare alkaloids, such as strychnine and curarine. However, curare can also be made from other plant sources, like those in the genus Chondrodendron. Therefore, while Strychnos plants are a significant source, they are not the only original source of curare.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does Curare function by stimulating the acetylcholine receptor?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Curare is a neuromuscular blocking agent. It works by blocking the acetylcholine receptors at the neuromuscular junction, preventing the neurotransmitter acetylcholine from binding and causing muscle contraction. Therefore, Curare does not stimulate the acetylcholine receptor but instead inhibits its function.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is AZD9668 a VEGF mRNA drug?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"AZD9668 is a small molecule drug candidate developed by AstraZeneca for the treatment of chronic obstructive pulmonary disease (COPD). It is a neutrophil elastase inhibitor. VEGF mRNA drugs are related to vascular endothelial growth factor and are typically used in the context of promoting angiogenesis, such as in certain cancer therapies or other conditions requiring enhanced blood vessel growth. Since AZD9668's mechanism of action is related to inhibiting neutrophil elastase and not related to VEGF or mRNA technology, it is not a VEGF mRNA drug.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has AZD9668 been tested in clinical trials?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"AZD9668 is a drug candidate that has been studied in the context of respiratory diseases. To determine if it has been tested in clinical trials, one would typically consult clinical trial databases, scientific literature, or official announcements from the pharmaceutical company developing it (AstraZeneca). Based on available information up to 2023, AZD9668 has undergone early-phase clinical trials, including Phase I and Phase II studies, primarily for conditions like chronic obstructive pulmonary disease (COPD) and cystic fibrosis. These trials focused on assessing its safety, tolerability, and preliminary efficacy.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are TAMs good anticancer therapeutic targets?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"TAMs (Tumor-Associated Macrophages) are immune cells that can promote tumor growth and progression. Targeting TAMs may help in cancer therapy by altering their behavior or reducing their presence in the tumor microenvironment. Research suggests that modulating TAMs could enhance the effectiveness of other treatments, such as immunotherapy. Therefore, TAMs are considered promising anticancer therapeutic targets.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Tocilizumab (Actemra) used to block/antagonize the  IL-6 receptor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tocilizumab (Actemra) is a monoclonal antibody that targets the IL-6 receptor. By binding to the IL-6 receptor, it prevents IL-6 from signaling, which reduces inflammation. Therefore, it acts as an antagonist of the IL-6 receptor. This mechanism is used in the treatment of conditions like rheumatoid arthritis and other inflammatory diseases.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are PDXK mutations linked to polyneuropathy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To answer this question, I need to determine if mutations in the PDXK gene are associated with polyneuropathy. PDXK (pyridoxal kinase) is involved in vitamin B6 metabolism, which is important for nerve function. I will check scientific literature and databases for any reported links between PDXK mutations and polyneuropathy. If studies or case reports show such a connection, the answer is 'yes'; otherwise, 'no'.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do bacteria release extracellular vesicles?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Bacteria do release extracellular vesicles as part of their normal physiological processes. These vesicles can play roles in cell-to-cell communication, pathogenesis, and the transport of various molecules.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Gram positive bacteria able to release extracellular vesicles?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Gram-positive bacteria have a thick peptidoglycan layer and lack an outer membrane. Extracellular vesicles (EVs) are typically associated with Gram-negative bacteria, which release outer membrane vesicles (OMVs) derived from their outer membrane. However, recent studies have shown that Gram-positive bacteria can also produce extracellular vesicles, although the mechanisms and composition may differ from those of Gram-negative bacteria. These vesicles can carry various biomolecules and play roles in intercellular communication, virulence, and immune modulation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the apilimod inhibitor effective against SARS-CoV-2?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is whether the apilimod inhibitor is effective against SARS-CoV-2. Apilimod is a drug that has been studied for its potential antiviral properties, particularly in relation to coronaviruses. Research has indicated that apilimod may inhibit the replication of SARS-CoV-2 in vitro by targeting specific pathways involved in viral replication. However, it is important to note that in vitro results do not always translate to clinical effectiveness. As of the latest available information, clinical trials have not conclusively demonstrated significant efficacy of apilimod against SARS-CoV-2 in humans. Therefore, while there is some preliminary evidence suggesting potential effectiveness, it is not yet confirmed to be effective in a clinical setting.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is Hunter's disease is associated with the X Chromosome?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Hunter's disease, also known as Mucopolysaccharidosis II (MPS II), is a rare genetic disorder caused by the deficiency of the enzyme iduronate-2-sulfatase. This enzyme is responsible for breaking down complex sugars called glycosaminoglycans (GAGs). The gene that codes for iduronate-2-sulfatase is located on the X chromosome. Since it is an X-linked recessive disorder, it primarily affects males, as they have only one X chromosome. Females, having two X chromosomes, are typically carriers unless they inherit two affected X chromosomes. Therefore, Hunter's disease is indeed associated with the X chromosome.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Toll-like receptors (TLRs) induced by microbes?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Toll-like receptors (TLRs) are a class of proteins that play a key role in the innate immune system. They recognize pathogen-associated molecular patterns (PAMPs) which are structures specific to microorganisms. When TLRs detect these PAMPs, they trigger signaling pathways that lead to the activation of immune responses. However, TLRs themselves are not induced by microbes; rather, they are expressed constitutively in immune cells and become activated upon encountering microbial components. Therefore, while TLRs respond to microbial presence, they are not produced as a result of microbial induction.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can Freund's complete adjuvant induce arthritis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Freund's complete adjuvant (FCA) is an immunopotentiator used in research to stimulate the immune system. It contains inactivated mycobacteria, which can provoke a strong immune response. In experimental settings, FCA is often used to induce autoimmune responses, including models of arthritis. By activating the immune system against self-antigens, it can lead to inflammatory arthritis in laboratory animals. Therefore, it can be used to induce arthritis in experimental models.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can saponins be used as adjuvant?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Saponins are natural compounds found in plants, known for their surfactant properties. Adjuvants are substances that enhance the immune response to vaccines. Some saponins, like QS-21, are used as adjuvants in vaccines due to their ability to stimulate the immune system. Therefore, saponins can act as adjuvants.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is phosphoenolpyruvate carboxykinase 1 (PCK1) the rate-limiting enzyme in gluconeogenesis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether phosphoenolpyruvate carboxykinase 1 (PCK1) is the rate-limiting enzyme in gluconeogenesis. Gluconeogenesis is the metabolic pathway that results in the generation of glucose from non-carbohydrate carbon substrates. There are several key enzymes involved in this process, and some of them are considered rate-limiting because they catalyze the irreversible steps in the pathway. The main enzymes involved in gluconeogenesis include pyruvate carboxylase, phosphoenolpyruvate carboxykinase (PEPCK), fructose-1,6-bisphosphatase, and glucose-6-phosphatase. PCK1 is one of the isoforms of PEPCK, which catalyzes the conversion of oxaloacetate to phosphoenolpyruvate. This is one of the irreversible steps in gluconeogenesis, and PEPCK is often considered a rate-limiting enzyme in this pathway. However, the term 'rate-limiting' can be context-dependent and may vary based on the specific conditions or the organism being studied. Therefore, while PCK1 plays a critical role in gluconeogenesis and is often considered a key regulatory enzyme, whether it is universally the 'rate-limiting' enzyme may depend on the specific context.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is histone variant H3.3K27M associated with gliomas?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Histone variant H3.3K27M is a mutated form of histone H3.3, where lysine 27 is replaced by methionine. This mutation is known to be involved in the pathogenesis of certain cancers, particularly gliomas. Studies have shown that this mutation is commonly found in pediatric and young adult gliomas, especially in diffuse intrinsic pontine gliomas (DIPG) and other high-grade gliomas. The presence of H3.3K27M leads to global reduction in H3K27me3, a repressive histone mark, resulting in dysregulation of gene expression and contributing to tumorigenesis. Therefore, H3.3K27M is indeed associated with gliomas.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do honey contain diastases/amylases?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Honey is a natural product made by bees from the nectar of flowers. It contains various enzymes that are added by the bees during the honey-making process. One of these enzymes is invertase, which helps break down sucrose into glucose and fructose. However, diastases (amylases) are enzymes that break down starch into sugars. While honey does contain some enzymes, it does not typically contain diastases or amylases because these enzymes are not involved in the processing of nectar into honey. Instead, honey's primary enzymes are related to the breakdown of sugars already present in the nectar.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is HbA1c an ideal biomarker of well-controlled diabetes?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"HbA1c is a commonly used biomarker for assessing long-term blood glucose control in individuals with diabetes. It reflects average blood glucose levels over the past 2-3 months. While it is widely accepted and recommended by many clinical guidelines, there are some limitations. For example, HbA1c may not be accurate in people with certain hemoglobin variants, anemia, or other conditions that affect red blood cell turnover. Additionally, some studies suggest that HbA1c may not fully capture glycemic variability or hypoglycemic episodes. Therefore, while HbA1c is a valuable tool, it may not be ideal in every clinical situation.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is erabutoxin b usually found in plants?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Eribotoxin B is a toxin usually found in the venom of the green pit viper (Trimeresurus gramineus). It is a neurotoxin that affects the nervous system by blocking neuromuscular junctions. Since it is a component of snake venom, it is not usually found in plants. Plants generally do not produce such animal-derived toxins.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is autism thought to be related to the  Arginine Vasopressin Peptide (AVP)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Research suggests that the Arginine Vasopressin Peptide (AVP) may be related to autism. AVP is involved in social behavior and communication, which are areas affected in autism. Studies have shown that AVP can influence social interaction and bonding, and abnormalities in AVP functioning have been observed in individuals with autism. However, the exact nature of the relationship between AVP and autism is still being investigated, and it is likely that multiple factors contribute to the condition.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Ixodes a species of tick?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Ixodes is a genus of ticks, not a species. The genus Ixodes includes several species of ticks, such as Ixodes scapularis (black-legged tick) and Ixodes ricinus (castor bean tick). Therefore, Ixodes itself is not a species but a genus.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are mucins glycosylated proteins?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Mucins are a family of high molecular weight proteins that are produced by epithelial tissues in most animals. They are known for their ability to form gels and are heavily glycosylated, meaning they have many carbohydrate chains attached to them. This glycosylation is important for their function, such as in forming protective barriers in the respiratory and digestive tracts. Therefore, the question of whether mucins are glycosylated proteins can be answered affirmatively.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are mucin overexpression associated with disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Mucins are glycoproteins that play a critical role in forming mucus, which protects epithelial surfaces in various organs. Overexpression of mucins has been linked to several diseases, particularly cancers. For example, MUC1 overexpression is commonly observed in breast, ovarian, and pancreatic cancers, where it contributes to tumor cell survival, metastasis, and immune evasion. Similarly, MUC5AC overexpression has been associated with gastric cancer and respiratory diseases like chronic obstructive pulmonary disease (COPD). In some cases, excessive mucus production due to mucin overexpression can lead to airway obstruction in conditions like cystic fibrosis or asthma. Therefore, mucin overexpression is indeed associated with various diseases.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are interferons defensive proteins?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Interferons are proteins produced by cells in response to viral infections. They help neighboring cells to prepare for potential viral attacks by activating their antiviral defenses. This suggests that interferons play a defensive role in the immune system.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is YKL-40 used as a biomarker for Alzheimer's disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"YKL-40, also known as chitinase-3-like protein 1 (CHI3L1), is a glycoprotein that has been studied in the context of various diseases, including neurodegenerative disorders. Research has explored its potential role as a biomarker in Alzheimer's disease (AD). Studies have indicated that YKL-40 levels may be elevated in the cerebrospinal fluid (CSF) of individuals with AD, suggesting it could serve as a biomarker for neuroinflammation or disease progression. However, it is not as commonly used or well-established as other biomarkers like amyloid-beta, tau, or phosphorylated tau. YKL-40 may be more indicative of glial activation and inflammatory processes associated with AD rather than being a primary diagnostic marker. Therefore, while it shows promise as a supplementary biomarker, it is not the standard biomarker used for diagnosing Alzheimer's disease.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is G3BP1 found in stress granules?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"G3BP1 (Rasputin) is a protein that plays a role in stress granule assembly. Stress granules are cytoplasmic aggregates that form in response to cellular stress, such as heat shock, oxidative stress, or viral infection. G3BP1 is known to be a key component of stress granules and is involved in the regulation of mRNA metabolism and stress responses. Therefore, G3BP1 is found in stress granules.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has FTY720  been considered for the treatment of stroke?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"FTY720 (fingolimod) is an immunomodulatory drug primarily used for the treatment of multiple sclerosis. Its mechanism of action involves sequestering lymphocytes in lymph nodes, thereby reducing their migration to the central nervous system. While most commonly used in MS, there is some research exploring its potential neuroprotective effects in other conditions, including stroke. Preclinical studies have suggested that FTY720 might have beneficial effects in models of ischemic stroke by reducing inflammation and brain injury. However, clinical evidence for its use specifically in stroke treatment is limited, and it is not currently approved for this indication. Therefore, while it has been studied in preclinical models, it is not a standard treatment for stroke.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is FTY720 FDA approved?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"FTY720, also known as fingolimod, is a medication used to treat multiple sclerosis. I believe it has received FDA approval for this indication, but I need to confirm the specific details and current status.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does the royal jelly contain proteins?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Royal jelly is a substance produced by honey bees, and it's known to be rich in various nutrients. It's fed to all bee larvae initially and to queen bees throughout their lives. Considering its role in promoting growth and development in bees, it's likely to contain proteins as they are essential for biological functions. Scientific literature and sources indicate that royal jelly does indeed contain proteins, along with sugars, fats, and various micronutrients.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are the major royal jelly proteins similar to the yellow proteins?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Major royal jelly proteins (MRJPs) and yellow proteins are both found in honeybees, but they serve different functions. MRJPs are the primary proteins in royal jelly, responsible for the development of queen bees, while yellow proteins are involved in pigmentation and other physiological processes. Although they may share some structural similarities, their roles in the honeybee biology are distinct. Therefore, while they may have some similarities, they are not the same.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the Apis mellifera genome available?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether the genome of Apis mellifera, which is the Western honey bee, is available. I need to confirm if the genome sequencing for this species has been completed and made publicly accessible. Based on prior knowledge, the genome of Apis mellifera has been sequenced and is available in public databases such as NCBI or Ensembl. Therefore, the answer should be yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has the olive tree pollen proteome been studied?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether the proteome of olive tree pollen has been studied. To answer this, I need to determine if scientific research has been conducted on the complete set of proteins present in the pollen of olive trees (Olea europaea). Olive tree pollen is a significant allergen, so it is plausible that its proteins have been analyzed in the context of allergy research. Studies on allergenic pollens often include proteomic analyses to identify specific proteins responsible for allergic reactions. Therefore, it is likely that the olive tree pollen proteome has been studied, particularly in allergology and plant biology research.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is hemoglobin antimicrobial?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Hemoglobin is primarily known for its role in transporting oxygen in the blood. However, some studies suggest that hemoglobin and its derivatives may exhibit antimicrobial properties, particularly against certain bacteria and fungi. These properties might be due to the ability of hemoglobin to generate reactive oxygen species or to disrupt microbial membranes. However, the antimicrobial activity of hemoglobin is not its primary function and may vary depending on the context and concentration.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there antimicrobial proteins in royal jelly?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Royal jelly is a substance produced by honeybees and is known for its various biological activities. It contains several proteins, some of which have been studied for their potential antimicrobial properties. Research has indicated that certain proteins in royal jelly, such as royalisin and jelleins, exhibit antimicrobial activity against various microorganisms. Therefore, it is likely that there are antimicrobial proteins present in royal jelly.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does Amblyopia affect the eye?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Amblyopia, also known as lazy eye, is a vision development disorder in which an eye fails to achieve normal visual acuity, even with prescription eyeglasses or contact lenses. It affects the way the brain processes visual information from the affected eye, leading to reduced vision in that eye. Therefore, the answer is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is atenolol metabolized by CYP2D6?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Atenolol is a beta-blocker medication used to treat high blood pressure and other cardiovascular conditions. It is known to be primarily excreted unchanged in the urine, indicating that it undergoes minimal metabolism. CYP2D6 is an enzyme involved in the metabolism of many drugs. However, since atenolol is not significantly metabolized, it is unlikely to be a substrate for CYP2D6. Instead, it is mainly eliminated through renal excretion.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is cadherin a plasma membrane marker?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Cadherins are a family of transmembrane proteins that play a key role in cell-cell adhesion. They are indeed located in the plasma membrane, where they help cells stick to each other. Therefore, cadherin can be considered a plasma membrane marker.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there an upper limit on the functional fraction of the human genome?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question asks whether there is an upper limit on the functional fraction of the human genome. The \\\"functional fraction\\\" refers to the portion of the genome that has a biological function, such as coding for proteins, regulatory elements, or other functional non-coding sequences. Scientific understanding of this topic has evolved over time. Initially, due to the \\\"junk DNA\\\" concept, it was thought that only a small fraction (around 2%) of the human genome, which codes for proteins, was functional. However, projects like ENCODE (Encyclopedia of DNA Elements) have suggested that a larger percentage (up to 80% or more) of the genome is involved in biochemical activities, such as transcription, regulation, and chromatin structure. However, there is debate in the scientific community about what exactly constitutes a functional element. Some researchers argue that biochemical activity does not necessarily equate to function, and that evolutionary conservation may be a better indicator of functionality. From this perspective, the functional fraction might be lower, perhaps around 5-10%. Therefore, while there may be an upper limit to what can be considered functional based on current definitions and evidence, the exact value of this upper limit is still a matter of scientific debate and depends on how \\\"function\\\" is defined. If \\\"function\\\" is defined broadly (e.g., any biochemical activity), then the upper limit might be quite high (e.g., 80% or more). If \\\"function\\\" is defined more strictly (e.g., sequences that are evolutionarily conserved and contribute to organismal fitness), then the upper limit may be lower (e.g., 5-10%). In summary, there is no universally agreed-upon upper limit on the functional fraction of the human genome, as it depends on the definition of \\\"function.\\\" However, based on current scientific understanding and debates, there is an upper bound that is generally cited, though its exact value remains uncertain.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are synonymous sites in primates and rodents functionally constrained?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Synonymous sites are positions in the DNA where mutations do not change the amino acid that is encoded. These sites were traditionally thought to be functionally unconstrained because the resulting protein remains unchanged. However, recent studies have suggested that some synonymous sites might be under functional constraints due to factors such as mRNA stability, codon usage bias, and regulatory elements within coding regions. In primates and rodents, research has indicated that while many synonymous sites are indeed neutral or nearly neutral, there are instances where these sites can be subject to selective pressures. For example, synonymous mutations can affect gene expression levels, splicing efficiency, and even contribute to disease susceptibility. Therefore, while not all synonymous sites are functionally constrained, there is evidence suggesting that a subset of these sites in primates and rodents can be under functional constraints.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does IL18 signaling have a role in thymus?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To determine if IL18 signaling has a role in the thymus, I need to check if IL18 and its receptor components are expressed in thymic cells and if they are involved in any thymus-related processes such as T cell development, thymic stromal cell function, or immune tolerance. Research articles or databases confirming these aspects would validate the role of IL18 signaling in the thymus.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is metoprolol metabolized by CYP2D6?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Metoprolol is a beta-blocker commonly used to treat hypertension and other cardiovascular conditions. The metabolism of many beta-blockers, including metoprolol, is primarily hepatic. The cytochrome P450 enzyme system, specifically CYP2D6, is known to play a significant role in the metabolism of various drugs. Metoprolol undergoes extensive first-pass metabolism, and CYP2D6 is the primary enzyme responsible for converting metoprolol into its metabolites, such as alpha-hydroxymetoprolol. Therefore, individuals with genetic variations in CYP2D6 may have altered metabolism of metoprolol, leading to differences in drug efficacy and potential side effects.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the glucocorticoid receptor a transcription factor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The glucocorticoid receptor (GR) is a receptor for glucocorticoids, which are a type of corticosteroid. When activated by its ligand (e.g., cortisol), the GR can translocate to the nucleus and bind to specific DNA sequences called glucocorticoid response elements (GREs) in the promoter regions of target genes. This binding can either activate or repress gene transcription, indicating that the GR functions as a transcription factor. Transcription factors are proteins that bind to DNA and regulate the transcription of genes into RNA. Therefore, based on its ability to bind DNA and modulate gene expression, the GR can be classified as a transcription factor.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has dupilumab been FDA approved for atopic dermatitis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Dupilumab is a monoclonal antibody that targets the interleukin-4 receptor, and it's used in the treatment of atopic dermatitis. I recall that it has received FDA approval for this indication, but I'm not entirely certain about the exact timeline or any recent updates. To confirm, I would need to check the FDA's official website or a reliable medical database to verify the approval status.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has the companion diagnostic HercepTest received FDA approval?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether the companion diagnostic HercepTest has received FDA approval. I need to check the status of HercepTest with the FDA. HercepTest is a diagnostic test used to determine if a patient's breast cancer is HER2-positive. I recall that the FDA has approved certain companion diagnostics related to HER2 testing. However, I need to confirm if specifically HercepTest has received that approval. Checking FDA databases or recent updates would be necessary. If the FDA has listed HercepTest as an approved companion diagnostic, then the answer is yes. If not, the answer would be no.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is FKBP52 encoding a chaperone ?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"FKBP52, also known as FK506-binding protein 4 (FKBP4), is a member of the immunophilin family. Immunophilins are a group of proteins that bind immunosuppressive drugs such as FK506 and rapamycin. FKBP52 has peptidyl-prolyl cis-trans isomerase (PPIase) activity, which is involved in protein folding. Chaperones are proteins that assist in the proper folding of other proteins. Given that FKBP52 has PPIase activity and is involved in protein folding, it can be considered a chaperone.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is colistin an antibiotic?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Colistin is an antibiotic used to treat bacterial infections, particularly those caused by Gram-negative bacteria. It is often used as a last-resort treatment when other antibiotics are ineffective.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Keutel syndrome a common genetic disorder?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Keutel syndrome is a rare genetic disorder. It is characterized by abnormal cartilage calcification, distinctive facial features, and other developmental issues. Since it is rare, it is not considered common.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Daprodustat effective for anemia?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Daprodustat is a drug used for the treatment of anemia, particularly in patients with chronic kidney disease. It works by stimulating the production of red blood cells. Clinical trials have shown that daprodustat can effectively increase hemoglobin levels in patients with anemia. However, its effectiveness may vary depending on the individual patient's condition and other factors. Therefore, while daprodustat is generally considered effective for treating anemia, its effectiveness in specific cases should be evaluated by a healthcare professional.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there an association between pyostomatitis vegetans and Crohn's disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Pyostomatitis vegetans is a rare skin condition characterized by pustules and vegetative lesions, primarily affecting the oral mucosa. Crohn's disease is an inflammatory bowel disease that can affect any part of the gastrointestinal tract. There is some evidence in the medical literature suggesting that pyostomatitis vegetans can be associated with underlying inflammatory bowel diseases, including Crohn's disease. Cases have been reported where patients with Crohn's disease developed pyostomatitis vegetans, indicating a possible association between the two conditions. However, the exact relationship and pathophysiological mechanisms are not fully understood. Further research may be needed to establish a definitive link.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Sotrovimab effective for COVID-19?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Sotrovimab is a monoclonal antibody therapy developed for the treatment of COVID-19. It targets the spike protein of the SARS-CoV-2 virus, which is used by the virus to enter human cells. Clinical trials have shown that Sotrovimab can reduce the risk of hospitalization or death in high-risk patients when administered early after symptom onset. However, its effectiveness may vary depending on the viral variant circulating at the time. For example, some studies suggest that Sotrovimab remains effective against certain variants like Omicron, but ongoing monitoring is necessary as new variants emerge. Therefore, based on current evidence, Sotrovimab is considered effective for treating specific cases of COVID-19, particularly in high-risk individuals when used early in the course of infection.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Ozanimod effective for Ulcerative Colitis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Ozanimod is a medication used to treat certain autoimmune conditions. It has been studied for use in inflammatory bowel diseases, including Ulcerative Colitis. Clinical trials have shown that Ozanimod can help reduce symptoms and achieve remission in some patients with Ulcerative Colitis. However, its effectiveness can vary among individuals, and it may not work for everyone.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Cabotegravir effective for HIV prevention?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Cabotegravir is an integrase strand transfer inhibitor (INSTI) used in the treatment and prevention of HIV. It works by blocking the integrase enzyme, which is necessary for the HIV virus to replicate. For prevention, Cabotegravir is used as part of pre-exposure prophylaxis (PrEP). Clinical trials have shown that Cabotegravir is highly effective in preventing HIV infection when taken as prescribed. However, its effectiveness can vary based on factors such as adherence to the medication regimen and the specific population studied. Therefore, Cabotegravir is considered effective for HIV prevention, particularly when used consistently and correctly.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is sacituzumab govitecan effective for breast cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Sacituzumab govitecan is an antibody-drug conjugate that targets the Trop-2 receptor, which is commonly expressed in various cancers, including breast cancer. It has been studied in clinical trials for the treatment of metastatic triple-negative breast cancer (TNBC) and other subtypes. The drug has shown efficacy in some patients, particularly those who have not responded to other treatments. However, its effectiveness can vary based on individual patient factors and the specific characteristics of the cancer. Regulatory approvals and ongoing research continue to evaluate its role in breast cancer treatment.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is rilonacept effective for pericarditis?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Rilonacept is a biologic medication primarily used for conditions like cryopyrin-associated periodic syndromes (CAPS) and gouty arthritis. It works by inhibiting interleukin-1 (IL-1), which plays a role in inflammation. Pericarditis involves inflammation of the pericardium, and while IL-1 inhibitors like rilonacept have been studied in inflammatory conditions, there is limited evidence specifically supporting its use for pericarditis. Clinical guidelines do not currently list rilonacept as a standard treatment for pericarditis. Therefore, its effectiveness for this condition is not well established.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is Sotatercept effective for Pulmonary Arterial Hypertension?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Sotatercept is a drug that has been studied for the treatment of pulmonary arterial hypertension (PAH). Clinical trials have shown that it can improve exercise capacity and reduce the risk of clinical worsening in patients with PAH. Based on the available evidence, it appears that Sotatercept is effective for treating PAH.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Belimumab used for lupus nephritis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Belimumab is a monoclonal antibody that targets B-lymphocyte stimulator (BLyS), which is involved in the survival of B cells. It is approved for the treatment of systemic lupus erythematosus (SLE). Lupus nephritis is a complication of SLE affecting the kidneys. While Belimumab is used in SLE management, its specific approval or common usage for lupus nephritis needs verification. Clinical guidelines or recent studies should be consulted to confirm its application in lupus nephritis cases.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there an association between Guillainâ€“BarrÃ© syndrome and covid vaccine?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking about the association between Guillain-BarrÃ© syndrome (GBS) and the COVID-19 vaccine. I need to determine if there is a link between the two. First, I should recall what is known about GBS and vaccines in general. GBS is a rare autoimmune disorder where the immune system attacks the nerves, leading to muscle weakness and sometimes paralysis. It has been associated with certain infections and, in rare cases, vaccinations. For example, there was a slightly increased risk observed with the 1976 swine flu vaccine. However, since then, the association with other vaccines, including influenza vaccines, has been very small, if any. Regarding the COVID-19 vaccines, regulatory agencies like the CDC and FDA have monitored adverse events. Some reports have suggested a very rare possible association between certain COVID-19 vaccines (particularly the Johnson & Johnson/Janssen vaccine) and GBS. For instance, after the rollout of the J&J vaccine, a small number of GBS cases were reported, leading the CDC to add a warning label. However, the overall risk is considered extremely low, and the benefits of vaccination generally outweigh the potential risks. It's important to note that establishing causation is difficult; the presence of a temporal association does not prove causation. Other factors, including the occurrence of GBS following natural infections like COVID-19 itself, must be considered. In summary, while there may be a very rare possible association between some COVID-19 vaccines and GBS, the evidence is not conclusive, and the risk, if present, is extremely low.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do mutations in KCNT2 only cause phenotypes with epilepsy?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"KCNT2 is a gene that encodes a sodium-activated potassium channel subunit. Mutations in KCNT2 have been associated with various neurological disorders, including epilepsy. However, it is necessary to verify whether these mutations are exclusively linked to epilepsy or if they can cause other phenotypes. Research indicates that mutations in KCNT2 can lead to different types of epilepsy, such as autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) and other seizure disorders. Additionally, some studies suggest that mutations in this gene might contribute to other neurological conditions beyond epilepsy, such as intellectual disability or developmental delays. Therefore, mutations in KCNT2 do not only cause phenotypes with epilepsy.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do only changes in coding regions of MEF2C cause developmental disorders?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether only changes in the coding regions of the MEF2C gene cause developmental disorders. To answer this, we need to consider whether non-coding region changes in MEF2C can also lead to such disorders. MEF2C is a gene that plays a critical role in neurodevelopment, and mutations in its coding regions have been linked to developmental disorders such as autism spectrum disorder and intellectual disability. However, it is also known that regulatory or non-coding regions of genes can influence gene expression levels and function. If variations in these non-coding regions of MEF2C disrupt its expression or regulation, they could potentially contribute to developmental disorders as well. Therefore, it is not exclusively changes in the coding regions that could be responsible.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Algenpantucel-L effective for pancreatic cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Algenpantucel-L is an immunotherapy vaccine designed to stimulate the immune system to attack cancer cells. It has been studied in clinical trials for pancreatic cancer, particularly in the adjuvant setting following surgery. Some trials, like the IMPRESS study, aimed to evaluate its efficacy. However, the overall effectiveness remains under investigation, and it is not yet widely approved as a standard treatment. The results from clinical trials have shown mixed outcomes, so the effectiveness of Algenpantucel-L for pancreatic cancer is not conclusively established.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is tivantinib effective for MET-high hepatocellular carcinoma?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tivantinib is a selective MET inhibitor that has been studied in clinical trials for hepatocellular carcinoma (HCC). Research suggests that it may be effective in patients with MET-high HCC, as it targets the MET receptor which is overexpressed in some cases of this cancer. However, its overall efficacy and approval status can vary based on regulatory assessments and additional clinical data.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Can Isradipine slow progression of Early Parkinson Disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Isradipine is a calcium channel blocker primarily used to treat hypertension. Some research has suggested that it may have neuroprotective properties and could potentially slow the progression of Parkinson's disease by reducing calcium influx in neurons, which might help prevent neuronal damage. However, clinical trials have not conclusively proven its effectiveness for this purpose, and more research is needed.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is nerinetide effective for ischaemic stroke?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Nerinetide is a drug that has been studied for its potential use in treating ischaemic stroke. Clinical trials have been conducted to evaluate its effectiveness in improving outcomes for patients with ischaemic stroke. Some studies have suggested that nerinetide may be effective in reducing neurological deficits and improving recovery when administered promptly after the onset of stroke symptoms. However, other studies have shown mixed results, with some indicating no significant benefit over standard treatments. The effectiveness of nerinetide may also depend on factors such as the timing of administration and the specific patient population. Regulatory approval and guidelines may vary based on the available evidence. Therefore, while there is some evidence supporting the effectiveness of nerinetide for ischaemic stroke, the results are not universally conclusive.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Should perampanel be used for amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Perampanel is an anticonvulsant medication primarily used to treat epilepsy. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motor neurons. There is no evidence or approved indication for perampanel in treating ALS. Therefore, perampanel should not be used for ALS.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are variants in FHF2 (also known as FGF13) associated with encephalopathy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To answer whether variants in FHF2 (also known as FGF13) are associated with encephalopathy, I need to check if there is any scientific evidence or studies linking mutations or variations in the FHF2/FGF13 gene to encephalopathy. Encephalopathy refers to brain dysfunction, and some genetic variants have been linked to neurological conditions. FHF2 (FGF13) is a member of the fibroblast growth factor family, which plays a role in various biological processes, including nervous system development. Research has shown that FGF13 is involved in brain development and function. For example, studies have identified associations between FGF13 variants and neurological disorders such as intellectual disability and seizures. Since encephalopathy can involve cognitive impairment and seizures, it is possible that FHF2 (FGF13) variants may be associated with encephalopathy. However, I need to verify if there is direct evidence supporting this specific association.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Adamts18 deficiency associated with cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Adamts18 is a gene that encodes a protein involved in various biological processes, including cell adhesion and extracellular matrix remodeling. Deficiencies or mutations in this gene could potentially lead to various diseases. To determine if Adamts18 deficiency is associated with cancer, we need to check if there are any scientific studies or medical literature that establish a link between Adamts18 mutations or deficiencies and cancer development or progression. If such studies exist, then the answer would be yes; otherwise, no.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Erythropoietin effective for neuroprotection of Preterm Infants.",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is whether Erythropoietin (EPO) is effective for the neuroprotection of preterm infants. EPO is a hormone that stimulates red blood cell production and has been studied for its potential neuroprotective effects in preterm infants. Research suggests that EPO may have neuroprotective properties due to its anti-inflammatory and anti-apoptotic effects. Several clinical trials have investigated the use of EPO in preterm infants to reduce the risk of neurological complications such as cerebral palsy and cognitive impairments. Some studies have shown promising results, indicating that EPO administration may improve neurodevelopmental outcomes in preterm infants. However, the evidence is not entirely conclusive, and more research may be needed to establish definitive guidelines. Based on the available evidence, the effectiveness of EPO for neuroprotection in preterm infants is supported to some extent.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Should Intepirdine be used for Alzheimer's disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Intepirdine (also known as RVT-101) is a drug that was being developed for the treatment of Alzheimer's disease. It acts as a selective 5-HT6 receptor antagonist, which was thought to potentially improve cognitive function. However, clinical trials have shown mixed results. In particular, in 2017, the pharmaceutical company Axovant Sciences announced that intepirdine failed to meet its primary endpoint in a Phase 3 clinical trial for Alzheimer's disease. Based on the available evidence, intepirdine is not currently recommended or approved for the treatment of Alzheimer's disease.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should istiratumab be used for Pancreatic Cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Istratumab is a monoclonal antibody that targets the EphA2 receptor, which is overexpressed in several cancers, including pancreatic cancer. However, its use in pancreatic cancer is not yet established. Clinical trials are ongoing to evaluate its efficacy and safety in combination with other treatments. Therefore, it is not currently recommended as a standard treatment for pancreatic cancer.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is vocimagene amiretrorepvec effective for recurrent high-grade glioma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Vocimagene amiretrorepvec (formerly Toca 511) is a retroviral replicating vector used in experimental cancer treatments. It is designed to deliver a gene into tumor cells, making them susceptible to antiviral drugs like ganciclovir. Clinical trials have explored its use in recurrent high-grade gliomas, such as glioblastoma. However, as of the latest available data, there is insufficient evidence to confirm its effectiveness in significantly improving outcomes for patients with recurrent high-grade glioma. Ongoing research may provide more clarity in the future.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Was ALVAC-HIV effective for HIV prevention in the HVTN 702 trial?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The HVTN 702 trial, also known as Uhambo, was a Phase 2b/3 clinical trial conducted in South Africa to evaluate the efficacy of the ALVAC-HIV vaccine regimen in preventing HIV infection. The trial began in 2016 and involved over 5,400 participants. In February 2020, the results indicated that the vaccine regimen did not provide significant protection against HIV, leading to the conclusion that ALVAC-HIV was not effective for HIV prevention in this trial.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does Î±CGRP have amyloidogenic properties?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether alpha-calcitonin gene-related peptide (Î±CGRP) has amyloidogenic properties. Amyloidogenic properties refer to the ability of a protein or peptide to form amyloid fibrils, which are abnormal protein aggregates associated with various diseases, such as Alzheimer's disease, Parkinson's disease, and others. To answer this question, I need to determine if Î±CGRP is known to form amyloid fibrils or contribute to amyloidosis. Î±CGRP is a neuropeptide involved in vasodilation and pain transmission. Some studies have explored the role of CGRP in various pathologies, but the key point here is whether it has been shown to have amyloid-forming potential. Based on current scientific literature, Î±CGRP itself is not typically classified as an amyloidogenic protein. It is primarily known for its physiological roles in the nervous system and cardiovascular function rather than forming amyloid deposits. However, some research suggests that under certain conditions, peptides can exhibit amyloidogenic behavior. Therefore, while Î±CGRP may have the potential to form amyloid-like structures in specific experimental conditions, it is not commonly recognized as a major amyloidogenic protein in the context of known amyloid diseases.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Do SETD1A mutations predispose to schizophrenia?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether mutations in the SETD1A gene predispose to schizophrenia. I need to determine if there is evidence linking SETD1A mutations to an increased risk of developing schizophrenia. SETD1A is a gene that encodes a histone methyltransferase, which is involved in chromatin remodeling and gene regulation. Studies have shown that rare, loss-of-function mutations in SETD1A are associated with an increased risk of schizophrenia. For example, a study published in Nature in 2014 identified SETD1A as a significant risk gene for schizophrenia through exome sequencing of individuals with the disorder. Additionally, subsequent research has supported the role of SETD1A in neurodevelopment and its implication in schizophrenia pathology. Therefore, based on current genetic evidence, mutations in SETD1A are considered to be a predisposing factor for schizophrenia.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is covid-19 induced anosmia caused by disruption of nuclear architecture?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Covid-19 induced anosmia is primarily associated with inflammation and damage to the olfactory epithelium and olfactory neurons, rather than a direct disruption of nuclear architecture. While the SARS-CoV-2 virus can affect various cellular structures, there is no strong evidence to suggest that anosmia in Covid-19 patients is caused by changes to the nucleus or nuclear architecture. The loss of smell is more likely due to the virus's impact on the olfactory support cells and the subsequent inflammatory response, which can lead to temporary or, in some cases, prolonged loss of smell. Therefore, the answer to whether Covid-19 induced anosmia is caused by disruption of nuclear architecture is no.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there any role of the 'Greek islands' in olfactory receptor choice?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question asks about the role of 'Greek islands' in olfactory receptor choice. Olfactory receptors are proteins involved in the sense of smell, and their 'choice' might refer to how different receptors are selected or expressed in the olfactory system. The term 'Greek islands' could refer to actual geographical locations, but it's unclear how these would directly relate to olfactory receptor biology. There is no known scientific connection between the geographical Greek islands and the biological process of olfactory receptor selection. Therefore, it's likely that the answer is 'no' unless there's a metaphorical or indirect connection being referenced.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is HDAC1 required for GATA-1 transcriptional activity?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether HDAC1 is required for GATA-1 transcriptional activity. GATA-1 is a transcription factor involved in hematopoiesis, particularly in erythroid and megakaryocytic differentiation. HDAC1 (Histone Deacetylase 1) is an enzyme that removes acetyl groups from histones, leading to chromatin condensation and transcriptional repression. However, HDAC1 can also interact with various transcription factors, sometimes acting as a co-repressor and other times as a co-activator depending on the context. Studies have shown that GATA-1 can interact with HDAC1, but the functional outcome of this interaction is context-dependent. In some cases, HDAC1 may repress GATA-1 activity by deacetylating histones around GATA-1 target genes, while in other contexts, HDAC1 may be required for GATA-1 to activate transcription, possibly by deacetylating non-histone proteins or by interacting with other co-factors. Therefore, the requirement of HDAC1 for GATA-1 transcriptional activity depends on the specific cellular context and the target gene in question.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there a dependence between chromatin organization and dorsoventral gene expression in Drosophila?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To answer this question, we need to determine if there is a relationship between chromatin organization and dorsoventral gene expression in Drosophila. Chromatin organization refers to the three-dimensional structure of DNA within the nucleus, which can influence gene expression by regulating access to DNA. Dorsoventral gene expression refers to the pattern of gene activity along the dorsal-ventral axis of the organism, which is crucial for proper development. Existing research suggests that chromatin structure can affect gene expression patterns, including those involved in developmental processes. In Drosophila, studies have shown that chromatin organization plays a role in regulating gene expression during development, including genes involved in body axis formation. Therefore, it is likely that there is a dependence between chromatin organization and dorsoventral gene expression in Drosophila.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does atemoya juice inhibit the CYP1A2 enzyme?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether atemoya juice inhibits the CYP1A2 enzyme. CYP1A2 is a member of the cytochrome P450 family of enzymes, which are involved in the metabolism of many drugs and other xenobiotics. Inhibition of CYP1A2 can lead to drug interactions, as it can increase the levels of drugs metabolized by this enzyme. To answer this question, we need to determine if there is any scientific evidence or studies that have investigated the effect of atemoya juice on CYP1A2 activity. Atemoya is a hybrid fruit derived from the cross between Annona squamosa and Annona cherimola. There is limited information available on the specific effects of atemoya juice on drug-metabolizing enzymes. However, other fruits, such as grapefruit, are well-known inhibitors of CYP enzymes, including CYP3A4 and CYP1A2. This is due to the presence of furanocoumarins and other compounds that can inhibit these enzymes. Given that atemoya is a different fruit, it is not clear whether it contains similar compounds that could inhibit CYP1A2. Without specific studies on atemoya juice and CYP1A2 inhibition, it is not possible to definitively answer this question. However, based on the available information, there is no strong evidence to suggest that atemoya juice inhibits the CYP1A2 enzyme.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does atemoya juice inhibit tye CYP3A4 enzyme?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether atemoya juice inhibits the CYP3A4 enzyme. CYP3A4 is a major enzyme in drug metabolism, and certain foods and drugs can inhibit its activity. Atemoya is a fruit, and similar to other fruits like grapefruit, which is known to inhibit CYP3A4, there may be potential for interaction. However, there is limited research specifically on atemoya juice and its effects on CYP3A4. Most studies focus on other fruits like grapefruit, pomelo, or pomegranate. Without specific studies confirming the inhibition of CYP3A4 by atemoya juice, it is not possible to definitively state that it does. Therefore, the answer is no based on current available evidence.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does daily atemoya juice intake change the pharmacokinetics of CYP1A2 substrates?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether consuming atemoya juice on a daily basis affects the way the body processes medications that are broken down by the CYP1A2 enzyme. CYP1A2 is responsible for metabolizing certain drugs, and substances that inhibit or induce this enzyme can alter drug levels in the blood. Atemoya is a tropical fruit, and similar fruits like grapefruit are known to interfere with drug metabolism. However, there is limited research specifically on atemoya's interaction with CYP1A2. Since there is no strong evidence or established data indicating that atemoya juice significantly affects CYP1A2 activity, it is unlikely to have a major impact.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can bergapten cross the blood-brain barrier?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Bergapten is a furanocoumarin compound found in plants like bergamot. The blood-brain barrier (BBB) is a protective barrier that restricts the passage of substances from the bloodstream into the brain. Whether a compound can cross the BBB depends on its molecular size, lipophilicity, and other properties. Bergapten is relatively lipophilic, which may allow passive diffusion across the BBB. However, there is limited direct evidence in scientific literature confirming bergapten's ability to cross the BBB. Some studies suggest that certain furanocoumarins may have neuroactive effects, implying potential BBB penetration, but specific data on bergapten remains scarce. Further research is needed to confirm this definitively.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can bergapten cause phototoxicity?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Bergapten is a compound found in certain plants, including those used in traditional medicine. It has been studied for its various biological activities. Phototoxicity refers to a reaction that occurs when a substance becomes toxic upon exposure to light. Some compounds can induce phototoxic effects by interacting with light and causing damage to cells or tissues. Based on available scientific literature, bergapten has been reported to exhibit phototoxic properties under specific conditions.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can whole genome sequencing be used for diagnosis of mitochondrial disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Whole genome sequencing (WGS) can be used for the diagnosis of mitochondrial diseases. Mitochondrial diseases are caused by mutations in either mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) that affect mitochondrial function. WGS captures both mtDNA and nDNA, allowing for the detection of mutations in genes related to mitochondrial function. This comprehensive approach can identify pathogenic variants that may be missed by more targeted methods, making WGS a valuable tool for diagnosing mitochondrial diseases, especially in cases where the genetic cause is unknown or when there is a complex clinical presentation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is AGO2 related to cytokinesis?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"AGO2 (Argonaute 2) is a protein involved in RNA interference (RNAi) pathways, primarily functioning in gene silencing through the degradation of target mRNAs. Cytokinesis is the process of cell division where the cytoplasm divides to form two daughter cells. Current literature does not indicate a direct role for AGO2 in cytokinesis. While AGO2 is crucial for post-transcriptional gene regulation, there is no evidence suggesting it participates in the mechanical or regulatory processes of cytokinesis.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does TIMELESS-TIPIN participate in replisome disassembly?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To answer this question, I need to determine whether TIMELESS-TIPIN is involved in replisome disassembly. The TIMELESS-TIPIN complex is known to play a role in DNA replication and the DNA damage response. It is involved in stabilizing replication forks and regulating the replication checkpoint. However, replisome disassembly typically involves the disassembly of the replication machinery, such as the replisome helicase, in response to replication stress or completion of replication. While TIMELESS-TIPIN is important for replication fork stability and checkpoint activation, there is no direct evidence indicating that it participates in the actual disassembly of the replisome. Instead, it may help in maintaining the integrity of the replication fork rather than promoting its disassembly.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is METTL1 overexpression associated with better patient survival?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine whether METTL1 overexpression is associated with better patient survival, we need to examine studies that have investigated the relationship between METTL1 expression levels and clinical outcomes in patients. METTL1 (Methyltransferase Like 1) is an enzyme involved in RNA modification, specifically in the methylation of tRNAs and possibly other RNAs. Its role in disease, particularly cancer, is an area of ongoing research.\\n\\nIn cancer biology, the overexpression of certain genes can lead to more aggressive tumor behavior, while in other cases, it may be associated with better prognosis. The association of METTL1 overexpression with patient survival would depend on its functional role in the specific type of cancer or disease context.\\n\\nA review of the literature reveals that METTL1 has been studied in various cancers, including hepatocellular carcinoma (HCC), gliomas, and others. In some studies, METTL1 overexpression has been linked to poor prognosis and reduced survival. For example, in HCC, METTL1 overexpression has been associated with increased tumor growth and worse clinical outcomes. Similarly, in gliomas, higher METTL1 expression has been correlated with more advanced tumor stages and lower survival rates.\\n\\nConversely, in some other contexts or cancer types, METTL1 overexpression might have different implications. However, the majority of current evidence suggests that METTL1 overexpression tends to be associated with worse prognosis rather than better survival.\\n\\nTherefore, based on the available research, the association between METTL1 overexpression and better patient survival is generally not supported.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has CPX-351 been approved by the FDA and the EMA?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Cpx-351 (Vyxeos) is a liposomal formulation of cytarabine and daunorubicin that is used in the treatment of acute myeloid leukemia (AML). The drug was approved by the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. The European Medicines Agency (EMA) also approved CPX-351 in 2018 for similar indications. Therefore, the drug has received regulatory approval from both agencies.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is REGN5458 a single-targeted antibody?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"REGN5458 is a bispecific monoclonal antibody, which means it targets two different antigens. Therefore, it is not a single-targeted antibody.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is MEDI2228 a bispecific antibody?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if MEDI2228 is a bispecific antibody, I need to check its structure and function. Bispecific antibodies can bind to two different antigens or two different epitopes on the same antigen. I will look up information on MEDI2228 to confirm its specificity.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is there a role for CADM1 in Myelodysplastic syndrome (MDS)?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To determine if CADM1 plays a role in Myelodysplastic syndrome (MDS), I need to review existing research on CADM1's involvement in MDS. CADM1 (Cell Adhesion Molecule 1) is known to be involved in cell adhesion and tumor suppression in various cancers. Myelodysplastic syndromes are a group of disorders characterized by ineffective blood cell production and a risk of progression to acute myeloid leukemia. Research into the molecular mechanisms of MDS may reveal if CADM1 is implicated, either through genetic mutations, altered expression, or epigenetic modifications. A literature search would be necessary to confirm any direct links between CADM1 and MDS.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does UBE4B promote renal cancer?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"UBE4B is a ubiquitin ligase that has been implicated in various cellular processes, including protein degradation. Its role in cancer, particularly renal cancer, is not well established. Some studies suggest that UBE4B may have tumor-suppressive functions, while others indicate it might contribute to tumorigenesis depending on the cellular context. However, there is no conclusive evidence directly linking UBE4B to the promotion of renal cancer. More research is needed to clarify its specific role in this type of cancer.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can IFNg induce the expression of IDO?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"IFNg, or Interferon-gamma, is known to play a role in immune responses. IDO, or Indoleamine 2,3-dioxygenase, is an enzyme involved in tryptophan metabolism. Research indicates that IFNg can activate IDO expression in certain cell types, such as antigen-presenting cells, which can lead to immune modulation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Mycobacterium abscessus a human pathogen?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Mycobacterium abscessus is a species of bacteria that is known to cause infections in humans, particularly in individuals with compromised immune systems or underlying lung conditions. It is part of the Mycobacterium chelonae-abscessus group and is recognized as an opportunistic pathogen. The bacteria can cause a variety of infections, including skin and soft tissue infections, as well as respiratory infections. Given this information, Mycobacterium abscessus is indeed a human pathogen.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do we find bacteriophages in the gut?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Bacteriophages are viruses that infect bacteria. They are found in various environments, including the human body. The gut is home to a diverse community of bacteria, which could be hosts for bacteriophages. Therefore, it is likely that bacteriophages are present in the gut.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is NfL (neurofilament light chain) a biomarker of neurodegeneration?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"NfL is a protein found in neurons, and its levels can increase in the blood or cerebrospinal fluid when there is damage to the nervous system. Studies have shown that elevated NfL levels are associated with various neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Therefore, NfL is considered a potential biomarker for neurodegeneration.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do the proteins Talin and Amot interact?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if Talin and Amot interact, I need to check scientific literature or databases for evidence of a direct or indirect interaction between these proteins. Talin is known for its role in cell adhesion, while Amot (Angiomotin) is involved in the Hippo signaling pathway and cell migration. Current databases like STRING or BioGRID might provide information on their interaction. Based on existing knowledge, there is no widely recognized direct interaction between Talin and Amot, but further verification through specific studies is required.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is serotonin transported by platelets?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Serotonin is a neurotransmitter that is primarily found in the central nervous system, as well as in the gastrointestinal tract. It is known to be stored and released by certain cells, such as enterochromaffin cells in the gut. Platelets, which are cell fragments involved in blood clotting, have been known to take up and store serotonin from the surrounding plasma. They do not synthesize serotonin themselves but can transport and release it under certain conditions. Therefore, the answer to whether serotonin is transported by platelets is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Otolin-1 a matrix protein?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"I need to determine if Otolin-1 is classified as a matrix protein. Matrix proteins typically refer to proteins found in the extracellular matrix (ECM), which provide structural and biochemical support to surrounding cells. I will check available scientific literature and databases to confirm the classification of Otolin-1. According to available data, Otolin-1 is a component of the inner ear's otoconia, which are calcium carbonate crystals involved in balance and gravity sensing. These structures are not part of the extracellular matrix in the traditional sense but are specialized components of the vestibular system. Therefore, Otolin-1 is not a matrix protein.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is the protein HOXA11 associated with endometrial disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To determine if the protein HOXA11 is associated with endometrial disease, I will search for scientific literature or reliable medical resources that discuss the role of HOXA11 in endometrial biology or pathology. HOXA11 is a homeobox gene known to play a role in reproductive tract development. Studies have shown that HOXA11 is expressed in the endometrium and may be involved in its development and function. Abnormal expression of HOXA11 has been linked to endometrial diseases such as endometriosis and endometrial cancer. Therefore, based on existing research, HOXA11 is associated with endometrial disease.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Lysozyme abundant in human tears?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Lysozyme is an enzyme that is present in various bodily fluids, including tears. It plays a role in the immune system by breaking down bacterial cell walls. Studies have shown that lysozyme is indeed found in human tears, where it helps protect the eyes from bacterial infections. Therefore, lysozyme is abundant in human tears.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is SMOC2 expressed during wound healing?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if SMOC2 is expressed during wound healing, I need to check scientific literature or databases that link SMOC2 to wound healing processes. SMOC2 (SPARC-related modular calcium-binding protein 2) is involved in extracellular matrix interactions. Wound healing involves tissue repair and extracellular matrix remodeling, suggesting a possible role for SMOC2. However, without direct evidence from studies showing SMOC2 expression in wound healing models, I cannot confirm this. I will need to search for specific studies or datasets addressing SMOC2 expression in wound healing contexts.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is esophageal adenocarcinoma associated with aberrant glycosylation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Esophageal adenocarcinoma is a type of cancer that occurs in the esophagus. Aberrant glycosylation is a common feature in many cancers, where the sugar molecules on proteins and lipids are altered, leading to changes in cell behavior. Studies have shown that in esophageal adenocarcinoma, there are changes in glycosylation patterns, which can affect tumor growth, invasion, and metastasis. These alterations can also be used as biomarkers for diagnosis and prognosis. Therefore, esophageal adenocarcinoma is associated with aberrant glycosylation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is cytokeratin a tumor marker?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Cytokeratin is a type of protein found in epithelial cells. It is often used as a tumor marker in certain cancers, such as carcinomas, to help identify the presence of cancer cells.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there any R packages that help with visualizing data on spirals?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"I know that the R package 'ggplot2' is commonly used for data visualization, but I'm not sure if it specifically supports spiral visualizations. There might be other specialized packages like 'spiralize' or 'circlize' that handle spiral plots. I should check if these packages are available in R.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there roles for cohesin mutations in AML?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Cohesin is a protein complex that plays a role in cell division and DNA repair. Mutations in cohesin have been found in various cancers, including acute myeloid leukemia (AML). Studies have shown that cohesin mutations can contribute to the development and progression of AML by disrupting normal cell division and DNA repair processes. These mutations may also be associated with specific clinical features and outcomes in AML patients. Therefore, cohesin mutations do have roles in AML.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Epoxyeicosatrienoic acids (EETs) synthesized by cytochrome P450 epoxygenases from arachidonic acid?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Epoxyeicosatrienoic acids (EETs) are known to be synthesized from arachidonic acid through the action of specific enzymes. Cytochrome P450 epoxygenases are a group of enzymes that catalyze the epoxidation of arachidonic acid, leading to the formation of EETs. This biochemical pathway is well-documented in scientific literature, indicating that EETs are indeed produced by these enzymes from arachidonic acid.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Epistaxis associated with dental implant placement?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Epistaxis refers to nosebleeds. Dental implant placement involves inserting implants into the jawbone. The maxillary sinuses are near the upper jaw, and implant placement in this area could potentially cause sinus-related complications. However, there is no direct association between dental implant placement and nosebleeds. Any connection would likely be indirect, such as trauma during surgery affecting nearby blood vessels, but this is not a common occurrence.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are Tregs CD4(+)CD25(+) regulatory T cells a positive regulator of the immune response?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Tregs, or regulatory T cells, are known for their role in maintaining immune tolerance and preventing autoimmune diseases. They typically suppress immune responses to prevent overactivation and maintain homeostasis. The question asks if they are a positive regulator of the immune response. Since their primary function is suppression rather than activation, they are generally considered negative regulators. Therefore, the answer is no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Unlike DNA, RNA is not methylated, yes or no?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"RNA can be methylated, for example, in the form of N6-methyladenosine (m6A), which is a common modification in messenger RNA. Therefore, the statement that RNA is not methylated is incorrect.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do RNA binding Proteins  that bind to adenine uridine (AU)-rich elements (AREs) in the 5' untranslated region (UTR) of mRNAs (AU-RBPs) regulate the DNA Damage Response?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether RNA binding proteins that bind to AU-rich elements in the 5' UTR of mRNAs (AU-RBPs) regulate the DNA Damage Response.  I know that AU-rich elements are typically found in the 3' UTR of mRNAs and are involved in regulating mRNA stability and translation.  The presence of AU-RBPs in the 5' UTR is less common.  The DNA Damage Response is a complex process involving the detection and repair of DNA damage.  This process is primarily regulated at the transcriptional and post-translational level.  While some RNA binding proteins are involved in the DNA Damage Response, the specific role of AU-RBPs in this process, especially in the 5' UTR, is not well established.  Further research would be needed to confirm a direct regulatory role.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are G-quadruplexes(G4) possible drug targets for glioblastoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"G-quadruplexes (G4) are four-stranded DNA structures that can form in regions rich in guanine. They are involved in the regulation of gene expression, particularly in the promoters of oncogenes. Targeting G4 structures with small molecules can stabilize them, potentially inhibiting the expression of oncogenes like c-Myc, Bcl-2, and VEGF, which are implicated in glioblastoma. Research suggests that G4-targeting compounds could have therapeutic potential for glioblastoma by interfering with key oncogenic pathways. However, the development of specific and effective drugs targeting G4 structures is still in early stages, and further studies are needed to validate their efficacy and safety in clinical settings.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is CircRNA produced by back splicing of exon, intron or both, forming exon or intron circRNA?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"CircRNAs are primarily formed through back-splicing events involving exons. In back-splicing, a downstream splice donor site joins to an upstream splice acceptor site, creating a circular RNA molecule. While most circRNAs are derived from exonic sequences, some can also include intronic regions. However, the majority are exonic circRNAs, with intronic circRNAs being less common. Therefore, circRNAs can be produced from exons, introns, or a combination of both, resulting in different types of circRNAs.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are circRNAs susceptible to degradation by RNase R?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Circular RNAs (circRNAs) are covalently closed loop structures formed by back-splicing events. Due to their circular structure, they lack free ends, which makes them resistant to exonucleases like RNase R that typically degrade linear RNAs by attacking their 5' or 3' ends. This resistance to degradation is one of the key characteristics distinguishing circRNAs from linear RNAs.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is RUNX1T1 associate with obesity?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"RUNX1T1 (Runt-related transcription factor 1, translocated to, 1), also known as ETO (Eight-Twenty-One), is primarily known for its role in leukemia, particularly acute myeloid leukemia (AML), where it forms a fusion protein with RUNX1 due to chromosomal translocation t(8;21). This fusion protein disrupts normal hematopoiesis and contributes to leukemogenesis. However, regarding its association with obesity, there is limited direct evidence in the literature. While RUNX1T1 is involved in transcriptional regulation, its role in metabolic processes or adipogenesis is not well established. Some studies suggest that transcription factors involved in hematopoiesis may have secondary roles in other tissues, but specific links to obesity have not been conclusively demonstrated. Therefore, current evidence does not strongly support a direct association between RUNX1T1 and obesity.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can FTO promote pancreatic cancer development?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"FTO (Fat Mass and Obesity-Associated Protein) is an enzyme involved in the regulation of RNA modifications, particularly m6A demethylation. Studies have shown that FTO plays a role in various biological processes, including metabolism, energy homeostasis, and cancer development. However, the specific role of FTO in pancreatic cancer is not well established. Some research suggests that FTO may have tumor-suppressive effects in certain cancers, while in others, it may promote tumorigenesis. As of now, there is limited direct evidence linking FTO to the promotion of pancreatic cancer development. More research is needed to clarify its role in this specific cancer type.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Ameloblastoma (AB) a common benign tumor occurring in the brain?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Ameloblastoma (AB) is a benign tumor that originates from the epithelial cells of the tooth-forming organ. It is commonly found in the jawbones, particularly the mandible. Although it is a benign tumor, it can be locally aggressive and may require surgical removal. However, AB is not typically associated with the brain; it primarily affects the oral and maxillofacial region. Therefore, AB is not a common benign tumor occurring in the brain.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is disruption of immune regulation mechanisms associated with adverse pregnancy outcomes, including preeclampsia (PE)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking if disruption of immune regulation mechanisms is associated with adverse pregnancy outcomes, including preeclampsia (PE). I need to determine if there is a link between immune regulation disruptions and these outcomes. Preeclampsia is a known complication during pregnancy, and immune factors are known to play a role in its pathogenesis. Immune regulation is crucial during pregnancy to maintain tolerance to the fetus. Disruptions in this regulation could lead to immune-mediated complications, such as PE. Existing research suggests that immune system imbalances, including abnormal activation of immune cells and cytokine dysregulation, are involved in the development of PE. Therefore, it is reasonable to conclude that disruption of immune regulation mechanisms is associated with adverse pregnancy outcomes, including PE.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can METTL3 methylate long noncoding RNAs?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"METTL3 is an enzyme that adds methyl groups to RNA molecules, a process known as RNA methylation. This enzyme is part of the methyltransferase complex that catalyzes the formation of N6-methyladenosine (m6A), a common modification in messenger RNAs (mRNAs). While METTL3's role in methylating mRNAs is well established, its ability to methylate long noncoding RNAs (lncRNAs) is less clear. Some studies suggest that METTL3 can methylate lncRNAs, influencing their stability and function. However, the extent and specificity of this methylation may vary depending on the cellular context and the specific lncRNA involved. Therefore, while METTL3 may have the capacity to methylate certain lncRNAs, the overall evidence is not yet conclusive for all lncRNAs.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is PCAT6 a microRNA?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine whether PCAT6 is a microRNA, we need to examine its classification and biological characteristics. MicroRNAs (miRNAs) are small non-coding RNA molecules, typically around 22 nucleotides in length, that regulate gene expression post-transcriptionally by binding to the 3' untranslated regions (UTRs) of target messenger RNAs (mRNAs). They play crucial roles in various biological processes, including development, differentiation, and disease. PCAT6, also known as Prostate Cancer Associated Transcript 6, is a long non-coding RNA (lncRNA) that has been implicated in the progression of prostate cancer. Unlike miRNAs, lncRNAs are generally longer than 200 nucleotides and can function in various regulatory roles, such as chromatin remodeling, transcriptional regulation, and post-transcriptional processing. Given that PCAT6 is classified as a lncRNA and not a small non-coding RNA, it does not meet the criteria to be categorized as a microRNA.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can autophagy related lncRNAs be used for colorectal cancer prognosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether autophagy-related long non-coding RNAs (lncRNAs) can be used for the prognosis of colorectal cancer. To answer this, I need to determine if there is evidence in the scientific literature that these specific lncRNAs are associated with the prognosis of colorectal cancer patients. Autophagy is a cellular process involved in the degradation and recycling of cellular components, and dysregulation of autophagy has been implicated in various diseases, including cancer. Long non-coding RNAs are known to play roles in gene regulation and have been linked to cancer development and progression. If studies have shown that certain autophagy-related lncRNAs are predictive of patient outcomes, such as survival or recurrence, then the answer would be yes. If no such studies exist or if the evidence is inconclusive, the answer would be no.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are circular RNAs implicated in diseases of the eye?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Circular RNAs (circRNAs) are a type of non-coding RNA that have been found to play roles in various biological processes and diseases. Research has shown that circRNAs can act as microRNA sponges, regulate gene expression, and influence cellular functions. In the context of eye diseases, studies have implicated circRNAs in conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma. For example, certain circRNAs have been found to be differentially expressed in the retinas of patients with these diseases, suggesting their involvement in disease mechanisms. Therefore, there is evidence supporting the implication of circRNAs in eye diseases.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Ameloblastoma (AB) a benign tumor that never metastasizes?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Ameloblastoma (AB) is a benign tumor that arises from the epithelial remnants of the tooth-forming apparatus. Although it is considered benign, it can exhibit locally aggressive behavior and has a high recurrence rate if not completely excised. However, metastasis is extremely rare. There have been very few reported cases of ameloblastoma metastasizing, typically to the lungs or regional lymph nodes. Therefore, while ameloblastoma is generally non-metastatic, it is not entirely accurate to state that it never metastasizes.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Acute Necrotizing Encephalopathy (ANE) which typically affects young, healthy children usually triggered by exposure to air pollution?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Acute Necrotizing Encephalopathy (ANE) is a rare neurological disorder that primarily affects children. It is typically associated with viral infections, particularly influenza, rather than environmental factors like air pollution. The condition involves inflammation and damage to the brain, often following a viral illness. While environmental factors can influence health, there is no established link between air pollution and the onset of ANE. Therefore, the usual trigger is not air pollution.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is retinol binding protein 4 an adipokine?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Retinol binding protein 4 (RBP4) is a protein that transports retinol (vitamin A) in the bloodstream. Adipokines are cytokines secreted by adipose tissue. RBP4 is primarily produced by the liver, not adipose tissue, and its main function is related to vitamin A transport rather than signaling between fat cells. Therefore, RBP4 is not classified as an adipokine.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Do Afamin bind Vitamin E?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Afamin is a protein that has been studied for its potential binding properties with various molecules. Research indicates that Afamin has a high affinity for Vitamin E, suggesting that it may play a role in the transport or regulation of Vitamin E in the body. Studies have shown that Afamin can form complexes with Vitamin E, which supports the idea that there is an interaction between the two. However, the exact nature and significance of this binding may require further investigation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is HYDIN (Hydrocephalus-inducing protein homolog) an axonemal protein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"HYDIN (Hydrocephalus-inducing protein homolog) is a protein that has been associated with ciliary function and structure. Axonemal proteins are components of the axoneme, which is the core structure of cilia and flagella. Research indicates that HYDIN is part of the axoneme and plays a role in the motility of cilia. Therefore, HYDIN is considered an axonemal protein.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is ASF1 phopshorylated by  the Tousled-like kinases?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"To answer this question, I need to determine if the protein ASF1 is phosphorylated by Tousled-like kinases (TLKs).  First, I'll consider what is known about ASF1 and TLKs.  ASF1 is a histone chaperone involved in DNA replication and repair.  Tousled-like kinases are a family of serine/threonine protein kinases involved in various cellular processes, including DNA damage response and chromatin remodeling.  The question is whether there is evidence in the scientific literature that TLKs directly phosphorylate ASF1.  I would need to search for research articles that have investigated the interaction between TLKs and ASF1, specifically looking for experiments that demonstrate phosphorylation of ASF1 by TLKs.  If such studies exist and show a direct interaction and phosphorylation event, then the answer would be yes.  If no such studies exist, or if the evidence suggests that TLKs do not phosphorylate ASF1, then the answer would be no.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is paxillin affected by RANKL?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To determine if paxillin is affected by RANKL, I need to check if there is any scientific evidence or research studies that show a direct or indirect interaction between RANKL and paxillin. RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) is a protein involved in bone metabolism and immune responses. Paxillin is an adapter protein involved in cell adhesion and signal transduction. I would need to search for studies that investigate the effects of RANKL on paxillin expression, phosphorylation, or localization. If such studies exist, they might indicate that paxillin is affected by RANKL. If no such studies exist, it is possible that there is no known effect of RANKL on paxillin.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is taxilin a cancer marker?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Taxilin is a protein that has been studied in relation to cancer. Research indicates that taxilin may play a role in the progression of certain cancers, such as colorectal cancer, by affecting cell migration and invasion. However, it is not widely recognized as a primary cancer marker like other well-established biomarkers (e.g., PSA for prostate cancer). Its potential as a cancer marker is still under investigation.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can parasite infections by Schistosoma japonicum prevent or improve asthma?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Schistosoma japonicum is a parasitic flatworm that causes schistosomiasis, a disease prevalent in parts of Asia. Research has explored the relationship between parasitic infections and allergic diseases like asthma, based on the hygiene hypothesis, which suggests that early exposure to certain pathogens might modulate the immune system and reduce the risk of allergies. Some studies have indicated that helminth infections, including schistosomiasis, may have immunomodulatory effects that could potentially reduce the severity of asthma. However, the evidence is not conclusive, and such infections can also have harmful effects. Therefore, while there may be some indirect effects due to immune system modulation, it cannot be definitively stated that S. japonicum infections prevent or improve asthma.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does sphingosine-1 phosphoate suppress epiregulin?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator involved in various cellular processes, including cell proliferation, survival, and migration. Epiregulin is a member of the epidermal growth factor (EGF) family and plays a role in cell growth and differentiation. To determine whether S1P suppresses epiregulin, we need to examine the existing literature on their interaction. Studies have shown that S1P can modulate the expression of various growth factors and cytokines. However, specific evidence regarding the direct suppression of epiregulin by S1P is limited. Some research suggests that S1P may influence epiregulin expression indirectly through signaling pathways such as the MAPK or PI3K/Akt pathways, which are involved in regulating the expression of various growth factors. However, without direct experimental evidence demonstrating that S1P suppresses epiregulin, it is not possible to definitively answer this question. Further research is needed to establish a clear relationship between S1P and epiregulin.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is telomestatin, a novel statin drug used to treat high cholesterol?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Telomestatin is not a statin drug. Statins are a class of drugs used to lower cholesterol levels, such as atorvastatin, simvastatin, and rosuvastatin. Telomestatin is a different type of compound that targets telomerase, an enzyme involved in aging and cancer. Therefore, telomestatin is not used to treat high cholesterol.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Satb1 a transcription factor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Satb1 is a transcription factor. It is known to play a role in gene regulation and chromatin organization.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the 22-item sino-nasal outcome test (SNOT-22) a widely used measure for Health-Related Quality-of-Life (HRQOL) associated with chronic rhinosinusitis (CRS)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The SNOT-22 is a validated and commonly used patient-reported outcome measure specifically designed to assess HRQOL in patients with rhinosinusitis, including chronic rhinosinusitis. It is frequently utilized in both clinical practice and research settings to evaluate the impact of CRS on patients' quality of life.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is SOX10 expressed in melanoma cells?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"SOX10 is a transcription factor that plays a key role in the development of neural crest-derived cells, including melanocytes. In melanoma, which originates from melanocytes, SOX10 is often expressed and is involved in maintaining the melanocytic lineage. Studies have shown that SOX10 is expressed in melanoma cells and contributes to their survival and proliferation. Therefore, the answer is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is EuroQol 5-Dimension Health Assessment (EQ-5D) [a widely used, simple instrument that monitors the general health-related quality of life (HRQoL) in chronic disease] a 5 question assessment?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The EQ-5D is a standardized instrument that measures health-related quality of life. It consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three levels of severity. The assessment includes a questionnaire with five questions, each addressing one of the dimensions. Therefore, the EQ-5D is a 5-question assessment.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is neurofilament light marker for disease?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Neurofilament light chain (NfL) is a protein found in neurons, and its levels can increase in the blood or cerebrospinal fluid when there is neuronal damage or neurodegeneration. Elevated NfL levels have been associated with various neurological diseases, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). However, NfL is not specific to any single disease and can be elevated in different conditions involving neuronal injury. Therefore, while NfL can serve as a biomarker indicating neuronal damage, it is not a definitive marker for a specific disease.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is Phospholemman a membrane protein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Phospholemman is a protein that is known to be involved in the regulation of ion transport in cells. It is a small protein that is primarily found in the plasma membrane of cells, particularly in the heart and skeletal muscle cells. Since it is located in the plasma membrane, it can be classified as a membrane protein. Therefore, the answer is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Mical an oxidoreductase?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Mical (Microtubule-Interacting and Cell Cycle-Regulated Kinase) is a family of enzymes that have been identified as flavoprotein monooxygenases. Oxidoreductases are a class of enzymes that catalyze oxidation-reduction reactions. Monooxygenases, such as Mical, are a subclass of oxidoreductases because they catalyze the incorporation of one atom of oxygen into a substrate while reducing the other oxygen atom, typically using NAD(P)H as a cofactor. Therefore, Mical, as a monooxygenase, functions as an oxidoreductase.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is resistance training usually associated with increasing muscle hypertrophy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Resistance training involves exercises that cause the muscles to contract against an external resistance with the goal of increasing strength, anaerobic endurance, and muscle hypertrophy. Muscle hypertrophy refers to an increase in muscle size, which is a common outcome of resistance training due to the micro-tears in muscle fibers that repair and grow larger. Therefore, resistance training is typically associated with increasing muscle hypertrophy.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is periampullary carcinoma (PAC) a relatively rare genitourinary malignancy",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Periampullary carcinoma (PAC) arises in the region around the ampulla of Vater, which is located in the duodenum near where the bile duct and pancreatic duct join and empty into the intestine. It is a type of gastrointestinal cancer rather than a genitourinary malignancy. Genitourinary malignancies typically refer to cancers of the urinary tract (kidneys, ureters, bladder, urethra) and the reproductive organs (prostate, testes, penis in males; uterus, ovaries, cervix, vagina, vulva in females). Since PAC is related to the digestive system and not the genitourinary system, it is not classified as a genitourinary malignancy. Additionally, PAC is considered relatively rare compared to more common cancers like colorectal or breast cancer, but its rarity is in the context of gastrointestinal cancers, not specifically genitourinary.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is pRETRO-SUPER an adenoviral vector?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"pRETRO-SUPER is a plasmid vector used in molecular biology for gene expression and RNA interference studies. It is not an adenoviral vector; adenoviral vectors are derived from adenoviruses and are used for gene delivery into cells, often for therapeutic purposes.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can epigenetic modifications be heritable?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Epigenetic modifications refer to changes in gene expression that do not involve alterations to the underlying DNA sequence. These modifications, such as DNA methylation and histone modification, can be influenced by environmental factors. Research has shown that some epigenetic marks can be passed from parents to offspring, affecting gene expression in subsequent generations. This phenomenon is known as transgenerational epigenetic inheritance. However, the extent and mechanisms of this heritability are still under investigation and not fully understood. Therefore, while some epigenetic modifications can be heritable, it is a complex and ongoing area of study.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) increase the likelihood of severe COVID-19?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are medications commonly used to treat hypertension and other cardiovascular conditions. There was initial concern that these medications might increase the expression of ACE2 receptors, which SARS-CoV-2 uses to enter cells, potentially leading to more severe COVID-19. However, subsequent research and clinical studies have not found a significant association between the use of ACE inhibitors or ARBs and an increased risk of severe COVID-19 outcomes. Major health organizations, including the World Health Organization (WHO) and the American Heart Association (AHA), have stated that there is no evidence to support discontinuing these medications in patients with COVID-19.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does p85Î± homodimerize?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"p85Î± is a regulatory subunit of phosphoinositide 3-kinase (PI3K), which plays a key role in cell signaling pathways. Homodimerization refers to the ability of a protein to form a dimer with another identical protein. To determine whether p85Î± homodimerizes, we need to consider its structure and known interactions. p85Î± contains SH2 and SH3 domains, which are typically involved in protein-protein interactions. However, p85Î± primarily forms heterodimers with the catalytic subunit p110 of PI3K. There is limited evidence suggesting that p85Î± can homodimerize under certain conditions, but this is not its primary function. Most studies indicate that p85Î± functions mainly as a regulatory partner for p110, rather than forming homodimers.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is thalidomide used as an immunomodulatory drug nowadays?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Thalidomide was originally developed as a sedative but was later found to have immunomodulatory properties. It was withdrawn from the market in the 1960s due to severe birth defects but has since been reintroduced for specific medical uses. Today, it is used under strict regulations for conditions like multiple myeloma and leprosy, where its immunomodulatory effects are beneficial. Therefore, thalidomide is indeed used as an immunomodulatory drug in modern medicine.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are functional tests a good biomarker for Duchenne Muscular Dystrophy?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Functional tests, such as the 6-minute walk test (6MWT) and motor function assessments, are commonly used in clinical settings to evaluate the progression of Duchenne Muscular Dystrophy (DMD) and the effectiveness of treatments. These tests measure physical capabilities and can indicate changes in muscle function over time. Biomarkers, on the other hand, are typically biological indicators that can be measured in tissues, blood, or other bodily fluids. While functional tests are valuable for assessing disease progression and response to therapy, they are not considered biomarkers in the traditional sense because they do not directly measure a biological process. Instead, they provide a functional readout of the disease state. Therefore, while functional tests are important tools in managing DMD, they are not classified as biomarkers.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, particularly influenza?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether there is a way to distinguish between COVID-19 and other respiratory illnesses, particularly influenza, clinically. This means that the question is asking whether there are clinical signs, symptoms, or diagnostic tests that can be used to differentiate between these two illnesses. In this context, \\\"clinically\\\" refers to the diagnosis and treatment of diseases in a medical setting. To answer this question, I need to determine whether there are clinical features or diagnostic tests that can distinguish between COVID-19 and other respiratory illnesses, particularly influenza. If there are such features or tests, then the answer is \\\"yes\\\"; otherwise, the answer is \\\"no\\\".\\n\\nTo answer this question, I need to consider the clinical features of both COVID-19 and influenza. Both illnesses can cause similar symptoms, such as fever, cough, and shortness of breath. However, there are some differences in the clinical presentation of these illnesses. For example, loss of taste or smell is more commonly associated with COVID-19 than with influenza. Additionally, there are diagnostic tests that can be used to distinguish between these illnesses, such as PCR tests that detect the genetic material of the virus. These tests can be used to confirm the presence of the SARS-CoV-2 virus, which causes COVID-19, or the influenza virus.\\n\\nBased on this information, I can conclude that there are clinical features and diagnostic tests that can be used to distinguish between COVID-19 and other respiratory illnesses, particularly influenza. Therefore, the answer to this question is \\\"yes\\\".\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is lumbar puncture the first test that should be performed on a patient with increased intracranial pressure?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Lumbar puncture is a procedure where a needle is inserted into the lower back to collect cerebrospinal fluid (CSF) for testing. It is commonly used to diagnose conditions such as meningitis, encephalitis, and subarachnoid hemorrhage. However, in patients with increased intracranial pressure (ICP), lumbar puncture can be dangerous. Increased ICP can lead to brain herniation when the CSF pressure is suddenly reduced during the procedure. Therefore, lumbar puncture should not be the first test performed on a patient with suspected increased ICP. Instead, imaging studies such as CT scan or MRI should be done first to evaluate for mass lesions or other causes of increased ICP before considering lumbar puncture.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does mutation of ARTEMIS gene causes severe combined immunodeficiency?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question asks whether mutation of the ARTEMIS gene causes severe combined immunodeficiency (SCID). I know that SCID is a group of rare, life-threatening genetic disorders characterized by the absence of functional T and B cells, leading to a severely compromised immune system. Various genes are associated with different forms of SCID, such as the IL2RG gene for X-linked SCID and the ADA gene for adenosine deaminase deficiency. I recall that the ARTEMIS gene is involved in DNA repair and V(D)J recombination, which is crucial for the development of T and B cells. Mutations in ARTEMIS may impair this process, leading to immunodeficiency. I need to confirm if ARTEMIS gene mutations are indeed linked to SCID or if they cause a different type of immunodeficiency. Upon reviewing, ARTEMIS deficiency is associated with a form of SCID known as Artemis-deficient SCID, which is a rare autosomal recessive disorder. Therefore, mutations in the ARTEMIS gene do cause a type of severe combined immunodeficiency.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Cinpanemab effective for Parkinsonâ€™s Disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"I need to check if Cinpanemab is effective for Parkinson's Disease. First, I will search for information on Cinpanemab and its use in treating Parkinson's Disease. I will look for clinical trials, studies, or reviews that discuss its effectiveness. If there is evidence supporting its effectiveness, I will answer yes. If there is no evidence or evidence suggesting it is not effective, I will answer no.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Prasinezumab effective for Parkinsonâ€™s Disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Prasinezumab is a monoclonal antibody being studied for the treatment of Parkinson's disease. It targets alpha-synuclein, a protein associated with the progression of Parkinson's. Clinical trials are ongoing to determine its effectiveness. As of now, there is no conclusive evidence that it is effective, but research is continuing.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does CIDEB mutation protect from liver disease?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking whether a mutation in the CIDEB gene provides protection against liver disease. CIDEB (CIDE domain-containing protein B) is involved in lipid metabolism and has been implicated in non-alcoholic fatty liver disease (NAFLD) and other metabolic disorders. Research suggests that certain mutations or variations in CIDEB may influence the development of liver diseases. For example, some studies have shown that specific CIDEB polymorphisms might be associated with altered lipid storage and metabolism, which could either increase or decrease the risk of liver disease depending on the context. However, the evidence is not yet conclusive, and more research is needed to determine whether CIDEB mutations are protective or harmful. Therefore, the answer is no, as there is no definitive evidence that CIDEB mutation protects from liver disease.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there any association between Tripe palms and cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tripe palms is a rare skin condition characterized by thickened, velvety palms. It is often associated with underlying medical conditions, particularly internal malignancies. Studies and medical literature have shown that tripe palms can be a paraneoplastic syndrome, which means it can occur in association with cancer, even though the exact mechanism is not fully understood. Therefore, the presence of tripe palms may indicate an underlying cancer, especially in older adults.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Was AAVS3 developed for hemophilia A?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"AAVS3 is a gene therapy approach that targets a specific location in the genome for the treatment of hemophilia A. It involves inserting a functional copy of the factor VIII gene into the AAVS3 site, which is a safe harbor site in the human genome. This allows for stable expression of the factor VIII protein, which is deficient in patients with hemophilia A. Therefore, AAVS3 was developed specifically for hemophilia A.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Was DNX-2401 tested for treatment of Diffuse Intrinsic Pontine Glioma?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"DNX-2401 is a virus-based therapy that has been studied for the treatment of various cancers, including gliomas. However, the specific indication for Diffuse Intrinsic Pontine Glioma (DIPG) needs to be confirmed. Checking clinical trials and published research, DNX-2401 has been primarily investigated in adult gliomas, particularly glioblastoma multiforme. There is limited evidence or publicly available information indicating that DNX-2401 has been tested specifically for DIPG, which is a pediatric brain tumor. Therefore, it is unlikely that DNX-2401 has been tested for the treatment of DIPG.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is Baricitinib effective for Alopecia Areata?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Baricitinib is a Janus kinase (JAK) inhibitor primarily used for rheumatoid arthritis. Recent studies have explored its off-label use for Alopecia Areata, an autoimmune condition causing hair loss. Clinical trials have shown some promise, with certain patients experiencing hair regrowth. However, it is not yet FDA-approved specifically for Alopecia Areata, and its efficacy can vary among individuals. Consultation with a dermatologist is recommended to determine suitability.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is erenumab effective for trigeminal neuralgia?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Erenumab is a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, approved for the prevention of migraine in adults. Trigeminal neuralgia is a chronic pain condition affecting the trigeminal nerve, characterized by severe, episodic facial pain. While both conditions involve the trigeminal nerve, erenumab's mechanism of action is specifically related to migraine prevention. There is currently no evidence or approval indicating that erenumab is effective for treating trigeminal neuralgia.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is alternative splicing associated with heart disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Alternative splicing is a process that allows a single gene to produce multiple protein isoforms by varying the combination of exons during mRNA processing. This mechanism is crucial for increasing proteomic diversity and regulating gene expression. Dysregulation of alternative splicing has been implicated in various diseases, including cancer and neurodegenerative disorders. In the context of heart disease, studies have shown that abnormal splicing patterns can lead to the production of dysfunctional proteins involved in cardiac structure and function. For example, mutations affecting splicing factors or splice sites in genes critical for heart development and maintenance may result in cardiomyopathies or congenital heart defects. Additionally, changes in splicing patterns have been observed in response to pathological conditions such as heart failure, suggesting that alternative splicing plays a role in the progression of cardiovascular diseases. Therefore, there is evidence supporting an association between alternative splicing and heart disease.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is PRP-40 involved in microexon splicing?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"PRP-40 is a protein involved in pre-mRNA splicing. Microexon splicing refers to the inclusion or exclusion of very small exons (typically 3-27 nucleotides long) during the splicing process. To determine if PRP-40 is involved in microexon splicing, we need to check if PRP-40 has a role in recognizing or processing these small exons. Current research suggests that PRP-40 is part of the spliceosome and helps in the recognition of splice sites, which could include microexons. However, specific evidence linking PRP-40 directly to microexon splicing is limited. Further studies are needed to confirm a direct role in microexon splicing.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does microexon alternative splicing of small GTPase regulators have implication in central nervous system diseases?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Microexons are small exons, typically 3-27 nucleotides in length, that can be alternatively spliced into mRNA transcripts. They are often conserved across species and play roles in protein function by altering protein domains or interaction sites. Alternative splicing of microexons in genes encoding small GTPases or their regulators (such as GEFs, GAPs, or GDIs) could potentially affect the function of these proteins, which are critical for various cellular processes including cell signaling, cytoskeletal dynamics, and vesicle trafficking. Dysregulation of small GTPases has been implicated in various diseases, including cancers and neurological disorders. In the context of the central nervous system (CNS), small GTPases like Rho, Rac, and Cdc42 are known to regulate neuronal morphology, synaptic plasticity, and axon guidance. Aberrant splicing of microexons in these pathways could lead to dysfunctional protein isoforms, potentially contributing to CNS diseases such as autism spectrum disorders, schizophrenia, or neurodegenerative diseases. Research in this area is ongoing, and while there is evidence linking alternative splicing and small GTPase dysfunction to CNS disorders, the specific role of microexon splicing in these conditions requires further investigation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does silencing of SRRM4 promote microexon inclusion?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"SRRM4 is a splicing factor that regulates the inclusion of microexons in gene transcripts. When SRRM4 is silenced, its ability to promote microexon inclusion is reduced, leading to decreased microexon inclusion in the resulting mRNA. Therefore, silencing of SRRM4 does not promote microexon inclusion.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does silencing of SRRM4 inhibit tumor growth across cancers?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question asks whether silencing SRRM4 inhibits tumor growth across different types of cancer. To answer this, we need to evaluate existing scientific evidence regarding the role of SRRM4 in tumor development and the effects of its silencing in various cancer models. SRRM4 (Serine/Arginine Repetitive Matrix 4) is a splicing factor involved in alternative splicing regulation. Its role may vary depending on the cancer type. If studies show consistent tumor growth inhibition upon SRRM4 silencing across multiple cancers, the answer would be 'yes'. However, if the effect is context-dependent or limited to specific cancers, the answer would be 'no'.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does SRRM4 regulate neuronal-specific microexon splicing of TAF1 mRNA?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To answer this question, we need to determine if SRRM4 is involved in the regulation of neuronal-specific microexon splicing of TAF1 mRNA. SRRM4, also known as Neuro-oncological ventral antigen 1 (NOVA1), is a splicing factor that is known to play a role in regulating alternative splicing in neurons. Microexons are small exons, typically 3-27 nucleotides in length, that are often spliced in a tissue-specific manner, and their inclusion can alter the function of the resulting protein. TAF1 is a gene that encodes for TATA-box binding protein associated factor 1, which is involved in transcription initiation. Neuronal-specific splicing of microexons in TAF1 mRNA would mean that certain exons are included or excluded in the mRNA transcript specifically in neurons, potentially leading to a different isoform of the TAF1 protein in these cells. To confirm if SRRM4 regulates this process for TAF1 mRNA, we would need to look for scientific studies or literature that directly investigate the role of SRRM4 in the splicing of TAF1 microexons in neurons. If such studies show that SRRM4 binds to the TAF1 pre-mRNA and influences the inclusion or exclusion of specific microexons in a neuronal context, then the answer would be yes. If there is no evidence or if the evidence suggests that SRRM4 does not play a role in this specific splicing event, then the answer would be no. Without specific evidence from the literature, it is not possible to definitively answer this question. However, based on current knowledge, SRRM4 is known to regulate splicing of various neuronal-specific transcripts, but its specific involvement in TAF1 mRNA microexon splicing would require direct experimental evidence to confirm.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is PRP-40 regulation of microexons a conserved phenomenon?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question asks whether the regulation of microexons by PRP-40 is a conserved phenomenon. Microexons are small exons, often 3-27 nucleotides long, that can be differentially included in mRNA transcripts. PRP-40 is a splicing factor involved in the recognition of splice sites during pre-mRNA splicing. Conservation of this regulatory mechanism would imply that PRP-40's role in microexon regulation is maintained across different species. To determine this, one would need to examine studies that compare PRP-40 function across species, particularly looking at whether PRP-40 homologs in various organisms similarly regulate microexons. If research indicates that PRP-40 or its homologs play a similar role in microexon splicing in multiple species, then the regulation is considered conserved. However, if the role is only documented in a single species without evidence in others, it may not be deemed conserved. Current research suggests that while PRP-40 has a role in splicing regulation, the specific conservation of its role in microexon regulation may depend on the organism and context.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does nintedanib improve response rate in patients with bladder cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Nintedanib is a tyrosine kinase inhibitor that targets multiple receptors, including VEGFR, FGFR, and PDGFR. It is primarily approved for the treatment of idiopathic pulmonary fibrosis and certain types of lung cancer, such as non-small cell lung cancer (NSCLC). Regarding bladder cancer, clinical evidence on nintedanib's efficacy, particularly its impact on response rate, is limited. While some studies may explore its use in bladder cancer, especially in combination with other therapies, there is no conclusive evidence or major regulatory approvals indicating that nintedanib significantly improves response rates in bladder cancer patients as of now.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Was prehospital transdermal glyceryl trinitrate effective for stroke in the RIGHT-2 trial?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The RIGHT-2 trial investigated the effectiveness of prehospital transdermal glyceryl trinitrate (GTN) for stroke. The study found that GTN did not significantly improve functional outcomes or reduce mortality in patients with acute stroke. Therefore, the evidence suggests that prehospital transdermal GTN is not effective for stroke.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Was erythropoietin effective for optic neuritis in the TONE trial?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The TONE trial (Treatment of Optic Neuritis with Erythropoietin) investigated the use of erythropoietin (EPO) for optic neuritis. The study found that EPO treatment did not significantly improve visual outcomes compared to placebo. Therefore, erythropoietin was not effective for optic neuritis in the TONE trial.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can losartan reduce brain atrophy in Alzheimer's disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Losartan is an angiotensin II receptor blocker (ARB) primarily used to treat hypertension. Some research suggests that drugs targeting the renin-angiotensin system (RAS), like ARBs, may have neuroprotective effects and could potentially reduce brain atrophy in neurodegenerative diseases such as Alzheimer's. However, clinical evidence specifically linking losartan to reduced brain atrophy in Alzheimer's disease is limited and inconclusive. More research is needed to determine its efficacy in this context.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is levosimendan effective for amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Levosimendan is a calcium sensitizer used primarily for the treatment of acute heart failure. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motor neurons. There is no established evidence or approved use of levosimendan for treating ALS. Its mechanism of action does not target the underlying pathology of ALS, which involves progressive motor neuron degeneration. Therefore, levosimendan is not considered effective for ALS.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should be used bexarotene for relapsing-remitting multiple sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Bexarotene is a retinoid X receptor agonist that has been studied for its potential neuroprotective and anti-inflammatory effects in multiple sclerosis (MS). However, current evidence does not support its routine use for relapsing-remitting MS (RRMS). Clinical trials have not demonstrated significant efficacy in reducing relapse rates or disease progression in RRMS patients. Additionally, bexarotene is associated with side effects such as hyperlipidemia, hypothyroidism, and liver toxicity, which may outweigh its potential benefits in this context. Therefore, it is not recommended for standard treatment of RRMS.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can Efgartigimod be used for myasthenia gravis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Efgartigimod is a medication that targets the neonatal Fc receptor (FcRn), which is involved in the recycling of immunoglobulin G (IgG) antibodies. By blocking FcRn, Efgartigimod reduces the levels of pathogenic IgG antibodies in the body. Myasthenia gravis (MG) is an autoimmune disorder characterized by the presence of IgG autoantibodies against the acetylcholine receptor (AChR) at the neuromuscular junction. These antibodies lead to impaired neuromuscular transmission, causing muscle weakness and fatigue. Since Efgartigimod works by decreasing IgG levels, it has been studied as a potential treatment for MG. Clinical trials have shown that Efgartigimod can improve symptoms in patients with generalized myasthenia gravis (gMG), particularly those who are AChR antibody-positive. Based on this evidence, Efgartigimod has been approved by regulatory agencies, such as the U.S. Food and Drug Administration (FDA), for the treatment of gMG in adults.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Pioglitazone, a thiazolidinedione used to treat type 2 diabetes, has been studied for its potential neuroprotective effects in Alzheimer's disease. Some preclinical studies suggest it may reduce inflammation and amyloid-beta accumulation, which are implicated in Alzheimer's pathology. However, clinical trial data on its efficacy in delaying cognitive impairment in at-risk individuals are limited and inconclusive. A few small trials have shown mixed results, with some indicating possible benefits in specific subgroups, but larger, more definitive trials are needed to confirm these findings. As of now, there is insufficient evidence from clinical trials to conclusively state that pioglitazone delays cognitive impairment in people at risk for Alzheimer's disease.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Tilavonemab effective for progressive supranuclear palsy?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Tilavonemab is a monoclonal antibody that targets tau protein, which is implicated in various neurodegenerative diseases, including progressive supranuclear palsy (PSP). However, as of the latest available data, clinical trials have not demonstrated significant efficacy of tilavonemab in treating PSP. Ongoing research may provide more insights, but currently, there is no strong evidence supporting its effectiveness for this condition.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is ocrelizumab effective for primary progressive multiple sclerosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Ocrelizumab is a monoclonal antibody that targets CD20-positive B cells and is approved for the treatment of multiple sclerosis. It has been studied in clinical trials for both relapsing forms of MS and primary progressive MS (PPMS). For PPMS, the ORATORIO clinical trial demonstrated that ocrelizumab reduced the risk of disability progression compared to placebo. Based on these results, ocrelizumab was approved by regulatory agencies, such as the FDA, for the treatment of PPMS. Therefore, ocrelizumab is considered effective for primary progressive multiple sclerosis.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is deucravacitinib effective for psoriasis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Deucravacitinib is a medication approved for the treatment of psoriasis. Clinical trials have shown that it can significantly reduce symptoms of psoriasis, including skin inflammation and plaque formation. It works by targeting specific pathways involved in the immune response that contributes to psoriasis. Therefore, deucravacitinib is considered effective for treating psoriasis.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is daridorexant effective for insomnia?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Daridorexant is a medication approved for the treatment of insomnia. It works by blocking orexin receptors in the brain, which helps regulate the sleep-wake cycle. Clinical trials have demonstrated that daridorexant can improve sleep onset and maintenance in patients with insomnia. Therefore, it is considered effective for treating insomnia.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is tebentafusp effective for uveal melanoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Tebentafusp is a bispecific fusion protein that targets gp100, a protein expressed on melanocytes, and CD3, which is part of the T-cell receptor complex. It is designed to redirect T cells to attack cancer cells expressing gp100. Uveal melanoma is a type of melanoma that occurs in the eye, and like cutaneous melanoma, it may express gp100. Clinical trials have shown that tebentafusp has activity in metastatic uveal melanoma. For example, in a phase III trial (IMCgp100-202), tebentafusp demonstrated improved overall survival compared to investigator's choice of therapy in patients with metastatic uveal melanoma. Therefore, tebentafusp is considered effective for the treatment of uveal melanoma, particularly in the metastatic setting.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can lenacapavir be used for HIV?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Lenacapavir is a long-acting injectable medication approved for the treatment of HIV-1 infection in adults. It is used in combination with other antiretroviral agents for patients who have not received prior treatment or who have achieved viral suppression. Therefore, lenacapavir can be used for HIV.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Wilson's disease described as an iron storage disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Wilson's disease is a genetic disorder that causes copper to accumulate in the body. It is not related to iron storage.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is medical hydrology the same as Spa therapy?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Medical hydrology is the study of water's role in health and disease, including the use of water for therapeutic purposes. Spa therapy, also known as balneotherapy, involves the use of water treatments for therapeutic benefit, such as soaking in mineral springs. While both involve water-based therapies, medical hydrology is a broader field that includes the scientific study of water's effects on health, whereas spa therapy is a specific application of water treatments for health improvement. Therefore, they are related but not the same.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is North Star Ambulatory Assessment score a reliable clinical outcome for disease progression assessment in Duchenne Muscular Dystrophy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The North Star Ambulatory Assessment (NSAA) is a standardized tool used to evaluate motor function in ambulatory children with Duchenne Muscular Dystrophy (DMD). It consists of a series of timed and functional tasks designed to assess lower limb strength and mobility. The NSAA has been widely used in clinical trials and practice to monitor disease progression and response to interventions. Studies have shown that the NSAA demonstrates good reliability, validity, and sensitivity to change over time in DMD patients. However, the reliability of the NSAA as a clinical outcome measure may depend on factors such as the patient's age, baseline functional status, and the specific context in which it is used (e.g., clinical trial vs. routine care). While the NSAA is considered a reliable and responsive measure for tracking disease progression in DMD, it should be used in conjunction with other clinical assessments to provide a comprehensive evaluation of the patient's condition.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can modulation of KCNQ1 splicing prevent arrhythmias?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"KCNQ1 is a gene that encodes a potassium channel subunit involved in cardiac repolarization. Abnormal splicing of KCNQ1 has been associated with long QT syndrome (LQTS), a condition that predisposes individuals to arrhythmias. Research has suggested that modulating the splicing of KCNQ1 could potentially correct the abnormal channel function associated with LQTS. By restoring normal splicing, it may be possible to prevent the arrhythmias linked to this syndrome. However, this area is still under investigation, and clinical applications are not yet established.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can the concept of digital twins be applied in Precision Nutrition?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Digital twins involve creating virtual replicas of physical entities or systems. In Precision Nutrition, personalized dietary plans are developed based on individual characteristics such as genetics, microbiome, and lifestyle. By modeling an individual's unique biological and behavioral traits, a digital twin could simulate how different nutritional interventions affect health outcomes. This would enable more accurate predictions and tailored recommendations. Therefore, the concept of digital twins can be applied in Precision Nutrition.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is prosopagnosia also known as lack of auditory recognition?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Prosopagnosia is a condition characterized by the inability to recognize faces. It is related to visual processing, not auditory recognition. The term 'lack of auditory recognition' would refer to difficulties in recognizing sounds or voices, which is different from prosopagnosia. Therefore, prosopagnosia is not known as lack of auditory recognition.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do cells undergoing necroptosis show disruption of their cell membranes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Necroptosis is a form of programmed cell death that shares features with both apoptosis and necrosis. Unlike apoptosis, which is typically characterized by cell shrinkage and membrane blebbing without membrane rupture, necroptosis leads to cell swelling and eventual rupture of the cell membrane. This disruption of the cell membrane is a key feature that distinguishes necroptosis from other forms of cell death, such as apoptosis, where the membrane remains intact until the later stages. The rupture of the membrane during necroptosis can lead to the release of intracellular contents and inflammation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Iron deficiency anemia a common complication of chronic kidney disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Chronic kidney disease can lead to various complications due to impaired kidney function. One common issue is anemia, primarily caused by decreased production of erythropoietin by the kidneys. However, iron deficiency can also contribute to anemia in these patients. The question is whether iron deficiency anemia is a common complication specifically.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Anemia is not associated with chronic kidney failure",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Anemia is a common complication of chronic kidney disease (CKD) because the kidneys produce less erythropoietin, a hormone that stimulates red blood cell production. As CKD progresses, the ability of the kidneys to produce this hormone decreases, leading to anemia. Therefore, anemia is indeed associated with chronic kidney failure.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is anaphylaxis a results of mast cell activation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Anaphylaxis is a severe, life-threatening allergic reaction that occurs when the immune system overreacts to an allergen. Mast cells play a key role in this process, as they release histamine and other inflammatory mediators when activated. This activation leads to symptoms such as hives, swelling, and difficulty breathing. Therefore, mast cell activation is a critical component of anaphylaxis.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is trichotillomania encountered with equali frequency in males and females?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Trichotillomania, a disorder characterized by the compulsive urge to pull out one's hair, is more commonly diagnosed in females than males. Studies suggest that females are more likely to seek treatment for the condition, which may contribute to the observed gender disparity. However, it is unclear whether this reflects a true difference in prevalence or if underdiagnosis in males plays a role. Cultural factors and societal norms around hair appearance may also influence reporting rates. While some research indicates a higher incidence in females, the exact reasons for this difference remain a topic of ongoing study.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can skin picking phenotype present following methylphenidate treatment?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Methylphenidate is a medication commonly used to treat ADHD. Some studies have reported that methylphenidate can cause or exacerbate certain psychiatric symptoms, including tics and compulsive behaviors. Skin picking, also known as dermatillomania, is a compulsive behavior that can be associated with ADHD or other psychiatric conditions. While there is no direct evidence that methylphenidate causes skin picking, it is possible that the medication could contribute to the development or worsening of this behavior in some individuals, particularly those with a predisposition to compulsive behaviors. Therefore, it is plausible that skin picking could present following methylphenidate treatment, but more research is needed to confirm this association.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Optogenetics refers to the study of gene expression optimization",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Optogenetics is a biological technique that involves the use of light to control cells in living tissue, typically neurons, that have been genetically modified to express light-sensitive ion channels. It does not primarily refer to the study of gene expression optimization. Instead, it combines genetics and optics to control and observe the activities of individual neurons or other cell types in real time. Therefore, the statement is incorrect.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Have chimeric antigen receptor (CAR)-T cell therapies been approved for the treatment of B cell malignancies?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Chimeric antigen receptor (CAR)-T cell therapies have been approved for the treatment of B cell malignancies. For example, tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) are FDA-approved CAR-T cell therapies for certain B cell lymphomas and leukemias.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is deflazacort more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Deflazacort and prednisone/prednisolone are both corticosteroids used in the management of Duchenne muscular dystrophy (DMD). Studies have compared their efficacy in treating DMD. Some research suggests that deflazacort may have similar or slightly better efficacy in certain aspects, such as maintaining muscle strength and function, compared to prednisone/prednisolone. However, individual responses can vary, and factors like side effect profiles and patient-specific considerations also influence treatment choices. Overall, while there may be some indications of better efficiency with deflazacort, the difference might not be substantial enough to universally declare it more efficient for all patients.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is casimersen effective for the treatment of Duchenne muscular dystrophy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Casimersen is an antisense oligonucleotide designed to target specific mutations in the dystrophin gene, which is responsible for Duchenne muscular dystrophy (DMD). It works by skipping exon 45 during mRNA processing, allowing the production of a shorter but functional dystrophin protein. Clinical trials have shown that casimersen can increase dystrophin production in patients with DMD who have mutations amenable to exon 45 skipping. However, its effectiveness in improving clinical outcomes, such as muscle strength or function, is still under investigation. Regulatory agencies like the FDA have granted accelerated approval for casimersen based on dystrophin production as a surrogate endpoint, but further studies are required to confirm its long-term benefits.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is viltolarsen effective for the treatment of Duchenne muscular dystrophy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Viltolarsen is an antisense oligonucleotide designed to treat Duchenne muscular dystrophy (DMD) by skipping exon 53 during dystrophin mRNA processing. Clinical trials have shown that viltolarsen can increase dystrophin production in patients with DMD who have mutations amenable to exon 53 skipping. However, the long-term clinical benefits, such as improvements in muscle function or disease progression, are still under investigation. Regulatory agencies like the FDA have granted accelerated approval based on dystrophin increase as a surrogate endpoint, but further studies are needed to confirm its effectiveness in clinical outcomes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is golodirsen effective for the treatment of Duchenne muscular dystrophy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Golodirsen is an antisense oligonucleotide designed to treat Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. Clinical trials have shown that golodirsen can increase dystrophin production in muscle cells, which may help slow the progression of the disease. However, its overall clinical effectiveness in terms of long-term functional outcomes is still under investigation. Therefore, golodirsen shows potential as a treatment for a specific subset of DMD patients, but its broader efficacy remains uncertain.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is eteplirsen effective for the treatment of Duchenne muscular dystrophy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Eteplirsen is a medication used to treat Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration. It works by skipping exon 51 during mRNA processing, allowing the production of a shorter but functional dystrophin protein. Clinical trials have shown that eteplirsen can increase dystrophin levels in some patients, which may slow disease progression. However, its overall clinical effectiveness in significantly improving muscle function or long-term outcomes remains debated, with some studies showing modest benefits and others showing limited efficacy. Regulatory agencies like the FDA have approved it under accelerated approval based on dystrophin production, but the actual therapeutic benefit is still under investigation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is SARS-CoV-2 transmitted through breast milk?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is whether SARS-CoV-2 can be transmitted through breast milk. I need to check if the virus can be present in breast milk and if it can be passed from mother to child through breastfeeding. Current studies suggest that while the virus can be detected in breast milk in some cases, there is no evidence of transmission to the infant through this route. The benefits of breastfeeding generally outweigh the potential risks, but precautions may be advised for infected mothers.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do machine learning-based methods outperform statistical methods for survival analysis?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is whether machine learning-based methods outperform statistical methods for survival analysis. Survival analysis involves predicting the time until an event occurs, such as patient survival times in medical studies. Traditional statistical methods, like the Cox proportional hazards model, Kaplan-Meier estimator, and parametric survival models, have been widely used for decades. These methods are well-understood, have strong theoretical foundations, and provide interpretable results. Machine learning-based methods, such as random survival forests, gradient boosting machines, and deep learning models, have been increasingly applied to survival analysis in recent years. These methods can capture complex non-linear relationships and interactions between variables without making strong assumptions about the data. However, they often require larger datasets and more computational resources, and their results can be less interpretable. The performance of machine learning-based methods versus statistical methods depends on the specific context, including the size and complexity of the dataset, the presence of non-linear relationships or high-dimensional interactions, and the need for interpretability. In scenarios with large, complex datasets where non-linear patterns are present, machine learning methods may outperform traditional statistical methods. However, for smaller datasets or situations where interpretability is crucial, statistical methods may still be preferred. Therefore, the answer is not universally 'yes' or 'no' but depends on the specific use case and data characteristics.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does iron regulate oligodendrocyte maturation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Iron is an essential nutrient for various cellular processes, including myelin formation. Oligodendrocytes are responsible for producing myelin in the central nervous system. Studies have shown that iron deficiency can lead to impaired myelination and oligodendrocyte dysfunction. Additionally, iron plays a role in the regulation of gene expression related to oligodendrocyte maturation. Therefore, iron likely regulates oligodendrocyte maturation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are LOQ and LOD the same?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"LOQ (Limit of Quantitation) and LOD (Limit of Detection) are related but distinct concepts in analytical chemistry. LOD refers to the lowest concentration of a substance that can be reliably detected, while LOQ is the lowest concentration that can be quantified with acceptable precision and accuracy. Therefore, they are not the same.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can Amyotrophic Lateral Sclerosis (ALS) be associated with a mutation of the Super Oxide Dismutase 1 (SOD) gene?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether there is a link between Amyotrophic Lateral Sclerosis (ALS) and mutations in the Super Oxide Dismutase 1 (SOD1) gene. I know that ALS is a neurodegenerative disease, and SOD1 is an enzyme involved in protecting cells from oxidative damage. From what I recall, mutations in the SOD1 gene have been identified in some cases of familial ALS. These mutations can lead to the production of a toxic version of the SOD1 protein, which contributes to motor neuron degeneration. However, not all ALS cases are linked to SOD1 mutations, as there are other genetic and environmental factors involved. The association exists, particularly in inherited cases of ALS.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Have Quercetin-biapigenin nanoparticles been shown to be effective in penetrating the blood-brain barrier",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Quercetin-biapigenin nanoparticles have been studied for their potential in drug delivery, particularly in crossing the blood-brain barrier (BBB). The BBB is a highly selective barrier that protects the brain from harmful substances, making it challenging for drugs to reach the central nervous system. Nanoparticles are often engineered to enhance drug delivery across this barrier. Research on flavonoid-based nanoparticles, such as those combining quercetin and biapigenin, may focus on their ability to improve bioavailability and target specific areas, including the brain. However, the effectiveness of Quercetin-biapigenin nanoparticles specifically in penetrating the BBB would depend on existing scientific studies or clinical trials that have investigated this property. If such studies demonstrate successful BBB penetration and subsequent therapeutic effects, then the answer would be 'yes'; otherwise, if there is no conclusive evidence or research on this specific nanoparticle formulation and its BBB penetration capability, the answer would be 'no'.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"OXLUMO (lumasiran) is a medication approved for the treatment of primary hyperoxaluria type 1 (PH1), a rare genetic disorder characterized by excessive production of oxalate. Lumasiran works by reducing the production of oxalate in the liver. Therefore, it is used as a targeted therapy for this condition.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can untranslated regions (UTRs) regulate gene expression?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Untranslated regions (UTRs) are segments of messenger RNA (mRNA) that do not code for proteins. However, they play important roles in regulating gene expression. The 5' UTR is involved in the initiation of translation and can influence the stability and localization of the mRNA. The 3' UTR contains regulatory elements such as microRNA binding sites, which can affect mRNA stability and translation efficiency. Therefore, UTRs can regulate gene expression at the post-transcriptional level.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can the epigenetic status of introns affect gene expression?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Epigenetic modifications, such as DNA methylation and histone modifications, can influence gene expression by altering chromatin structure and affecting the accessibility of DNA to transcriptional machinery. While much research has focused on epigenetic changes in gene promoters and exons, introns can also be subject to these modifications. Epigenetic marks within introns may affect splicing efficiency, transcription elongation, or the stability of mRNA transcripts. For example, methylation within intronic regions could potentially influence alternative splicing by affecting the binding of splicing factors. Additionally, histone modifications in introns might impact the overall chromatin environment, thereby influencing gene expression. Therefore, it is plausible that the epigenetic status of introns can have an impact on gene expression.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking whether there is a way to distinguish between COVID-19 and other respiratory illnesses, such as influenza, based on clinical features. Both COVID-19 and influenza are respiratory illnesses with overlapping symptoms, such as fever, cough, and fatigue, which can make clinical differentiation challenging. However, certain symptoms may be more common or characteristic of one illness over the other. For example, loss of taste or smell is more commonly associated with COVID-19. Additionally, the progression of symptoms and the presence of certain signs, such as specific imaging findings or laboratory markers, may help in distinguishing between the two. However, definitive diagnosis typically requires specific diagnostic tests, such as PCR testing for SARS-CoV-2 or influenza. Therefore, while there may be some clinical clues, definitive distinction usually requires laboratory confirmation.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question asks whether the severity of illness caused by the Omicron variant of SARS-CoV-2 is less than that caused by other variants. Research has shown that Omicron tends to cause milder symptoms compared to previous variants like Delta, especially in vaccinated individuals. However, this can vary based on factors such as vaccination status, prior immunity, and individual health conditions. While the overall trend suggests reduced severity with Omicron, it is not universally true for all cases. Therefore, the answer is nuanced but leans towards 'yes' when considering general trends.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Inhaled glucocorticoids are commonly used to manage asthma and COPD by reducing inflammation in the airways. There is no evidence to suggest that these medications increase the risk of contracting COVID-19. In fact, stopping them could lead to uncontrolled respiratory symptoms, which might increase the risk of complications if infected. Therefore, patients should continue their prescribed inhaled glucocorticoids unless advised otherwise by their healthcare provider.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is adenosine methylation an epigenetic modification?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Adenosine methylation, specifically N6-methyladenosine (m6A), is a common RNA modification. Epigenetic modifications typically refer to changes in DNA or histone proteins that affect gene expression without altering the DNA sequence. Since adenosine methylation occurs on RNA and not directly on DNA or histones, it is not classified as an epigenetic modification in the traditional sense.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is whether analgesics or antipyretics can be taken for side effects following COVID-19 vaccination. Analgesics are medications used to relieve pain, while antipyretics are used to reduce fever. Common side effects of COVID-19 vaccines include pain at the injection site, fatigue, headache, muscle pain, chills, and fever. These side effects are typically mild and resolve on their own within a few days. According to health authorities such as the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), individuals experiencing discomfort from vaccine side effects can take over-the-counter medications such as acetaminophen (paracetamol) or ibuprofen to alleviate symptoms. However, it is generally recommended to consult with a healthcare provider before taking any medication, especially if the symptoms are severe or persistent. Therefore, the answer is yes, analgesics or antipyretics can be taken for side effects following COVID-19 vaccination, provided they are used appropriately and under medical guidance if necessary.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Luminopsins a fusion proteins of luminol and Rhodopsin ?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Luminopsins are a class of proteins that combine elements of rhodopsin and luciferase. Rhodopsin is a light-sensitive receptor protein involved in vision, while luciferase is an enzyme that catalyzes light-emitting reactions. Luminopsins are designed to function as light-activated proteins for applications in optogenetics. Luminol, on the other hand, is a chemical compound that emits light when oxidized, typically used in chemiluminescence. Although luminopsins involve luciferase, they are not a fusion of luminol and rhodopsin, because luminol is a small molecule, not a protein, and is not directly fused with rhodopsin. Therefore, the statement is incorrect.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "In twin-twin transfusion syndrome, are the twins identical?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Twin-twin transfusion syndrome (TTTS) occurs in monochorionic twin pregnancies, where the twins share a single placenta. This condition involves the unequal sharing of blood between the twins through connecting blood vessels in the placenta. Since TTTS specifically affects monochorionic twins, who develop from a single fertilized egg that splits, the twins must be identical (monozygotic). Therefore, the twins in TTTS are always identical.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Zanubrutinib is a BTK inhibitor. First-generation BTK inhibitors include ibrutinib and acalabrutinib. Zanubrutinib is a second-generation BTK inhibitor. The FDA approved Zanubrutinib for certain indications, but it is not a first-generation inhibitor.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"CRISPR/Cas12a is a gene-editing tool that has been adapted for diagnostic purposes. It can be programmed to detect specific DNA sequences, including mutations. EGFR mutations in circulating DNA (like those found in liquid biopsies) are clinically relevant for cancer diagnostics, particularly in lung cancer. Studies have demonstrated that CRISPR/Cas12a-based assays can detect low-frequency mutations in DNA samples, including those from circulating tumor DNA. Therefore, it is feasible to use CRISPR/Cas12a for detecting EGFR mutations in circulating DNA.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Functional Neurological Disorder (FND) classified as a psychosomatic disorder?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Functional Neurological Disorder (FND) is a condition that affects the nervous system and can cause various neurological symptoms. While the exact classification of FND may vary, it is generally considered to have both neurological and psychological components. However, whether it is specifically classified as a psychosomatic disorder depends on the diagnostic criteria and the perspective of the medical community. Some sources may categorize it under psychosomatic or psychogenic disorders due to the involvement of psychological factors, but it is primarily recognized as a neurological condition with functional rather than structural abnormalities.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Are any medications available to prevent COVID-19 following exposure?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"The question is asking about medications that can be used to prevent COVID-19 after someone has been exposed to the virus. I need to consider what drugs are currently available for this purpose. I know that vaccines are the primary method for preventing COVID-19, but the question specifically asks about medications following exposure, which implies treatment rather than vaccination. I recall that post-exposure prophylaxis (PEP) is sometimes used in other diseases, like HIV, but I'm not sure if there are any approved medications for PEP in the case of COVID-19. There may be some antiviral drugs that are used in certain situations, but I need to check if any are widely available and approved for this specific use. I believe that as of now, there are no widely approved medications specifically for preventing COVID-19 after exposure, though some may be under emergency use authorization or in clinical trials.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can reinfection occur after SARS-CoV-2 infection?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Yes, reinfection can occur after SARS-CoV-2 infection. Although most individuals develop some level of immunity following initial infection, the duration and strength of this immunity can vary. Cases of reinfection have been documented, particularly with the emergence of new variants that may partially evade existing immune responses. Factors such as waning immunity over time and the presence of novel viral strains contribute to the possibility of reinfection.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can other vaccines be given with COVID-19 vaccine?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"The question is asking if other vaccines can be administered alongside the COVID-19 vaccine. According to current medical guidelines, it is generally safe to give other vaccines at the same time as the COVID-19 vaccine, but there may be specific exceptions or recommendations depending on the country and the type of vaccines involved. However, the most up-to-date guidance should be consulted for accurate information.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is omaveloxolone a suppressor of Nrf2?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Omaveloxolone is a synthetic triterpenoid compound that has been studied for its potential therapeutic effects, particularly in neurodegenerative diseases. It is known to activate the Nrf2 pathway, which plays a role in cellular defense against oxidative stress. Since Nrf2 activation is typically associated with upregulation of antioxidant response elements, it is unlikely that omaveloxolone acts as a suppressor of Nrf2. Instead, it functions as an activator or inducer of Nrf2-mediated pathways.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is omaveloxolone an activator of NFkB?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"To answer this question, I need to determine whether omaveloxolone activates NF-ÎºB. I know that omaveloxolone is a synthetic triterpenoid compound that has been studied for its potential therapeutic effects in various diseases, including cancer and neurodegenerative disorders. I also know that NF-ÎºB is a transcription factor that plays a key role in regulating the expression of genes involved in inflammation, immune responses, and cell survival. Some studies have suggested that omaveloxolone may modulate NF-ÎºB signaling, but the direction of this effect (activation or inhibition) is not clear to me. To answer this question accurately, I would need to review the scientific literature on omaveloxolone and its effects on NF-ÎºB signaling.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has RTA 408 received FDA approval?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"RTA 408 is a drug that is currently in clinical trials. The FDA has not yet approved it for use.\",\n  \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can salivary cortisol be used to evaluate pain in neonates?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Salivary cortisol is a biomarker that reflects the body's stress response. In neonates, assessing pain can be challenging due to their inability to communicate verbally. Cortisol levels can increase in response to stress and pain, making it a potential indicator for evaluating pain in neonates. However, other factors can also influence cortisol levels, such as circadian rhythm, feeding, and other stressors. Therefore, while salivary cortisol may provide some insight into a neonate's stress or pain levels, it should be used in conjunction with other clinical assessments for a more accurate evaluation.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can breastfeeding be used to alleviate the procedural pain in neonates?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Breastfeeding has been studied as a method to reduce procedural pain in neonates, such as during vaccinations or blood draws. Research suggests that the combination of sucking, skin-to-skin contact, and the sweet taste of breast milk can have a soothing effect on newborns, potentially reducing their perception of pain. Some studies have shown that breastfeeding during painful procedures can lead to lower pain scores compared to other methods or no intervention. However, the effectiveness may vary based on the procedure's intensity, the neonate's age, and individual differences. While it may not completely eliminate pain, it can be a part of a multimodal approach to pain management in neonates. The answer depends on whether the evidence supports its use as an effective method for alleviating procedural pain.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is music therapy effective for pain management in neonates?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Music therapy may help reduce pain in neonates by promoting relaxation and decreasing stress levels. Studies have shown that it can be an effective complementary approach when used alongside standard medical care. However, effectiveness can vary based on the individual and specific circumstances.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is there any treatment for the Facioscapulohumeral Muscular Dystrophy?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic disorder that causes progressive muscle weakness. While there is no cure for FSHD, treatments focus on managing symptoms and improving quality of life. These may include physical therapy, assistive devices, and medications to address specific issues. Research into potential therapies is ongoing.\",\n  \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Are there any other types of Spinal Muscular Atrophy except for types 1-4?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Spinal Muscular Atrophy (SMA) is typically classified into four main types (1-4) based on the age of onset and severity. However, there are also rare forms such as SMA with respiratory distress (SMARD) and X-linked SMA, which are not included in the standard types 1-4. Therefore, the answer is yes.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do all proteins start with methionine?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Most proteins start with methionine because the start codon (AUG) codes for methionine. However, there are exceptions where proteins can start with other amino acids due to alternative start codons or post-translational modifications.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do epigenetic changes change the DNA sequence?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Epigenetic changes refer to modifications that affect gene expression without altering the underlying DNA sequence. These changes can include DNA methylation, histone modification, and non-coding RNA molecules. They play a role in regulating how genes are expressed and can be influenced by environmental factors. However, they do not change the actual sequence of DNA bases.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are epigenetic changes heritable?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n  \"draft\": \"Epigenetic changes refer to modifications in gene expression that do not involve alterations to the DNA sequence itself. These changes can be influenced by environmental factors, lifestyle, and age. The question is whether these modifications can be passed from one generation to the next. Research has shown that some epigenetic marks, such as DNA methylation and histone modifications, can be inherited through cell division and, in some cases, through generations. However, the extent and mechanisms of transgenerational inheritance in humans are still under investigation and not fully understood. In certain organisms like plants and some animals, there is stronger evidence for heritable epigenetic changes. Therefore, while there is evidence supporting the heritability of some epigenetic changes, the answer may depend on the context and species being considered.\",\n  \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do enhancers have to be close to their gene targets?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Enhancers are DNA sequences that can increase the transcription of genes. They can be located far away from their target genes, sometimes even in different chromosomes. They work by interacting with the gene's promoter region through DNA looping, which brings them into close proximity in three-dimensional space. Therefore, enhancers do not have to be close to their gene targets in the linear DNA sequence.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are accessible enhancers necessarily active?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n  \"draft\": \"Enhancers are DNA sequences that can increase the transcription of genes. Accessible enhancers refer to those that are in a chromatin state that allows them to be bound by transcription factors and other regulatory proteins. However, being accessible does not necessarily mean they are actively functioning at a given time. They may be accessible but not currently engaged in enhancing transcription, perhaps due to the absence of specific transcription factors or other regulatory conditions. Therefore, accessible enhancers are not necessarily active.\",\n  \"answer\": \"no\"\n}",
    "correct": true
  }
]